var title_f8_56_9088="Mobilization of the breast off the chest wall for mastectomy";
var content_f8_56_9088=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F52804&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F52804&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 546px\">",
"   <div class=\"ttl\">",
"    Mobilization of the breast off the chest wall for mastectomy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 526px; height: 339px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Mobilization of the breast off the chest wall can be aided by place of Allis clamps along the superior border of the breast, including the investing \"fascia\" of the muscle (perimysium). The tissue is pulled up or inferiorly with gentle traction. The dissection is performed utilizing electrocautery or sharp dissection, traveling in parallel to the chest wall muscle ���������bers. Since the pectoralis major muscle ���������bers splay, the angle of dissection shifts as one progresses within the dissection.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Shaughnessy EA. Simple mastectomy. In: Master Techniques in General Surgery: Breast Surgery, Bland KI, Klimberg SV (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2011. Copyright &copy; 2011 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_56_9088=[""].join("\n");
var outline_f8_56_9088=null;
var title_f8_56_9089="Local anesthetic block of the sacroiliac joint";
var content_f8_56_9089=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F65226&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F65226&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Local anesthetic block of the sacroiliac joint",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 289px; height: 351px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Local anesthetic block of the sacroiliac joint is used to confirm the sacroiliac joint is the source of posterior hip pain. The patient is positioned lying prone, completely flat. A 1.5 inch (3.8 cm), 22-gauge needle is inserted perpendicular to the skin,&nbsp;2.5 to 3.8 cm (1 to 1.5&nbsp;in) lateral to the midline, to a depth of 2.5 to 3.8 cm (1 to 1.5 in). 1 mL of local anesthetic is placed at the interface of the subcutaneous fat and the outer muscle fascia. The needle is withdrawn a 0.7 cm (0.25 in) and redirected laterally at an angle of 10-15 degrees (this point of entry and angulation allows safe passage under the wing of the posterior iliac crest).&nbsp;The needle is advanced through the fascia gently&nbsp;until the firm resistance of bone is reached. 1 to 2 mL of anesthetic is injected&nbsp;adjacent to the posterior aspect of the sacroiliac joint.",
"    <br>",
"     <br>",
"      &nbsp;",
"      <div class=\"footnotes\">",
"      </div>",
"      <div class=\"reference\">",
"       Courtesy of Bruce C Anderson, MD.",
"      </div>",
"     </br>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_56_9089=[""].join("\n");
var outline_f8_56_9089=null;
var title_f8_56_9090="Patient information: Hirsutism (excess hair growth in women) (The Basics)";
var content_f8_56_9090=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?27/29/28115\">",
"         Patient information: Polycystic ovary syndrome (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?13/24/13698\">",
"         Patient information: Hirsutism (excess hair growth in women) (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?29/46/30437\">",
"         Patient information: Polycystic ovary syndrome (PCOS) (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Hirsutism (excess hair growth in women) (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/hirsutism-excess-hair-growth-in-women-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H195394747\">",
"      <span class=\"h1\">",
"       What is hirsutism?",
"      </span>",
"      &nbsp;&mdash;&nbsp;&ldquo;Hirsutism&rdquo; is the medical term for excess body hair in women. The hair is dark and thick, and grows in places where only men tend to grow dark hair. This includes the upper lip (mustache area), chin, sideburn area, chest, back, and belly. Hirsutism is common. It affects as many as 1 in 10 women who have not gone through menopause yet. (Menopause is the time in a woman&rsquo;s life when she naturally stops having periods.)",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H195394754\">",
"      <span class=\"h1\">",
"       What causes hirsutism?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Many women have extra body hair because of their family background. They might be bothered by it, but it is not a sign of a hormonal problem. Other women get hirsutism because they have high levels of male hormones, called &ldquo;androgens.&rdquo; Testosterone is the most important androgen. High levels are normal in men. Women normally have much lower levels than men.",
"     </p>",
"     <p>",
"      The most common condition that leads to extra androgens in women is called &ldquo;polycystic ovary syndrome&rdquo; (PCOS). This condition also causes missed periods, weight gain, acne, and other symptoms.",
"     </p>",
"     <p>",
"      There are some more serious causes of hirsutism (tumors in the ovary or adrenal glands, which are located on top of the kidneys). But these are very rare.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H195394761\">",
"      <span class=\"h1\">",
"       What other symptoms should I watch for?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Watch for other symptoms of PCOS. Women with PCOS might have:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Irregular periods",
"       </li>",
"       <li>",
"        Acne",
"       </li>",
"       <li>",
"        Hair loss from the scalp",
"       </li>",
"       <li>",
"        Weight gain or obesity",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H195394768\">",
"      <span class=\"h1\">",
"       Should I see a doctor or nurse?",
"      </span>",
"      &nbsp;&mdash;&nbsp;You should see your doctor or nurse if you:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Have hirsutism that appeared suddenly, or is getting worse quickly",
"       </li>",
"       <li>",
"        Think you have PCOS",
"       </li>",
"       <li>",
"        Are bothered by your excess hair and want treatment",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H195394775\">",
"      <span class=\"h1\">",
"       Are there tests I should have?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Your doctor or nurse will decide which tests you should have based on your age, other symptoms, and individual situation.",
"     </p>",
"     <p>",
"      Possible tests include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Blood tests to measure hormone levels",
"       </li>",
"       <li>",
"        Pelvic ultrasound &ndash; This test uses sound waves to make a picture of your uterus and ovaries. The pictures can show if you have PCOS or another problem.",
"       </li>",
"       <li>",
"        Imaging tests, such as CT or MRI scans &ndash; These can show if a tumor is causing the problem.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H195394782\">",
"      <span class=\"h1\">",
"       Is there anything I can do on my own to treat the condition?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. If you are overweight or obese, losing weight can lower androgen levels and improve symptoms. Losing just 5 percent of your body weight can help a lot. That adds up to 10 pounds of weight loss for a 200-pound woman.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H195394789\">",
"      <span class=\"h1\">",
"       How is hirsutism treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;That depends on what is causing your hirsutism and how bad your symptoms are. You might not need treatment. If you do, possible treatments include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Birth control pills. These are the most common treatment. They change hormone levels and make periods regular.",
"       </li>",
"       <li>",
"        Medicines called anti-androgens, which lower androgen levels or block the effects of androgens.",
"       </li>",
"       <li>",
"        Removing extra hair or making it harder to see. Ways of doing this include:",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"hyphen-block\">",
"       <li>",
"        Shaving or plucking",
"       </li>",
"       <li>",
"        Chemicals and wax that remove hair",
"       </li>",
"       <li>",
"        Bleaching to make hair lighter",
"       </li>",
"       <li>",
"        Creams that slow the growth of hair on the face",
"       </li>",
"       <li>",
"        Electrolysis, which uses a tiny needle and a mild electrical zap to destroy hair roots one by one. Electrolysis works best on small areas of skin.",
"       </li>",
"       <li>",
"        Laser hair removal, which uses a laser to destroy hairs. This procedure works faster and is less painful than electrolysis. It is also more expensive. Most women need 4 to 6 treatments that happen every month or so. Women need to stay on their medication after laser treatment, or the hair will gradually grow back.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H195394796\">",
"      <span class=\"h1\">",
"       What if I want to get pregnant?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Many women with hirsutism are able to get pregnant. If you have PCOS, and you are overweight, losing weight can also make it easier to get pregnant. There are also medicines that can help you get pregnant. You should not take medicines to control hair growth if you are pregnant or trying to get pregnant.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H195394803\">",
"      <span class=\"h1\">",
"       What will my life be like?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Having extra hair makes most women feel self-conscious. None of the treatments make the hair go away completely. But they make it grow more slowly and help to decrease the amount of hair. Most women eventually feel better about their appearance. If you are not happy with the results of your treatment, ask your doctor about other options.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H195394873\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?27/29/28115?source=see_link\">",
"       Patient information: Polycystic ovary syndrome (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?13/24/13698?source=see_link\">",
"       Patient information: Hirsutism (excess hair growth in women) (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?29/46/30437?source=see_link\">",
"       Patient information: Polycystic ovary syndrome (PCOS) (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?8/56/9090?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 15608 Version 2.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-122.72.76.133-5682FA82D5-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_56_9090=[""].join("\n");
var outline_f8_56_9090=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H195394747\">",
"      What is hirsutism?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H195394754\">",
"      What causes hirsutism?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H195394761\">",
"      What other symptoms should I watch for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H195394768\">",
"      Should I see a doctor or nurse?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H195394775\">",
"      Are there tests I should have?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H195394782\">",
"      Is there anything I can do on my own to treat the condition?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H195394789\">",
"      How is hirsutism treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H195394796\">",
"      What if I want to get pregnant?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H195394803\">",
"      What will my life be like?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H195394873\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?13/24/13698?source=related_link\">",
"      Patient information: Hirsutism (excess hair growth in women) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?29/46/30437?source=related_link\">",
"      Patient information: Polycystic ovary syndrome (PCOS) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?27/29/28115?source=related_link\">",
"      Patient information: Polycystic ovary syndrome (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f8_56_9091="Physiological model vulvar pain";
var content_f8_56_9091=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F55588&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F55588&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Schematic diagram of physiological model of vulvar pain",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 348px; height: 372px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A illustrates the immediate response to cutaneous trauma. Action potentials in C-nociceptors propagate through the dorsal root ganglion (DRG) to the spinal cord where they activate and sensitize wide-dynamic-range (WDR) neurons whose axons ascend to higher centers. In B, the WDR neurons remain sensitized and now respond to activity in large diameter A-mechanoreceptors which are activated by light touch. This state produces allodynia. In C, the same sensitized WDR neurons respond again to A-mechanoreceptors activity, but this activity is initiated by sympathetic efferent actions on the sensory receptor, in the absence of cutaneous stimulation. This phase represents sympathetically maintained pain. Although spinal interneurons are shown to be interposed in the 'pain' pathway, this is just one of the many possible arrangements.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Roberts, WJ. A hypothesis on the physiological basis for causalgia and related pains. PAIN 1986; 24:297. Copyright &copy; 1986 Elsevier Science.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_56_9091=[""].join("\n");
var outline_f8_56_9091=null;
var title_f8_56_9092="Scopolamine (ophthalmic): Pediatric drug information";
var content_f8_56_9092=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Scopolamine (ophthalmic): Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?23/58/24484?source=see_link\">",
"    see \"Scopolamine (ophthalmic): Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?4/8/4228?source=see_link\">",
"    see \"Scopolamine (ophthalmic): Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F9522576\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Isopto&reg; Hyoscine",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F10514674\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Anticholinergic Agent, Ophthalmic",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Ophthalmic Agent, Mydriatic",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F10514681\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?23/58/24484?source=see_link\">",
"      see \"Scopolamine (ophthalmic): Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Refraction:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Children: Instill 1 drop of 0.25% to eye(s) twice daily for 2 days before procedure",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Adults: Instill 1-2 drops of 0.25% to eye(s) 1 hour before procedure",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iridocyclitis:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Children: Instill 1 drop of 0.25% to eye(s) up to 3 times/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Adults: Instill 1-2 drops of 0.25% to eye(s) up to 3 times/day",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F9522699\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, ophthalmic, as hydrobromide [drops]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Isopto&reg; Hyoscine: 0.25% (5 mL) [contains benzalkonium chloride]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F9522586\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F10514682\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Instill drops to conjunctival sac of affected eye(s); avoid contact of bottle tip with skin or eye; finger pressure should be applied to lacrimal sac during and for 1-2 minutes after instillation to decrease risk of absorption and systemic reactions. Remove contact lenses prior to administration; wait 15 minutes before reinserting if using products containing benzalkonium chloride. Wash hands following administration.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F10514679\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store at 8&deg;C to 27&deg;C (46&deg;F to 80&deg;F); protect from light",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F10514675\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     To produce cycloplegia and mydriasis; treatment of iridocyclitis",
"    </p>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F9522610\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Systemic adverse effects have been reported following ophthalmic administration.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Drowsiness, somnolence, visual hallucination",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Eczematoid dermatitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Xerostomia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Blurred vision, edema, exudate, follicular conjunctivitis, increased intraocular pressure, local irritation, photophobia, vascular congestion",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F10514676\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to scopolamine or any component; patients hypersensitive to belladonna or barbiturates may be hypersensitive to scopolamine; narrow-angle glaucoma",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F10514677\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Discontinue if patient reports unusual visual disturbances or pain within the eye.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13300030\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F9522612\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AbobotulinumtoxinA: Anticholinergic Agents may enhance the anticholinergic effect of AbobotulinumtoxinA.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetylcholinesterase Inhibitors (Central): Anticholinergics may diminish the therapeutic effect of Acetylcholinesterase Inhibitors (Central). Acetylcholinesterase Inhibitors (Central) may diminish the therapeutic effect of Anticholinergics. If the anticholinergic action is a side effect of the agent, the result may be beneficial.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aclidinium: May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticholinergics: May enhance the adverse/toxic effect of other Anticholinergics.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of CNS depressants used in combination with buprenorphine.  Consider avoiding other CNS depressants in patients thought to be at high risk of buprenorphine overuse or self-injection.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cannabinoids: Anticholinergic Agents may enhance the tachycardic effect of Cannabinoids.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ipratropium (Oral Inhalation): May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce adult dose of CNS depressant agents by 50% with initiation of concomitant methotrimeprazine therapy. Further CNS depressant dosage adjustments should be initiated only after clinically effective methotrimeprazine dose is established.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: CNS Depressants may enhance the sedative effect of Metyrosine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirabegron: Anticholinergic Agents may enhance the therapeutic effect of Mirabegron. This may result in acute urinary retention.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirtazapine: CNS Depressants may enhance the CNS depressant effect of Mirtazapine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     OnabotulinumtoxinA: Anticholinergic Agents may enhance the anticholinergic effect of OnabotulinumtoxinA.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Potassium Chloride: Anticholinergic Agents may enhance the ulcerogenic effect of Potassium Chloride.  Management: Patients on drugs with substantial anticholinergic effects should avoid using any solid oral dosage form of potassium chloride.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramlintide: May enhance the anticholinergic effect of Anticholinergics. These effects are specific to the GI tract.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RimabotulinumtoxinB: Anticholinergic Agents may enhance the anticholinergic effect of RimabotulinumtoxinB.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Secretin: Anticholinergic Agents may diminish the therapeutic effect of Secretin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: CNS Depressants may enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tiotropium: Anticholinergics may enhance the anticholinergic effect of Tiotropium.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Topiramate: Anticholinergic Agents may enhance the adverse/toxic effect of Topiramate. Specifically, the risk of oligohidrosis and hyperthermia may be enhanced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem dose to 1.75 mg for men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F13872653\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     When administered intravenously or transdermally, scopolamine crosses the placenta; refer to Scopolamine (Systemic) monograph for details. Scopolamine is rapidly absorbed systemically after ocular application (Lahdes, 1990).",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F10514680\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Blocks the action of acetylcholine at parasympathetic sites in smooth muscle and the CNS, resulting in anticholinergic activity (dilated pupils, drowsiness)",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F10514683\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?4/8/4228?source=see_link\">",
"      see \"Scopolamine (ophthalmic): Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May cause drowsiness and impair ability to perform activities requiring mental alertness or physical coordination",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16046 Version 28.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-210.101.131.232-9BEAA163C5-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_56_9092=[""].join("\n");
var outline_f8_56_9092=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9522576\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10514674\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10514681\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9522699\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9522586\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10514682\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10514679\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10514675\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9522610\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10514676\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10514677\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13300030\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9522612\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13872653\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10514680\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10514683\">",
"      Patient Information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/16046\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/16046|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?23/58/24484?source=related_link\">",
"      Scopolamine (ophthalmic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?4/8/4228?source=related_link\">",
"      Scopolamine (ophthalmic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32375?source=related_link\">",
"      Scopolamine (systemic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?10/12/10437?source=related_link\">",
"      Scopolamine (systemic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?39/0/39941?source=related_link\">",
"      Scopolamine (systemic): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f8_56_9093="Acute rejection airway II";
var content_f8_56_9093=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F52040&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F52040&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Airway pattern of acute lung transplant rejection",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 240px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCADwAWgDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDTuLq3tNhup44Q5wm9sFj6Ad6oReI9GuLhre21S2luEfa8QJ3KQcEYIz1IH1NPs7G0iu4xPOtzqix+Y/mzbpFB4LqmflGTjpV77DaG/N8bWH7aVCGbHzbR0H69etfMe4t0/wAv02PctHuQ65qa6PYm5kgkn+cJsQheuSSSegAB/lTfDV++raUt3LHChduDBv2ONoORuAPBJB7ZHBNaW1WUqyhlPUEZBqXOTknJ6Uc0eS1te4XXLa2pHLHIxUpMY1HJUKDu9s+lc346sZtXstO0qJIZDcz7pllRhF5aj7xkHMeCexBbJXvXV49qbPBFcwPBcRpNBIu143GQw96dOo4SUl0I06nCnwprV34wtr28uDZaTZxfZ0gim+aSMjHlAD7qgBQdxyTkjPUd3a28cKLDawqiZOEjHUnqfc+9LbwxwQRwwqFijQIgyTtUDAGScnj1rjPiNLd3SrpVpdz2lsYPNuzB8ryh22pHu7LgOSO/Fax58TNQb0X4fL+vuNFzVHyxKnjjxNqUWuQaT4Ye3wULX90jK7RHOCg7KQByepyBxg1wV7LMNIvrfVQbAwATI8xHlXPzZ8pVxk5Hpn3wKnvZNM0FMS2ZXzCs0UkIaQLIAcbieARjgc/ePTGa1YbS4kjsb3Sv7MlVoQV+2szXR3A5ZflZFGDxu69CO1e5ThChBJL/ADb/AB/4B1KChFwTu3/X3fMw9PtF1S/t9Zj1CW41e43JHstAtrEqYUtK24bcg5CqPT1r0i5eT7CLaSYeaEUSSIgjEhHdgKyIIbPR1Ntc3d9MZcyI8lsPLB7ZRF2g8ZAquuma9c6dPv1ad3+99sisQiooB3Ed89Oe2OKynabUpOyW11+WnQqlTUNWvP5/N/5+o9mtUut1zsvCBtktruOOSIk8jCsp2HpyOT696jj1DxZb2dxcW9/HFbpEy28UNkqQq3Rex/UnnrUnge2La1c6hdWkVxosQ8u41S7mKSxEIMbo5AGIJ/uqMluvGK67xbq2Db6XZGMxSRpK5Qbtyn/VomMLg4ySeMY6VE5xVRQjFPu3bT/L/hhuUKkuVRv96POtGg1OONJp1R73yXnESTshuJyQoBzmMgKFzgZBA6ZzWVZ+G5rm0vbSe11CxMmGk8+IBpnUZDLkswJYE8dfXtXa6XqRjhvlhsnsY442eZ4IvODq3IALkFyAAoVRxz0HNWtZvEctb2U63F3FFuVLNn86IlQVMsbqoOeBhW4PB9tfbz5mkv8AgfoiGoOVn/X4fkZNlJrNhpOmb0sr0WZ3Xc0LOZ0TJIZQcKQB2OTlSOOK7Xw/e2uqWn2uzEjWt0vmKZQQSpyBz9cgiuV8MatF4me5v5rFbaVg0F4z5LJ8pJ2A9d2DkHow/GnB9UW80+58GyWz6YLV0lQnEQUfc47uDn3HIOBXPWp894y0ffp3t/kQ/ejeJnpblru+0aQYuIz9qtc9TLHyFHuVzj3HvWnpsUtrqkz6chOnXSicSMU2WyS8+VEvLE7ywYnGAo9az/EK3Da/ZTIottVZI5HgyCYZsZCnHUeh7gitvRWVp7i2jGx5WLRKSCQcjCr6nIwPqfUmtql+RS7r+v8AgHfXipxjV+f+f9epw8/2zxRqaGBvM0I3Cq10kAaW0k2ndg/eQNs69MAVrRq1lpkd0rW0l1L5FpE17GZHByRHvCKdx4PQcbQPetafSfKsryTSlXTDc7Zp5mhkdcAkYVV+9IDkYIXGSQc1zTWTajrd4to91Haadc/ZbJSuZPtW5QWMeSWCA7uwHHXnOqnGSaTsl/X9eS18+L4Oa27N6OJbTxVaWd/eXc119nKzQylFRAyjErgcDcOAMk5K1z0Njod7c6h/bNrqem6VYKxjktIsGWRCFHbBPJ7n3K99rUYYtU1O6eIWmrQKY7S0mitcxW0KEndJIBh+cnknLY7cVqeIjbCy8MaKYdVu72OYiGWNyjOT95HOMNGeM4IOB171mqjjZLd79Ldb62t8/wAetNtx20f9efl/W3BRaXPqF5eweXq8Fizho7i9yzFRx6dCpB68Y6nrTdVstN07QZYbJLlNSaQRPLKvACnJP49hWhpdjrWl6m+uaeiTWAmb7XEUbE2ScpjuG6DBHWptefU9di/tDWFljckhbVogpjwCAXIxkHGRkV2xm+dK/u+vX0Lgn8LW3U5/R9TaHUDNYwm0mjYSxvG5O0jtg9vavfvB+t/8JDoi3bqiyq5ikVD0IA59s14fpX2REEBt4bW4C+UZ3B3s2ScgnheMDA64zmu8+GWu2ttqVxpk1wJDeOPJmVtyFxkEFvU8c1y5nR9rTbUdV+QV4qdO9tUenAYAoP6VVuJXe7hhhcBVJaXI6jHAHvmnPI0eV37264z0r5nlPP5WTbeeO9KcewpEHyDn3pCQOtJokXP5Uh/CgjH0pPrSAM/Sm7h0zil6ioJQy880DJjxSVXjlw4U5wc9uBj/APX+lT9sjmgANNyCxUdRjP4//qp30ppX59wOOMEetIANM5/yKk9fSmHr70ANNNOMdKcaaw4z3oGN/Cil744H1oq4wUt3+X6sDlvDekizuLy/mQC6uSFaR1/eMqgAbj17A46Vu7lDhGdBIeQu4ZI+leY6x8Q2t9esbfTp0NmoLTSXGIxKAOCSeQD14AJ4pE1nT9U1l7/QnjS+i+/czQPNGCe6KWAJznr6e1ek8FVl79TS6/4ZP+mauDm337Hqo9aeoye9cLqvjSPTdONzM0rPtIjhCjfIwHsDiuTtfFGvazqkclzPNpdgwVktdnmCYEE4LY746fkM1NPL6s1zPRB7GXNynsc1zb2yM888UaoMsWYfKBzk+1YVh400XUo5ZNNuTcRRPtdgpXHHXBGce9cHqGozW0lzFqzWws441kiCyKWkBzlTF3OQQM8cVzU+g3uqSpO0l1a2cjNK1nM2wRYIHb5VznIGPauujl1O3vsv6vqra/1/Xr0PQ9d+ItzY3apY6KJbQLve4nm2DaDjgAH246ntXHSvZeItbutXv2jKRkMktyxiUDvhGOSoYccDGcHPArU0yG+GEs4Y55bgAWskgSyW8CYBEUkhCyMCRnBOOMCt4+H5beA6hr01lHM6KjwK5uXQZyFUsypnPJwOozzXRF0cP7sFZvTS9zRKlCWjT8t/y/IgSzW7sSouJrdWO8uMK5Xvtz93I74z7irUcJvImsrJrpiFCE2ZCuijgZcjC/Xr9K0ppPDkVykAt7jVLnYcGIFyFHJ5yox+dQReJp5fNt9DTSbYQHb9leRVfcRkLnpk+wNYc05axj9+n/B/I0dVyvZffoXtC8KGBHa/kkw2TsM7zMD6szk5/l7Vua1YTX1gba3vpdOAZH86HggKeV6jgjH5fhXK6b4vvhp4Ou6VC2oIWkC28gWNQAdpyc4PuM9zW7p2t3GoaQ0q2No2q4LR2Md0HWRcjBDkAHg8j2965KsK/Nzy+/T+rebOaSqqSbVu3Zfp95r6lY2upxOl9As6Omw7iclcg4yCD1UH+VZut6NDfRWn2aOaOeCMpb+W3lxoAMqr9wuQBwCRnpxWrbJIkMAZIYSE/eQx5ZVbuFPHAOe1LeSyQWk80NvJcyxoWSCMgNIQOFGeMmuaEpRa5WYqpKOzPN9cPimGQSiwjhd4oRGZb6KZorhnAYFI8fLzgHB7HOSQLFrdxC2mvLSOO9iFw1tAFDpGx43gtk7ueTsIHTvSat4mtNWkA0+0SfUo4oy9rGv+liUOc2xOOMMFz19gavfbj5NraXNktjIsAWWGLY7WzlizLnoSedx9Sa9Nc3Koyjb8NPxZ2UW5cvXv6fIghLahdrp+o28dgJbdwl5ASCXIAG4N1BXkN1yMelXdF0mDSmu9I0+C1iVtjMIjJ+83jG8licfcJIUkA9hkVnRRRylZIvLG18CPGwMAM5HbPYDvj6VBqWog6DPqMgk+36YjRWs0bldpKtyw/i/h6jr6c0ShKXux27efc0qUm3eJJ42jnnn0+CeLyb+BnKugO1osjaVJ7g8Ec9c9+K1/b3Ol6fHc6rcSvcXpEcf2ZB9o3N8uVCnOf4sjpn8K6W6WW68LeH725Bn1IRxb8jli6DeSOnbP1p0+tWGn6o8N2d0yRvHBcCAkleGEe8cA5zjpnA71NOtJRUIq9r/16E+1k6cVFbXKV1podzqkEFzcayYhazpb4M04ble4UY3AseBwc9K5vX/EM1hrslhDpkkGoy7ZUvBACN+GHAY4OR17npWffaLZeNdRiudDmaG2uIpEuIg7BFAUlZcdQwI2svfr3NYz64r/APCPx+ckekyW62N9bviONyQCWdWJyQArBgvOB3OK6qVBX11fZ9Px8tEYubp7r/hn+h0Nlputm1jtrm4i8rT2LPOFRWmLNnaUUZGPnBySd2Ku2VsukTai4FyyTOl2JmkdsFmxtyB8oweTxk8H25uPWYbW+gt9EsrOZkvVLRWUjMl28mVIViPl+UA5wQDgdMiuiuDrNj4xu4LYJeaQzvFJM8mCy9duT1OeAMHr2FayUl7r069uv9f0jWnKO2/9d/6/U5nXm11L6a212Q30d8vmKIZCfLiOQzIwGBgcHOQMEGtS51OzvrLSZbOa7ubbSGaFU+zFmkjOMJIAdp4/i6kDHpU/ifVHtNe09ry+mWzltnSC02AKqZBbcRzg5OBz36VytlqcypfWljeR6bG0wLPApDbckFcfxdsfzwa3hB1YKTW3bbt+XYnlSduv9Mn8Q3lvcLOi/ZrmWIBJGKHEPpyvUjpjkc1nWcE4iS4guIAyshjeBgNrD1x0Fd1pVt4VS1aG9jMinLLp0NvgtnB+aRh8hPfDegz2ritVti+rXUWh2EenWspAeLJnEQHQFiTz+PfFXSqXvBRat1f9f8A6Yyd/eWh9BaBdjVtKs72VUW4wDLtORvAwTn368VoPGWmHyLtwctuwQe3GOc/Xt3rkfhIZW8EpbzjAgmdEbPLA8n8iT+ddmwLRbQ2CRjI7e9fKYiHs6sorozzKqcZuPYgtY2hQRuwZgMZ9fepOM+/rUMqG3ELR7mVcI2TkkHv71YB6EcZrF9yH3GnrSY5/xp3FIfbrUiG0nt2p2KTHWgCvJENxK9PSpEGBQBTv50hidqOaWg0hjD9aa360/wBaZjpSEN6UhHfvSkUcetA0MP1opW6iigo+erjQXtvEZMr232S/ADLJKrFsnj7uSOcGtyw1CZpZbPT7HUL6aKbyQYLRmT/e3EdM5yT/APXqlqEmkm806KOzS1t7bLQGKNjEjHADMRy5LKBnPU1oRz6pNY20s1pdQXUbyNL5krxtGqAktFnr+XtznNfVT5mk5b/1/T1O/maVk7fj/wANqVn1uO7ZLO/07y76USbI548odv8AePcZB/KpGguZIbmbSTDNdRIkHlbwsUajnIToPpxxRp/iSPT7y6vZ9Wm1U3Mqx29vLEzwQbiGYjAILDP8Pqc5J4u3N3aWrX8k0FvDKqLNMkUhiEi84O1uVyRgkH8u9LmTso+n9MIVG73/AE/rzK3h7QV103GoJLBLPcL5ZlukLQ7kH8I/u5HUU/UtMhvNRWzvZr0WtvGkn9qSMv2e6lHO0QsuCoPYk8Lz14zLTxHqspFnHbw3SyZeFLSJ1/h4RQR0HBLnjGQM1Bo2rS6pd20mnov9sXERhsnuHV47dgMy4X+HPYkHPAz2qnCpdyk9Py/r7vIwqVFKyf3d/wCm/wDgnQ6okFpLAzSASXNwrLBaWqtDGyL8kioMsgyTzGMjkd6zJNXsH1ueC2mvr6YRlTBcW5WKViMl1cBnB6AKVAx3FR2UMel6RFrN3Mn9qW9vmB51KY2ktJDjaQzMGIB+XAP8Xbe0+xhn0Ma3HfwmO5hW2vyuxo4pMedndkkhQ+0gHPGCCMVneMNH6ev4fJA6jlKzdn+hl6b52vXf2i50CeO3h3M1zDLzCO+4ABpO5Kp24AJzV/WL+SC40X+0tIuLW4nUzWgurgGJ2GUVJAUO0hTuU8bd2COSagttmipp0t1rN8lrcXO2zl2LCsW8EqXjwNqdD2HAxjBxY0vXLme1tLbWLRrYbZFS4kUSK8pYgqwwdpwOM4J7GnJOT5krr5+f9P8Aphbmau/yNDTJrs311az3cLxiJJ7cRrxACu4JKx4LOh+UrnPtyKzNHsLzfLBPeQ4jkLWtuGGY2JJBVgMqhyOOSNuOnWLxF4hmhazjs0FzdpcIkyCSOOKZQpCo5PKvjGF6YyRzwH2NzLLcQXd5p07yXm2D7NGB5cD/ADDduAO8HIJAOe3PFJQlFNvr/X9f5mkGk7u91/X9I7rw/wCKpxZBfElk1lLF8peMtcK+P4sqDj8eat6f4mNzNcRQp5kyXG23lZPLjuUOMY5JG3JySADj1rzl79dDjuNM1LWFhtFbZaXYZ5bhSvDKTgKSuWHJBUYBqnoetabEblNUfWGnIDG5uo3WORfvcgMdpHrwMCsXgoSTklv/AF1/HX/MwUaTau7FrxfAml+K4IIpLxZ4r8RxOCvmSmTDSEZwADnl+Tnb0rb1S3SSLVZEuo2igRBcSwXAEkQIBDtnlCeucY681gatqVjrHmW9w91b3FuWnSSNmaaPy42csQRkooPOOpJweKdb6hp0tjeQ3bxz3csJdoTGFJtjFvdo2z+9XhnGeQRj5a6HGUVG+6/q5vGooS0a/pHVWNu9onzmZrYR7X85xJuAGclu575rn9ZuRb6RGzkNJOVdh1LFmGAf++hXS3CwzeEraOFiYmjEELRncAiRhRz1PDAZ9jXM3tq1/ZeYXUxNcwCJhgjaGU9voee+anDu75pdztozbTl1/wAjt/C0jzWVutyoK2oJOT04IH9azNd068u9t9pckf2uN1Rre6k8uCRMNjcVG4/e9QPXpVvwPZTb9VeZvKaeQkRnJ8tEG1PxbqfrUd0L6ea4uof3NjbRbfJAz5jkjczHuFAwAO5yeorj+GtLlf8AT/4JxTd6j5dDNOlwWvl6jo2YGkO+dVH+qmwCQfUHB57gVg+OVW7UXsUTi7jia8kS3GxnjVgBIkpGI2QrhgDkqF4wqmuis7xtK1jzreylv4Lq2LtBCMu6EH7o7sMHjqeQOtXLzSrO+gubO0uoLmCTJtnMg8tZsY8t8g4DMu0gjPA7iunn5JJy6dfLs/6/Edflf7uT6X+X/AOd1HVIrSxOpW1nEBqEq3D+SAqqJMZLMowAM8t098mo9DttQluLOaz1qz1WFkeGe2UmILMN2F2kb9owMORk9uorNk0y5j0S4mK6ilzYqReLdROsd754Yt5YO1gqldpI9mGKm8Nw389/aN5GoWLWk0dvcBY0WNcQ7hCxzuK8KQTk8nvg10e6qb5Wv6/roZKpezv/AMP/AF+BrakJ3bUbq6jNxp9rcbLQ+WqO6hAGZDycO+cE84U59K5Se9urGcyC0iuZZE3rCIwFiO770j4BGB7+5I79r4mvFstEluLuOecQyfJEoGWY9Og4Uc8n098Vk2MYvrqynvrWCTTG4mspIgryNj5QAB94Enn8TmlQlaF2jbpu7lVZrYNFf3F5DCkrMUuM8DH91RubjpwPxrptJ/smzgY6nbG6t5AyRTwzZIbGclOC2c/ebPtXFX9jPD4gmv7KC4jUq5iUSRs0XYDjjAHHT6c1radpGoXXl3yW0UlvMwhMsztHtYj72B2+gq68Iyim5WXr+H9fcaPVau34HffDmQyrqGzCwxsoKDGC55Lce2B+Fdg24r8hXdx1/X9M1n+HbO00/Sbe0sJI5Y0BLyKeZHzyx5POfetMda+ZxMueq5I8upJSm2iKQA7ge9IpGAB1A6Uk77RkAkghSMEdacgOWyu3BwDnqP8AP8qxa0J6DWQMQSTkehp2B9PwpxpKkLjCOetBwOp5p1IQcUANxnoB9KTHqeKdjHQZPp0zS/ypDGHjn0FM3etSkZ6/lTNmD7VIxCPxqEyRFiBIuRxjPNSv14qOaMzIAWww5Vv7tJ3toNW6kaOWYqVbKjO7GAaecYFOUMEUNgtjnAwM0jAenvmheYDMcjNFOA59fpRVxt1t+P6AeFeGGlurS3D7JH8zzFJZoysinG0kdRjtjuO/TOs7qDTfDkjadfm7byGkiiuSd8Y3gbTHkjja3Pb6GoNkekJbT3cH9n3EcscjTRTmTJT+HBJLKeDweDxyOjvEUqz3UF7dMZYLtTcWyrDtdIsjiMr0KnJGR0zkZr61K8/JnTJvrvb87f1tuPn1O4vbDS9YtLAQ6hbTo1ssY+U/NhQF4G3gjA6kfWrTXbX9hFHrcUJltwRfSSBW8oOxKoFGNrN8ozn5d2c5BAzrOzmtxfQraGQxyqYWjlIW7UjAZuxixyMAdau6NaxXsMv9sCC6/tKdQZIjhTKMgAYzvPBxgDknnmraio3XT+v8ylCUte6+Xr8/y+Q5LfVtNZp9Qu7jTNTu2f7PYIqRCUKmxWU8qY1GQM43ckE81o+ErC+0uxlgjhs47ppFmkMsTBki+VG2YOC43K2QSOT3GBTl1yG7026W6thNa2LbE0/zRbzCJXxgu0f3QxXCAlueehNXb5orvSb2NLeJG06RVa6u0Lr0wAVBBUbm+9j3FZ2k1yyX9dERFRSund/P8/kX/EhgbTHuDJYW+oSJiWSWQsw2AgxQA/Lkg5Bxzk5qDS9kkFpb2EUk2gTgTSQ3hCfZSwOREoIJLZBJHp74qpfz3H/CNz3mrWenzwwlPLcOGYgMqs4XoOvByRn1AqDUEhvrfT9SmurnS9PhBS1jljOEcjMc77ckqSw6+nGelEYLltfv/SKbSfpr/X9alvxLayvcWdiIrGTSBCkDr5kaPC27KszdVGeMjjrwe+fL/Z2kSLd3PmWF9fQXTmZZTdRGQ8IwKDa20FiccjcpNaFzq+nLplnY6tbS3F+YFD2YjKSynIxk8bS2Q2Bzg5OM8uK6I9pe2ElqQtjhzACwKuEfIV88H5iMchuueBmo3tZp/L7iZRUvga/y/pX+8uXcmnjUbprbTn1GTyba5uWt0XYhaIbfLEg3ZA+ZVB4BxknNVhpmkj7BaXTy6tY3I860F1IqGBSMhvlIZhg/MP4cdM81a8P3MP2TSNOguZUukZ7doptxbK7i6BmHJHBPbOAK1ob5FtLpLFbeNi7Kstyp+SUEdc87TjG5MZ7E1k24e6v66X/4b0NEk0uv9f1+ZiI9t4h8MOsUiLC8433NxGg8wBmUgcYEmDjcckgg5JHEFzcQaXpsFjdktavH5nmzAyWxjO7hJM53qpwBxnOOuK0brUJJdVbSRoz3arC010pjUq8W3OVJGQS2FA3ck4z0xn6s8V+NIh+wSxoSh8i5jMSbCApiYY55UcAdVBGeK0gne1tNxO70W5z3262vbnQrm88SSoPLjh8u3U74GzwTnOF6Z3HJ7cV1+jWy22u6nPb2cmmOsbrbTR3KSQ5Zsl1Q8DICsF4HzYx0rMFpaQ2U7WY0a00admtlmluiGnBztDAjC44Y5yB0FS+GdHtJNOMU1vp00Dss1pcWaSjzCpIJO4btynjkdDkZFVUs4/h/XQiEfeSbv/Xnd/kdT4rmvI9MNpaS7o0t/LtXKhXdtoDvjtls4qhDEto9tp8QUwwxo2M5xgHHPrxWpfTL5k9zclmZI/KjHPygDnH05/E1laRDNHa2/wBuYC7aHzZS5xsyd3P0FYUlanb+v6/U9CklFX8jZ8PTyWttrr72a/SJri3QK2xIchNxbG3cW3HaTk4rn7+bV3u7UvcFNIt7fYsAYfvpCzbt3ckcHJ7YxWv9ssLu60aa2t7tzLCwjlYusUStnczrnaM7gBkHr24qndpPJqFjHBMvk2crG6hyMtHIuA2O43Kwz/8AWyqStNya+/7v69TCm05c0l10+7+mRKJ7WzsZbJ3EkRbZIDygByPwqhoV1qjXk95qVjbaZFdN50S5O/z879x25wuAWw317munsESG3sIQyhWaTexHQc4H6VVvLNNL8270Z5bCTVHh82Z4y6Rg4UPj0UnBxzznsaU5Xlb+t/66MWKk3NS7XHPpkslzNqWi6hN9gvk8ybT1i83ypSQd0G7pG3JPI4OPQia/s7i105reyvryLfKkpVFV3CEAFUZuOmACc4xWJJeIiXcHidfEOqa39vkhRLKVoIYlOMMWXqCxOCcnitPUb17q6v8Aw5FNMv2iyVoZrdvPKS+ZgB1AyvygnJ7c8UWmmr7fLb8380jli0ly20EivvsupXVhdXsltfy3ixpGF5j3RBxHu6kOA3PvgVz2p/arO6nW2l1CaFAI5CwaJ4lPzb1fJBJXI78Z7gVNo90LDwhFawsNTvbJPtluvALxqzMzxMy7vkBb5Tz3BIIp+tyz6hGl3b3Fx9n85ZIrfe6rHbhsNIu7A3Fnfch/LGDW9Ncs7dP6+a/rU0jK613/AK/r+kV7NbyLRGtdPtgmmTBZC8RPmMjFSCzD7npwTnFMtZ0fxfbwWr3hOnDzZXlunkRGzgAAk/Pt44P5YzTfEd3bvaXctpdBJHt0YWbyhEwWGZSxxngDCf7XGcc2buT7dPZzWhi0+Szt1iWxjhMZuCV+VpOhAI7nJ+laatXa3v8A0+5Wjdral59Y1HTrl2tZ2QOpd40fqvTdjuBn8yK9W0/UYLq2idpkSRow7RyEK6cAncM8ev0NfPmoDWbK3nuLizjmkeQJ5zyNm33lTtx0/gH3s459as3FuDNHG12by8jH+vZzvkYHlt2fU8D6Vz18DCvZXt5oqdFVnbbz+4+hFZJlzG6uoPVDkU44BC5GfSvIfAvi6a1161sdZvHW3ZDFGxUKhkYgBmwMngBcngV69G3yAHJB55GP0PNeHi8LLDT5ZanFWpSoy5ZCY560HinkfiKqgXQvZWke2+xbAIkVW83f3LNnGOuAB368Vy2MlqSkc0Y/Oil/CkAmKMUtGKQDe/FIR/Ond+KT+dSURkZ4NNI4qT+tNYdaQxh/WmHrgHnuKkIOaZtAYsAoJGCcc8dP60ANwMf0opxFFA0fNH2/xAlvqiX67t9uswQ7AmwZQsrdR0I+UjdjvwaZLfG3m0QRtc2um2kBZCXDNF5rk7wuPmGcAjGD0PWtCz1u2stAtoTdm5l8o7JWtTtXLkDcSDwM4PXt6VhzWksLTtE0x022uEG8xgMqEkOqBvvKSRx39OtfZxW91b+rGktIrld/xt1+7p8jZ0K0nt/EKC4voUs5JGiS3hnCI7lsbNjZCgsDx+oq9qbw29jbQx6XLBZQ3B8wiEo0cnI3IPvE5H3j7DjisK+vBGk1nb6tYvp0rx3VuXhJ+zru+XyxjhgSwYHsDWlqVxcT3WkJHBqMT2wb5UTdI4QAowQkgoT3P05xSSbkpGlOaSagtvnv9+n9bm21jPcWxi1C10+/ETtJHBHK2JQQcZJbK9Sc9eo54xoW+mqmiSS6tbWlvpNyEt2MkwCbkOVHmZBJwOM9cHrXKW2oy6dplpbG28q4mk228F3IzeTDIcqyLjOwOHJHUEf7XOtqSrcPbSyxAWFi7PcWt84WQMR/rwmTlBtGWG7OcAHBrOUZd/68vmUqkXHTfT+vkW9V13Tr7SpRbyXd5DPGbeIWcfznjDbVI4AGBjGOB3NZemDU7CKCCO7LwSlVX7Rjznj24aFPdeSDkYxximXx162uVi0tp4BLJHI84MbwNG4G0I4x8uM4wMn2qnPqurSRyCQ2kkFiFE4s5DEwjOSGV2B+Vhj5lG7B68mtIwilaO39fITqRvqn+V+/f+u5o2ttbaWgCW5LvO72No6rHKcptLYDEHC55J54PXqPoFpJZ3mnR3pMbMzSz22JJFlU8I3z4fhmBUHO4qemaLq4S61Nv7TOmPdmNrqIbRtiiTcW2vgFzsBYFjgnGBiktnN7crqWl2CWdpE5LXP8Lr0fCKPmkAK89cHj1qrv0/rQt8lnH+vw/rZFae6jv31G3uzBpskSILKSR9rKzADawX7rMQCehALZzW6Ly30+O0uLueLVLzUwbQNDhvLBYMI37NtcdTyF6ViXNlJqFndXkssQivZEkAEYSTyE43uGGCeOcc56Ejg61q4nBLrcrbW6uz6fcxAmIRgEPA+f3gK8kcHIOM9aU4p27f8AA/r+mT1977yVP7S12S50601CTTnt1YSz3ZMfkTHlUyBh1YFgDjcu1iTgDOLPdQanDbW+vTO99DKATEplO5c8RlDzwATnjPerNudI1KXTk8NWl2Ht5t8tvDExUIRyJN7fKCFPK54AB7Y1bjS3lYTT2aW1xZq0sHksSJiX3K5TIIk2nbtzjgHoaScYuz/S6JhFyd7/AORX02xZtZhvLea3nUNNBqEFvEcyqvCrs3eWWKgKQoGMk471Z0+a90y4/sK5OmJqEg26dEYpYo1AYht6jDDOCVOcEgnkVQj1TTtFultLTT9SNxOxlmAjOY0Ygk4GRy2BkE/0rIubO61bXIpLuyvrmCCTypbiFmWVog2cKZPl3c5z3PpT5HK7lt8vl/XYmXu/Bv13O8+1XTny71le6aNQxVCF3MQWIz2zmnW1wETULy+RGOx3+8oJCZO1dxxk4wB3pJbaGw1G1gtSxijCxjed25QMjJPeq0YijKSOjT3ElusKLlXUkSswZVI+8C/f0zWFk46Lc9KTappRW5fgiuLhbG+m1FfsmqGC4ijM6NsZgAirhQACQwcE9cDk5FPu7XffSajKka3n2doZDEflC792Bx68/jWZ4OuLFNFtYLO5JjRgTHsb/R13Fs4OTnd1Bzyx5xgVrapG39i6miNiU2+5GX+JiD0x09cVmk41OVnLQezY28he3S1YnauFA9ywJz+taSXV4s9tC1vLFZtYJHFeswZGm/55bRyp5Pzk4+6CO9YrySXWnWSyMfOCoAG64wOT+NaVhqFxqdgIdksJtBuRk4WSQsV2kHjgE578g8YpVYPlTZrWi3GMn3M65vJbjxbJ4evmkVsh5biGbEzwCL5mlYDABPl7QOTySelZ2jvqU/hvV2tru3lt7WZrOfSpnZAI+RnJIyzDgckn61uXsNtDfX0ot5V1m7ihlile5Oy4QnIRS4CrnG7HIyBzyKzvEkiCexfMdlEW8rU3uYNgmVSM9V5IwfXk8HjFXSd0opdvw1289u/4nHG6JYH07TrfRzIfLhluITp5UbpLKVeNqkgnaQPmHfHPXNWbD7S0mpNqNvDFBcyMFkhfzEkTAAkLDOC2Ohx6HBFPNtf3Mukmw01VaMrMTcgqIEY8jIGQ5XDHpg8EdqzodU1KU6edM0uFIrlrkTWkjCIxspdhhuBlkG7OG5471Nua9vz/AK7F3UXdGN4k064s83FlY2NpDEfJluiROzRqo27UbO1ztbBGeSORir93qL6w134ovy8Es0cVlGY3yTI2VDjP90/MSfpxW1q9qFupXKylpY4wHWLzExuwHB5A9CTgetcfq14Vvo91pOLTTWaLz0I8ueU7Qwwehz1P4DtW9J+1S79/Lt8ypxjvEuWumSalcS2F/d/bLu3AuJQz/LEuCAC5Ax1JxgdRVXVLO30eC6fSZCojEcdyC2+5R5ASW29kxwp/XkVQ1KHTbzS9QuI7meTUJYUmvYYwDhQ+efmxkZUd/wADV6ScS6daRy2v2iK3jWVZ3twjXGMFIWIGSoIB2Zx39K2tO976dtv68iott6GBpdtd3Nsss1vJBGSzRuSS44+ViPX2r6B8KajJq3h+1vpmnaWQbZDOqqd68E4XgA4zx6mvFLY6kyGS6uf9JuSztDJjKKo5OP4QM9Pwr0H4ZeKoLlToN0+3WPMd4iUwsyY3FvZgM8dwK481pyqUuZa2/Lr/AF5E4pc1NN7o9AJJUduKMZ60pBC4Y7j64xTgO2K+bZ5wwdcEnNLRtxQKQB3oPbpTQecd8U4cUmhoDTe9O7Uhz/kVJSGn3pp6dKfTT7UgGGmMRnFPYfgaQ80wGEcYFFKeaKluXRFI8GubFZZp2s7lJYyUjEsgKpLHt+VPLXnBYM2cqO/U4p9yzWNwTo5y99OxIlkyiDGZAozgEk/d5yB04q1oM2mDw1eWepiezhlbEszzbYV8wHbsyMAlQTzzkYxilisNNtrS4uNIjvdGeXyY1luNsyshJCyKAcFuMHIBXJ6819T7Sz5WttPXb+tjs51eyX9f8HzsUore5lupri4TSbbSliJLvAq7gBkp8g3DJOMY96ztNSWbxBJe2azR2LgtKJ1wgCkKQTj7xwCP4v6p4ovBeM1vaxSQzwTeU0MoaMSsynbgjgk4O0VFpsV3a3B06yv7EySWcdzFEkq7S5YBssxIMmBjaD/KupW5bvRv8F/XUmc48++if9f5D9TTU4bzTVvHSa2mvC9st4iOkUZBDrI2Dj5dh4+vUDGtJDYCxM9g8FpZRXiyS5UORDEoGwscqWbrgjvj2OHNcX1ld2MF9rH9oTyyCSNobjdHA3KbyyghT1HAPAyegrU0yKybSbbTvsU5tZAzhLtgkjMzg/L0JCjGTjn6USW36fMmnaUnbr5+nX/J+Ro2l/pfiCzZIBZQWfllZEMZRFCncsap3IJJz6H64zrHT9OtdPd7phc2owm6NyqRxoWIy/XJ3MSeo6DAArptR1q61Wxgso9Ks4YrSYrPM5BeFQuDGEAwNwI+bceOw61zNva20WdGgsvLgkmacyPcK5kI6x7epHBBHUY561FK/L2+ZcFzWbWu39eXzIb4bIdPvbGKyezhcr5bIElBUcIx/iUnr1BBHWp4o9Ysr+S82q1ncBJms926W1yuCUC8qqnICjsBxVyz23+mPNHbJcwysAipHn7PEp2CTYcZjVuDjpx2qrJe3YuLiRPtqXqxJKlu0Kxy24B2lmViA8ZAJI5xntgGtb393qh1FGLund+Xp/WhZNzavqouIL69SDVH/wCPYSjfvAwJNp5HUE9MjPHasnTpL2XU7KTVEkaexd7uaErsEKqrPgqRyCFyGzjjHGa07zT4tc8UalBDcWkSDYiSvcqtzHEFzJtGRksTgZyQuRznmqYv7F0hfMtLnUHacq8z3RjDliVY78BgvyKOQud+eRxQmkrLd2MnJ38l+fp/WhPpfiJLqwaEzTahAryzq15dMGhTgF3IODlmVVU+hJA4JdLZTXNk2oBJDeWCFZtOiujGkUSgjzNoOcDjP3etUrHRIxpWorPb2IluG8wKknl5gBDKEcHCfNg5ZcHHSjwzp8eoW+q6fdWBa7EvnXDzXIdmTjhnHOAdvf5t1V7sbtCjzJcr6/12EvrW6Cx3Wr6WdT097ULHJbs0ZgQ9SSSTnGPmJIOK2/DOu+eLOytbaKK0KLBZk3SYuGA4QZOVkOMYORkjkZGbPhpkj+0aFFp0r2SxtbRrMFVpl3Es7HPGWfg4wDtHtVHwnpEEdj/ZutWLTwPei1Scyg7YWXJ2qvBZTHzgjls5I5rOpJOLUlt/W1wV4tW0f32/U2opo4porolZk2uwYLu7EYwfyx7U15rmx+yaczNLFBHva7mIYkYOUJwAvJG3HUeh6z+NUeTRZ5FkPnbJGBUAHOw4wR1zgH8amvba7vfDNtcG5hjvrqKMvBBaiRpFVPmEm5gq7jkbsZHHWseeLUZPrp/X4nZVm3yvqZDanHpsNg/hu1hvbAyNEBIG5YffUbv9YOqrgZ+ViBmunRoJbZZInMkLqEkyTjlflbkBh17jqKzZp9IsorVVilktNNDObO0njW4tlYZJClgTwewJOeD610htLvXbVdO128Noy5a21WIZiDfMuWyGZT2OGII59paUtdVvr/n5nPGTi7E8QzMoc5Crjn2rb027h0jTNQnuIr2QxXKKos4vOl3kcHb3Cj5jWVHtgv2hba4wSG7EnilsbuF2vdTEkscmnRnVIJkQloyvyOShI3DaSCD9adaPPHy0OnE3lTfL5fmUtU06C20++is7BtVtlme5hgklO7cWJKhPlO05YgAggk9TwX6Lp93Yo82lXGrX638cS6fo890T5PyglXLHGVxjoAAvU5pLBL3WLBLt5YLA3gYyRacyvE4IJEiEsSBjG5SQRjsa0NOu7i78ODVdWuGiu4bt7a/jkJQOihVkZGX5sHIbcMEZI96ltpWvf79/6XSxyS5W4tL0KixNrjWtp4l0NY7ze1wiyB1jJXILk55HPQ+x71Ts/Ewj1O5GpwTR2Q1AWkUrjCjAIZgcYAAXIXvjjmrWt+L5bXXLbRtSitbJbS4QrctIctCwOxhuGCNu1u5Nat5Jq13/AGmlsIreyuH8poLiNZYLv5C4kjxyu3v/AMBo6e8kk/Pz6b9BttaLf+v0/wAjEuY4DZTafqup3OoQTxJdNfWkW3EDnfE7dtgKvzjOCQQMCs3xE8EsMuq6RLDLL5cbM+GcrC7cDyzgBiQTknJxUd7LrHh+O3ZrO0vlCokrWkOVt7dTypIHyhiThSD14HOK6Y2IZZ7a8tzFpskA+y2flIuZjh/OO3lFUFhj/aPyjFaX9m1K9/610LgkmlLXa9v09LmHMjW17aXWlJYRNLZostwSoNw4UEyYGVUMT29q5dby9sZpbeeSW2ubpFkllJLARk47ZxyTk9cCt8jRbDWgLszR2NuVsWMaArt2qwZSPmKsvzc4IznHzcaeqoNRjtYNDisVgh2ySC6jLo6dx07/AIkc8jit4z5LK10+rFF3Xu9P66nPX+mQxSWCT6xpGqMWy6RR+bGY1PK7iQcnOcjoeuK9W+HkenyW119l01IJ7QrGrsis6RODgLJjfjhgc15VJqA0TWrfV5IrW2gicwwxWttlYRktgnecjJJ55P0roLfxD5U1j4jj33d60rxQswKCcMPnVsY46HngEZ7Vz4qjOtDlX9Pt0QpqU4uPX1PY8DAHYevP60YBPtTbaaO6tobm3bdDNGssZ9VYZH86JJBuMaqS/wBDtH1NfMtO9meegLKoO7gUgIJ9qSYBY3IwAx54/Wq0W6K3MZdRs4Dk9s8UrXVy0rotHFFNjGEHOffOaeR+fekxCHv1ptOx9aTFSMQjNNPNPIzTGxSGMI4pD0pxHBz0pp4oATHPNFIfwoqotLdXA8heyghgElxF9ojjjuWEDucYlUIw6/KT1BGMEcVSg1NImiRreBIUG1YliBKZ5wDjjnvnJ9TUGsWVwbnSiSTKqK2xXKoVbIyD0bk9DjpVx7xNMjZUt0nnjuTBC4kH712+VUK+u76Y5r6VRVrvVs9mEacE5SRn6zZ2V5q2lXrx7zOrRQpMoZW8piHOM4VB3JyWIwAB1TyrvU5Laew0xfssaSIbQwAxOu8KJ8fwqBlsnGAuM4NafiV7bSL2yTUirPYoloWj4TzZVLyNjHTdnn0zWT9suLzRYpNWt2n0b7L9pnS3mMcsrqfljPBIQnAJA6c5HSrheUFJfL0d/wBLHHLRNrcpazp0WqapeX6RC1tLO1V4Z3LBbkMR8zbQThVLFgOflxTrDU7ewuLN9Qa1lnEcxa4ljO2NX+WMrtBI4BbBBYd/bZ8J2umGwmdL8yXn+sFnbyKYI16szjkcDHPsOuai1bR7C/a7062dXuJY451UxmOIbATlscoCpGSPUnitVON3CV7L/hhcj96UXqNgtLp/DV9cQQ20N5FeeZGMgCQHCGSQZ4OM/LgdM49bWiWNleaX9ptb6KV9Nnmto5phmWRS24sMdVBb7x/v/QVlWF2l9qF/pskGwXEjTXEycIpzjGc8qOfm43ccevQeH9LsbLX7i4S0SHTkijt47mGRt6xk7XDqT3POVxjPepqtwi777/8AA/OxUU7qUS40F+95Ol1bKul+WYmeKYqu1o8FZE4bkd1yBkfWsrxfbCzuNOv98AWG38mG3uSSs4CDGWyCDsUjkgnAxnOKsHT7exXUrXQpJ1juUmntftgWZxKyfdRuCN+0DOc5xnOOZLs3EnhKwmubG3ub5MNc2sgLHIwpUf7XBJHPcd6yg+WcX8v6/r/Ma1dppr+vkZ+n39h9nutU0+MSmBmWSabmeZVjL4DFCSMqi5U99xwKrXj3+r6XFq+n6tBbJDCZXgXKoqJtLKCwDu2GHzDjqOxNT+Hi8WqPYJqDSaeYZYrOO5bZItwcFIc9eQNoKngMD8o6Y1urX15Z/wDCQCaPUEmkkNqYcRzKEUJh242jYODlcn3NdKjaV+35GMrt8v3/ANL+mWvD0OLxX1t5rK0DPFayjduvJcERg4UiUbwVIJAUEjrVsw2N/qck2n6LcWGoy+Yhn4gWBSCvmeXz8+/O0E5wCcD5SKdppV0kT2V8s8UaQYW4lVlkEspLB8qxBxyM8HAKnvWvpGlOtzLJcQ2VrCYXsora3cjywTlnYkn5nILZ9gAe1ObV3K4RhJtXMWwi16a1uofP26tdSJbT3SrhorX5spG3HJYHcBz90Z61vXl5e3VzfaPYW9uIxCsUlvBci1m8zaPnUscAAAnGeckUnhq3m0eS1it48eVAslvbwQGUy4kdmklKAls4GScbQQuM1LYSLB4yttW0+K3/ALKaSIzy3EgaRPNU/MhYb9uC4AJ53c1MnrJ221Xr/WxCjaP59TUNpGdG0y2W3+xXUaebcW4l81I2wcovp0PHOM1tqEKosMxWQRxynYc7VYkBufcH8qyLiP7P5zrJuMkwkOH3KBt2DGPYD9aXxFaXzpbtpsohgMP+kBZzbuxVOqyAHaehBxgD6muZx5rK/c65c0IRS1Kf9o2UGtWw1fTIxqeJkSWVkcy2+cFg68KxUk47YPY1T8WXEFn4oMtxqBd9Pljh+Ztghgk48xv+eyH5G46deam1qS4tr7+z9KhivJb+Eu9tN8yR+WuHJc4O2VcsTyAxxk5qKYXVoLrU30iO/wBPhZheaZ9lAZYDny3WV9wYox7AHHXjmtoRSal3X9enbs+5zSldXX5F4TXE8lvJd232e88oxzRMwYqynA5HBJAznvmptCTbqEiMyJJcQSW8UkgyI3YYDHBBwM+tU1hmttb1q6gfdDPHHLasBtJZUPIBzg8j1p9ndGzsba71OfY8Nuk00xBJ34HbqSSce9XKN4Wj2O9SvTcH2/IybJtZ8LeIbfR59Qb7NHhVEqhiwwRvRsfdJ5GSTWhqd8wuoraLUrm9uUgdrjfaqsAkbgeftICxtlFDDpyTwasadoX9o3mkw6VI2n2lqZGezltTtZg3L/NyoYkcgkYxjpVrV9Mkt2bVYdYihtLW5W1u7aUkp54YYjxn5TySD6H61LqU5SV/i9P+AzifLyrWzIX8T6fdWlno/jCea2lt7pY3tkjfyLpAoG1pFBO0evXHpnIivdXi0q/GmtaloDLJaRqn7wTwYG3bJ/CcEDPP3SCARxU8R216+qX1la3EmoQx4yFtN3lYGWKv0znI+nGaz7R59V0kyactp4enhukMdvcZiWdmzsCuQQrOd3HAPOcCnClTS5uj+5N+W/8AW5rOCpwU29H0t0/4OpLqV/c6i+iQT6w0ekXlw1xArxC3wY4w0XmyZ/1gZtvcN8p75ra0qDUdDbUV1XV0u7JszRSzIQyEnncex9cZplzpzoDeTXEIkeaKcafqduJLW3dV2qoAPHoWGM8EmmyXFrqWkalpgvzPq8EbSyR+R5THzHOFWPJB27lxgkEEdO8bpRW3XTz32/EyhHklr1DUY7PV7yzSOSxja5ja5giaIOX2kLvLnhc/dVQCemf7o46WG1vNOiXUNYuYrhGEck4iJUFmZgjxADp3OcD3zit1ZLJEg07XZ3ks9Nv7SSGeGHaZN+cs0ZXJUOf4eDuP3uKp+JbQLd6nci/0xxDeQtJG8LIu6RW2bWQfvWYo5O4D7o7Zrak+R8t9P6t08w9pf+v67E8i6fJHY2841IXUE5/1fyxyOByNxG04/PGeagv72x0e9MrWF7PNKgxGLgqip2OAP8+1OcOur3jaddxXNxeuY2iScrHDmLflHHBIHUD3Gc81gWqrdWsLaSl1c3bzMs73Un7tcAYOR2PoeTW0YJ6vb+vwNoyTbR6x8Ltejb7VYXUyRxNJGLKLJO0sCWjHXHQH8TXoxrxHStdPhjUIJYkgklkBR4idgf12k9Dnp+Ven6P4ih1SCBrL9/M7Krow2MgIPJH4GvBzHCy53VgvdZhi6Np88VozeIGPrVW6td65h2LKpyu4ZUn0Iq0R2zSHpXk7HJFtMhhDhPnUKx5wG3YNOzhsEceop/f3pCc80AJ7UYo70h7cVICHOPftTTuzjAxjqD3+lO/U0hpDIznAJGPY008cVIeOlMP6UhjT79KKXiirir9EGx5TfrBFDZ21+sttJ5wt7VzxljghMnp1HtzxzWVBNawXGoWuixpFrFtKs2buLzA05cbpQOegB+hIPOatQXFxJcQS6hBa2lpbzqGjuiGDxKcgqVOBJnHH61i3ni+EyYt7aWaG7nkg86NU3O67W2gHlhllGfyBxz9DCEmuXf8AL/g6dDtlPZS2+f8Aw5nakw1TxPNo9+010slsFSZRhhPkMZsD0+Zdo9SPetPVdSt4NXGnaMr2ukW0SzXCy2+37TFsBJye20kD6kgVn+K7qwt7g21uLm0vlMj7oWDKsLKxZTvIO5yRk9cZHtVbUiy2C35hvDa36u8Twy7x5h6JhuiqGYdPXGeo7Iw5uVvbt/XkQnyyk3/X3djo7m2uQ+kXGgx21vHOn2UJHFkmJjuJPfGNuB3J57ipPFF1c24QRy/Zke62HyIT5xUIwbLcbwCMls8bsDpxy+nX06m6sb+5vo9NizCjQInmQMMEFnzu7f4YHFdB4jt7fS10+8k36xY3UMbW7mVzIJhwQy7sBcZB65Y561Lg4zSe+tv+HNG+uyv/AF/Vzb1KUaZpcF4FOo37zxQylgfKaIYQyORnhiR83qfY0y/t5odSns45w4Mh2AMNrI43K34grxWEksMGuHyLdra0Ei28SB8QtLISzOAT8y9drEkYAI7CuomdGuLKVYgroiQyMTuVlUbVfHXpgfgKwadNr0/4Y2otpsoaFf2+ia29nZyMbi5LtC1wu7yt3JCjodrEnHpWjBo97o2mQWNzH8x3NH5cxlWbHzFlYgHdznBHUHGQRVMarHZ6YCLKA3MLsIZ3UF0BwCB79efQVFpkNjLcRW8F0sMb2rmRHkkzA3WN4wTswGHzAc4b1pSi787Vu/W9uoShKElO2mxYS7jtreTV3cpI21Jp40DEEcJJg8ZXcecHj15qbW49S1Dw5DLYHyJGZYZLuEH9ztPPI+7uzweB2zzU2n2725jt7lENtdx70bqGznK/XORj8K2NCZdPu5kkjYWk0YjlRT0GMbh+GKKk1F80Vdr8uwqqWvKefajYI2vpqniO5e1CSCKG509SQo2jYkpPAB+5uHGS2fSrWiQzaNrEtlqd7pyW4gW8gSORpCYpGO7IY7iwwvy4zxxkDNbGqWF9Lp2p6XI9q9+bgwafIwCC8UnmPPdyDgrnnOeDWZNpUbaLf2NpP5yLFJCj6sRJJZTxhGZS4XO0J5jA/wAPI5zW8anMkm9Nv+D+f49Tk2lzROXiM7Xv9n6oSD9pnvJHVmG1JFB3llBYfMqkY6d+tbMdwulvDeX+qWd1DJBHJYyFGzKvymRGcDdGF5I3AnJye9bNtpsN/ocCX7w3RZIYr1LRwJJFI3oUOAdp4YY4zgEVi+baXVzbSWWrTQReW9vk24aSNh8oZ1OOSCufXBx3roUlU0S0X9dv6QRhyrc6WPSod9xeWk1xDDdRJ5Vtn9ygwGV1Hq2c+2T9BviaKTTrcXGI5vs6KUJwUkB2gg9eSBiue0G6uvsd5b34iU2dxuDrIXLh0yxYkkjJ5568496/jOziu9R8OTYleSWT7OGj6REMr+YexIww2ng5PSuNwc5KEn8/kbSl7it3GeILS00zUYDPapJCIY30+1jLbgygecVPOeFBOcnPIqGzMt3qaXtzMIbuIQyuttuXz5FJGdxwfLZAQV/2ia3JhfX1+8rTiKG11CZZI48CRrYjzIge6IzbgR/EFArASSY62IHlZg4ztYcgLwT7El/0roo+9Gz3SHSjGas1/X9I3rwRyyW6rG0aY7t0zgY/lS61pd9JaSyWQtrmVZwTDcBikwRslPl+bfnaRyAasTLGUjHATYkIxk7SWyc/T+lO01UvtIubTU3msftcTs7pgPEMYLKDnkKeevXjkVjKTUVKPQ0qyfJZEHh60GmTPf6Yl0BDC80tirrPNb7gu+FBkKdmflU81zmjapAlzqb3Flf69Zahdrdz3SWoAjGGIOOnmDbjbjjJx79LrliNS03U1uLMT3cvlyW9xG7KZ5dihCxBH91PmJ5zz0yaOnaT9kS3vHNoLe+cwSeRLuH2ouPMEKgnGCTubPBIA+XFEJJpuW7/AOH33OXkbaX/AA5xkGoyXNhdw6lrF3olkmrtfIBasDHcMDgB1PynaCeFHJrsZdHcxyalBp0k2ovaG3+xuhihuSQSXaN8FJT1GMDOMY4zV0y8sru8l0i7stVsVv2Se6lWESRo5JJUEqRsVRGFbGSMjpybdpbC4iXT7BdRtxBAqRXcxW4YMGPynHBx36Dt1rWpJ30Vv68v+CTS2a2Xz3OcsXSw0m+0zxJa3dvpaShIYr8GG4YkZKtHkkLgZ474I9m3J1DStV1KK5geC1vbdLG3uBFvaFVKhHRlBYYGFKggcnuBWgTmeysr+bSbjVFK/wClLdSQGaNm+UJtHzsSpyq8djk4ItJq0+oXN1Y296sUukr50CQw4SQhWLRsuV3xtjHb7wYHtVOT1k16/wCaKUls1f8AMbZ6S1nq0yajqIuI7i2AkgjZmV8gKSo6gbunfJ45FdItupmCSt5ltK0bwJtj2xvGjKzsM5Lnu3JG3HArMvoYtVsNA1eyZ2ZI/tdpdN0TIy8f7vgsrDaQVzx261NLZRXOpR3UO2Oe4TEwQlXkiLbpBHjG0ltu5gA2OMjqeacvaWbf9L+v0Li+ZKUTiHvbDQdTTUrGye7TzHhhLxCO0uQyFSyptUgru7YznsODe16O306aC7gezsYWd0FqgbAk6bsDquASM9M981trbS6pp91pRvYJL21iezmuIIcCOUsHTyyBztxtbvyea4nWo4hZSGW4kMlhl44rjJeUtsVgCBgkYzz2rspNTku6/FdBxSTvsjqLHToLTQ0u9ZuhfX8pLxSkDbEvHTjoAc4GOtPTV5dKST7NF++fA8zPAHcYHfpzWJ4etrWOO9kumuFlitkdfOO1IjwfLweueBnjrW3YKL61t5gyyTudxEeCqqOc/XPbPaonFRb5tUdVNxS5Xqei+AdefWtNfzxItwh+ZXHI/HvXT8Yx2ryzwh4lTQVvLe7tJpo5XEqyxlQQMc5zjPrXpOl30Gp2EV3aNuhcDBr5/HUHTqOSXunmYmk6c3poWOppDTj04NMJ5IIOB+tcNjAUH/Ckz0oP60j56CkMU9vSmseKFPHNIf0qGMax+tIT+NBPFNJ4oGHf156etFA9cUVrT5ftfp+oHy/c6dqukQJdzNJaRWpMEcs4C7XByTEmSwZsfeIHUn6WJEdtS0a7hi/0iaJxcxuAqRSs7AMcctnKk/lW/pd/FqulPJrkbaj5LZjtuIJSDgZPY4wBkZ4A6Vdt7nQPKgk0yy1G1vl3NDd3rqI0bB27wSQQOMYxkivqHVls46+W3+f4HbCkl36PT/M5/W9N1R9WjluZ7OVrdECqUK+ZKg27ZNvOepOTjHcdKqC61HUpLqBGUNCPL4IW3QuwHyhj78Z610OmzWstwsniK/ZmkGGbTYFWR5C3LMQMAY/hxz1rnr6zOl3z22nKcvd+QilgHvUYk7mXnG3HHHBPqK1py+y1qvuKceTvr/X9a+SNRtBv4baK0jvrO1aJRK7zshllbkDA6sBz0zjvxUcGswXcS6dfIbd9RURzzTu37mNOjxhODuw3BB5J+tVIIj/wkSX+q2qxjb88ys0iWY2nYrdi3y8jIPPrV+406VRPf3JFlZpGIrSELtL7gWMjk8lARwORyPxfZS/r+nqL4tb21/D5/p+IzS7DRxY3GoW9z5lppgNzKLhwouMnaIoV7gcjeSQSTx69dpEtqnhvT4w1rZ2sp+zqpmLsj4JERY85JP0AHtWF4YQ6r4R1uxWz07UdStbKEo9y204eYuqoSQMYIIAI5wOc4rQ0CbUo9PivL5L+eS4h8p7I2vIl3nbLvyqqOAMHGAeM1y1nzNpvZ9/K/wCt7/IypSs9Py+8i1u3uDb2iWOzzFJ8+KU45IIxnthsVe8KPc3kF7aWkZF5KgtUWWRVRWV1MjgcggYPTqDgdasTfvLeG88oWk4Ubk37lIA7DrgY9TTfD1yGtJp3unsob5vMjeAlZ4ocEnacYBPIyCOSKU5t07Jf8Pc7Kkm4O39Mg0++b7DcxSyi6BeSTzFIKlN5KshHXjH1960NP1VtT01ZUcLOu6PdnO7jg57hlKn8ax5Gis1tZFHl24mWKSTbkIp4yMdt20E+9OhQ+H/D907qHht3BKqMtGhc4J/3QSPyrZwi1pu2VNRivTc0JdVME+oR6lH5mlXSK13GvBSbA2TJ6MDtYH6jtWjr+mm7ntN2pXVvtDv/AKMxSW4VlAXZyPnBA69iRzxWTqFk4vWuEJZUQQXEJGVdCMo4P4n8xWsbZ9S8LzYuhDqNhPutZ5clTk7grDup5BHofpWM1GPLOGnT7/6+63Ywqw93mX9djH1qzi1OGzu9GtZbh7O5KTWcc/lpdQjAWNRtH7wdBgAAcqD2fqrwWuvLqN1ZXDKlmlndZ+aW2OQ4aZAOQo+Vm9QfxfeSaNfW0d0Lv7Lp10G+y3JnZYoZZCDskVV+ULL/AMtDnYWOewrPkvW06bWL24WLRtYgkia5W8f7SJRuAbcACGDZYbsYOR0q6d3p/WrX9baHOnHV38za8MxR6gbq4iiSGPUXdQSRsnaPo6nGd53Fec5xxV1LuSbw5KxVbaSY/Z45QcYkbhBz0OTWNbIv9t2dkl5YWl2zSmxt9PuWaIdcyeWeY5DhAEPcZwKreJs3nh02d1eSrFPMq+aE6Py3mMB2JXGPU/mezU5etv1+/wD4BrHWm2un9fib1jdyPoOlSEMl3JBtmmli8uV8YGWHqCD3PB4rHtLfbMk7Oq3Jiw7k5wS/I/DP6VtmJd8ccJiJk3GURnIWYkM4I/hJZidvbI7YqqsAMyCJcPvKOue4z/Udaqk1FO3U3o2USaeRorpJYVZEMvRh+fFW9ct7B4f7bkjlt7y1hFz9qgdg3kr99OOqEEgjvmqHihimhk277rjySokH99uM/mRU1hqdm1vaaGPMgv7K1Vis1u+xownzMGA+ZT39T2NZyTcVOP8ASMarukNuhH5ekQW0Mwspbb7Qk7yeWI4zsEcSg5yxEnTOQMYzjji20oWn2wXpurMx3Buba9jU7XVWJKlk4y2em3dkYyRgDuIte0qW1tYZbwSxtP8AZ5kRPMPm5+TdkdGHAIHpyBzWRqsbTNqVvaDe8cawNJdvLDBbx5B86NlI7dcsDu4PHB0ozlD3ZK3/AA5mpWWu6MT7X/bV/czaHdXVprsEbSRzWdyVinlOD8+QPmIOOcH5cEACuj1ibUpm0rUnkjfUrSIJfsqkCQshVyQBgE/THOR6U+58OWcMUGy0jghtQHhdHaIhgc7mII3scY+fJ7ZrL8SaXfHWI9U0q5ls7q4RCQVwkskZymSeBx65BwMg1alCpJcum+/9bfkLka962vkaWnabpn/CPrbW8McVpDNFcWxuWAJcknKFjuByCDwB9R0ztFmkW0ttJvdH1mCSAGKO+tokke2G4lf36jhSM4BHygenNZ921t4htIb3U/Dqu7qC4gkxK8quVdRGSBnGWBGAcEdeBZ07Tn8N3F2RqrRnVpxDHPJGzGCRSf3UpB2A5+XIP98EYxhONk+Z63/H5f0xOT0a2/r+vzNyOO4021SyW6dXlYSNLkxwtJkZkZUP3jgZz16dCRXN6DoF4un+S+pPbzw36zWM8ilY5upcLznDblIxjO1h6EXTq0x061FteLeXj+YNiyK2ZM5XazBFdSCMR8N3G4DFL4V1LVoYCniFXs7TeTaolm0Ub89gABt69ge/NJKai7b/ANdLf0ik4yasjbufKsptC03TbeWO1JdJEiGRbqFJy3cMzdWPvzmsiXQ7rSdbF/BdStcTyGNVaEPGrYG0gk8/THbvitnSrgz3mrQpPO1xFKqPBMylgduUZMclG7ZGVwfxytQh/tDw3dHUZntfsUzGSRS2WQng7mGSBnaGxg5JFYwlKLtf163uarTbYyrux1Cy0jVZtUu4Ly4lyIopgzE5b7znAwSOnOapW+tG3gjtdKtXCeQ00m7CxQSbTkKcfdzyck9cdRVnX31CCa1jtljOnwwKV03zRI0mRgysAdxXpg9BnjuTm6o0cmq2V3f3lxavKDbC0SECPaoChhg7djZ9OoPXrXbTXNH3tb/1sgUra9TqRf2t5oNvKZ0QJEYf3n7vcR99zk/KuT37Cqvg7xGnh/xMEe4ePSJpDFdR43JE+PldcZ4OQcjqD3rJ8Q39jFHbWUqZt5I2DsqbEVT0Chev9Ks2VoZtRmQXCR2rIW8pAMmT3yDnHT9BWTox5JKa0dzXlcouEtvxPeSQVUghlIyCO49c0098V534C1z+z2k0iczTWQwbdyoCwdd+T125wcdua7vTtSsdUSWTTbyC7SJtkhibOw9gR2r5vEYeVCTW67nm1aMqTsyz9TzSEZ7dKDnNNbPSuYzHYpp5zSjpQef61IyJ89vx5qMnk89fSpH9fWon65pDQdTx344opB14NFS6dKf8RXK16HzvDaWsgbY6TyLm38hmySvdf9rngAHOT3qrcWs9ppEk1hepBEkv2dbe5UPJgsSoc4xwA3zAdgO9Vbu5e0gsrOKwMcrwsZMSF3kkJ25yOy44A71p6BZEaWlpqMDyXO/MJA3BcAkEkc5xngc+lfbS0V2d91NtK6ffttoWBJdbbOG7jtJTHlHmtoQhZskgE8BmHr3Hc0zzEHia2Yxx2kcEhtZZSfMkuWRAS5A5CgEHp09T0zvCTs19Ld3lxG1lA5aaR8OgXGCQpGSfmBHQ/jTzCsdhf3olMmq2dzvBWFt5TO1kfPGQMMpByADycjCcUny/1qRKqnytdP6/rudfY6C2o3MkeyxaOJvtEwE4dGTscDJZT/Q9KteJo7WW1WLVZ98qKI1cFvmhOQR9B0A5I9a5exv9tzdvocUsE5RGn8lQCV6Kdw6DnkdM9qoJq93cPsOsfawQHYW1vnZ82CWHU/5NZ+ym58zei/rzNZO7V/Pt+pLG+iX0l9Zz2t3DpdtJbKXTG+TYWQZz/D84yecAZx0FdV4Ru9WWxkivHihnS4ZkstnIwxIwGOGXOev51z+uXstrfXenS/arSOO4UNLGhKPGwBQH+Ipzu47cd6teFbeax1PULPUtPV7gunm+Wx8mc7sJzztJ9MZNKrFSg36eZzxiua39f10XzOnsjaQabPHqml6VpkkrtJAsDBpIRsyWYLjduA+VUXgAk0sS3Q0Hzb/yona68q1hj42wqoPzKeVck5IPoOKz/sEk19dzWmp6laRO/kxWpXy/IIIHyMM5HYZHIPJPWpcq9xeXbKZ/IQRxzq4aNwcZPAxuyvJ7jpkVgoJvf+vn/wAHb5mlGDukQ3c8dilxeuvm+Ra5MXYYJI/HLE1uapIsLWmBlLizieQYyrEjBGD1BxVEWyzWmoLcKoUW5ZyzfKwHXn6c4oUsbaQBC0iWx2qPRRgY/IfnW1lJp9v+AdXKr36DgwiEDQKUXaEUE8LgYwPbAHFO0zV4tOv4NNv03Wmonyo5iMqkmRtDD044qGOeG70C2vYyVQXHkZJ+R96hlI9+q49qJ7aCezCXa5gZg5U9mVwSM+/X86fLGSakvInSdO0Rbq+KyyaHHp9re2UtwbqznvIzJa3CY3TxI6NgkNtOQeofODiqwFxqcNrb6sE1LT7pLeLy4gFksgDyWOMvF5gIUnOB19DoSW+k+FL2W2083DSQOLhbKIM7qhfKTkewfacHJVRnHFZVxO0N3aWtvpkYn8+UFLkKXkjBY5UHOAWKnAJ5FTTSn8K+f6+XQ8+MHJXe/wCGpVZI/wC3YbhtStdTfTpktri4eJkmiiLD95gcZBJAxkKOpzXV39p5GoPZTrEyyw+W6A71ODkEH8CQfpXMDWZdI1e5l1G0jjFpAYJbdnMjSyMBsMeDgBuvU4x1rWTUFtNHt9Tubqe+S3thtaQ5dgyZAP4nGfatZxk7drf15f8ADm1CSTaT0sWtPt4bfxXdSON8V5b20qgMSjsqsA+7vwAM9SQaereTeFV3fMc5bvk4z+Gaq+HWJ0iwsBsU2FlAymMna3mNISVJ5IGMZ9c4yK144F+1h3dAvCkk8ZJArKVk9e1jSi0oczK4XFv5bb5DuPJ7k8Y/pTdSuWvNVhjFyI4IJJrRLpJRGLd1wYto/jdS68Hg78Y44ndseSyvkiRizEdOOPyyKx9SWXRLzR9miS3UF9cCZULlxLJzuO0Z8pl3blbHRTRo3rvqTXskmQ3Gpvouk6LbmzW2urvzvtszAbgiuRJIXUAFiEDKccDHXqbnibWLK9YWeklbjT9TgLGwZMM67eqt0DHgj0Pfiq3iYx3ejhmtrrUxJDCCqoU+0RZbncMlSjIQeMfga0LKfTNUjitfs17HLDbfaUaBAjtAcqY1ZRkHIB2jt9DVWikptd7/ANeRjay1dznXGm22t2+tQ6rezM+Zn0253rJGoOHWRVkyoUjpghhj1roIoLix8EPbaPf2/lJJLcw3kpzFbxn5wGPPKqpAyMEnb7HBvNMYG6uNTsNRg0G4QSZtBumgxkHzcHcykAE89OT041I9HeLXh9j1tZp721X/AIlz7XEyYHHlyBTJGR6jcCCRnBqqnK0tdvu+duxnFWfn/X9aDZLrXH037FPYabPqsltHHNp+o3Cs06YOZFMbKyt0JHykZ9qle1Nhp4Xw/LA9ukoDRLcpceWjZ8xS/Zsnr1IPJPWoPGEreIY3urBLcXSxvaRyyFYjHIVYSInmYU5TccEj1BzgVBo6W1lpUl4lnd3cmlWKTy3tjJi0u4gBHtZTlTIvfjJ2sc8VK92Kk16r+n/wfkVGTjJNlXV9Uu3udUtNIt7l7ucBysuJIzCmGLBGzubI4GDg9K6aRwk0m2SaGSWQxxCYNJGSysFyDnYGyPm7H0Jqtr8c1/8A2A+n2eot9rYAQSP5TQEgMHz1+7k/N0x34zZ8RNqFhYWaW621q1xL9njlvo3eC4SRWVkIQHBbPQ4HuOKzqSjJRUdL/wDDfp2NnUvdvXQyZ7qfS9M0hdcR49TWB0uLrHmGXyzuXp83Qj5+g2j1pfE8Gp33hu+v9MRprmWCG2WHCs2GlLOSQdrZxGox1BNblq+nQ6JFFbNAmnplVjE6mIgt0DFiMFsgAk5yR1qSxghtLY2mnxJaRRq5VY28vaPlxnseecnrWbq9UtU/1/D8R8rlDluc9d2N7ceJFL6cmqSSWCWclpuWGR5WAMkazsDt25xjk4wPcYmpSaboHiCaxtbY6nYzk2Ua+cW+yMABJGkmPmZS/DDgj1zgdbfw2GsWep2E839oWtxGLyObaDtIID7ZFBDHIOT+GOK5jWbeLQbuzWeaKwtZbqadILOEuViKqFd27AY5HUZ4B6DahO8rS7ba+v8AWnzsZuLTUtilc6G2pamGMka6ZbKIraFXLMoz1cnq2efr7CpopE0e2k0+0JkuSzOfNA3jju2OOe1PutJkmuBd29+ZY5WVLZEOTbuVBOQOD1BBBI5ycc1JrhvtIt7gxzB0iAllnm2vgEjAA5y3fJHTvXQpKVo3+R1U2lrYqWlncaVoZumDSvdsVuR8xAhxzs5G5i3BPQD1FW/AuqxaLrVtfKk9va3TiOZd4C88DcD2BJ57Uj3eqaLoL6o1ys3mAoZo8S7UZcgHpweBnpzVH+0G1MbxbXVuRbLIXZS/l9SC3pzjBqWudSUtUylyyvB9T6JYYJ6UhFZ3hvUX1TQbG+lDCWaIF94wd3f8PQ1oce9fIzi4ScX0PIs1ow6U00pNNNZjGkjvyKjdelPP5fjTSaQIYBzjFFKaKuMordDsfOMd0nn3lkHa1vlIKtKu5EAGct6g47f3h1ps1pqdnqCRfO0d5ZJdywwSfNbxschgQfl5x+eDU9hZ2zy32o2Atv3YJe1WTcRHzuKljkkNx9SMDFLu1KHTNNukMbafcQSQrEIQtxCFILIX2gkc5yDjrwK+v5tbR/H0ud0pSk1d/wBf1uGpWggt7E28b2y3CLiNwssCjGA7t13EjPI5xn2rY1wavq9h9tbUFuZ7KNPNjQiNZEBwzbcDLgkYznI/AVm61dyyadbzSRvd2UeLf7PcZVXUHcA7qVYqfrngc1FpFj/wkPnw6nqE8DmYNFdOFZYAFO1cAjcOmMYAK9KTvyqcunz/AOD/AF1FK99ixdWd5/Z+n24e3l1DVlLLKGKeWR97dxggqR2PQ4wepp8Gm6noiW8MSRXBiYvLbRBBKGyPLbIHKkdTk9DyeaTTbi5tdQ0/QtR1m2+xxAmS+QiXyvMf+Fv4lAx8vBzkdK17WSN/s8whFrA8skk1vc4VchtvOMYRgMknkc9QM1MpNLX1/P8ATp/miYe+1f7v60JtWsI47aZ47q/1W5+zLEYJvmZlC4CBQPvA45BJIP1qnpFib2zWO1kezurZktmtrqNpSjD5lQAkZYkfd+8CoI7U/XNNu7mOWa1jktms8TeTHKQ31HX5QeM4PBojmF1cM19HLb39z+6Mjsr/ADph1kCt8sqjgFiMjA6cVmrqHuv+vT0Ld0tCO1vLeCa1jfUNQRXLMyyObhH2KwKFHUMrq2Pk7gDrXTW1vCNesS2n29nLZttuPsjsI5Yyh3Jz3LBTtPHy8cnnnbyXVdRUm6bzGeU+ZLEjQzpLnhwoxjB7gkHNTa0zW9ti0uorWMxMyuW3u5Z03EEcEcncMccdKU4czSvZvT+v6+4i2lyNrCKxe/sYnkbShZeUjzH5sCRyS3vhs/lW6SI7xXQnYY9p4wcMM/nVPxbYK2qz2EJCKlyYx7LsI/LmrCBlCxygCSNUVs9toxj9Ku/NFS7/APAOuCStbawvhiG01Xwpf6MUWCS8t2vYIwGxFJE45B9QccdcZFQeIPtH9gCaFmBiP2ghMZZeQ4+nNFtc3UCXt3oqTS3EdzHZyQZ/dxkj5pkHZhvwTxkfnW5JBILiTTJwg2uVUg8r8o3KfUHKkH61DlyVHLpe/wDn+hzQklKX9bHPySXg8VyXS3Vnbxm0geS6PzSLbGHDDHRkB+cEd8ZyOiSWkuqDS54tWsVfTHDq2oS+X5qyRr5S+Y3RGAY565Jxz027MWhsrG9KwRYgCi48oNIIzzsHsD29R9az9Bit2N1LeI2oA/ug14qvvjLA7SuNuAQCBjAPIxTT0bStbT9P61JdKUk7IoeJJL+XxbFamNbV7hhbW1wkBbzpwFGWZ14iXBCkjplhXRpZxWN89okcVv5MZDqDuWE4wcZxkgseKyNA1e5uLgrNeMdNtIpIBdTts+1vztiUDCsBjj3HFQ+H1e4d45XEk8lrbTbSeu/c5+mFKA+uKtxaXK9EkFL3XZs3bJoIdJtLUN8lnF5bysxZmAJYEn2DHA7A1Qjll1nw/b3IiMQaaOSNc7SsQY4Yn1wAcd+lKIIIVmiwSsxd+TuLs3Un1yO30FUvEbRNoY0wPKs1yhjaCDaTEq7W3sMgqpHyg+rY7URirq27ZtOPLHTqaFj5yW0B1BdhLSSGNJGkC72JVdzdccZ7ccdq2rS/s77TzNa3kM0FwQscscnV03Hao6g4BPvzXIxG6nt9PgtwsswkVZFO4KWVdxUleQpYYJHQegqewtYr+50zVtESXTrYNFdKqxBAygSZj25wdrO2XHZhxU1qae7/AMjKq3FqCLE8rWmpa5Jrt5crpLpb2lqoDBiz4LOpUbjtyxbbngng9Ku20N1ZWGo6bHLdXuox2yXdldt926iYEhlOO2QMHuATxmo/Fer2rS6nYi2nGprNCI5oY8gi4QKjEE/dDFc47nA61L4X/tmzsZ4NbZpX0qKKKO53Bg5csZc4wSqnauT7+tZtt0+b00+7Vfr6mCb5izbxTWOq2OkzvNNqMdgbqW5FvtCogyZHKk7SRhcDPP1rkbKGyudEtLiK706wj1Ga4823UyyC5nU/upGmZiwKkAjGOS3A3GtNYrjxJbp4e12O7ktLaCaVb1o2WQTxvlPmB2sPLYjJBPWrNroNtJo0WkofsflpKkUEc33ZW+V+Seo5JOM4PTmqi1T+J6+Xz1/rawJNy97p/X/D/iZEGoahe2f2QfbbWCVzEmpWRyBcL8xYqcHHOCeAc5BPIq/azaHqN2NKnuJbGGW7WzMU8DR+ZJszmIr9xWJ6H+8PWtDTVlsdGs7a/miOoKu2R4YyFLdiSfUAZ6fN2ptxq+m77uzvZ4rdoVJf7RIEc/KSSp6kgZwR7HrinOd2+Vfd+ZbTfv3s2RWdi+kTf2Iw1G4SMALcW0y3At2DDY7KTvjU9CASvfA5FYuva9dy+JGu7G+mfUEVkljlRoTAE4y8Z+UEE8nB6g9Ca3LC3SyvEK6neS3NtAFliuJQ3nR/wybgOWUlcsOg25XuX6veC8W/h8SXVtZ6TqRit7a6mVkaWZkwUlUAlQGXBf5Rt6HniIz5Z80lfT89/wDMl+6ry2/IpWM93frZwXJ0gxKSLgwsjw3ALD7iqmY2HJwCAWXBHPG1NcRC5tYVubaSeWf7O0Lv8xLKWVd3AQnGVJ4I9DWRpcV9p7NY6/b2dxNbR+Wb2JP9IEucoQQdskO0AZILZ64qLxHcxWF5PaaNqMX2qdFIt5kKMCcESIwGHXcScc9wORipcVOdor/L+vuNIN200NZ4bi3lBVrqNfOWRIjITg4KlSrcAHHP1OMZqjcWNlea/FHPKkiyqwmsDudJF4+UnOFbchK9DyaZG8cPiqztIb1Y5F04NJbnaYd7YBdTwN2fUdOMDpUOuaPqOpyrcwWYgubQlY5Rdb0lDI4L+UoO1wSgGOvJ7CktHq7XX9f0jRyTRzV4usvo15p92Ipp/v2q2snlMrGRUNsEIBOF52/lnmrV6L2LTtJFgLGPT9QtXJNy6XBLKSDvcDGflwcepz6DqoNOs5rqwmvA13pEMCwRQwxbngmOU3KP4wS3fpjJrl5tRX+wtWi07T/s1xYFbeGy3B208JIVyQfvbslieRuJPpW0avM7Jdfz0/ye356wmoyt0Luq6o/maZERYwyrH5RMany5CP4hnj27dKoXTt5DLq00InaXbCFYszDtk+v09PeqmrQeK76e0vJFt7yRI0igm2qwAUcsT0556+pxVa3i1DUdZ8xRGumROcFlALDoSvfPoeP6VtGnFJarTsdNN2a3Pa/Ad+t/4Usv3qvPbgwTAHlWUnG4diRg1vH868/+Gu+z1nVNNEKIrIt0zkN5hPChfTHfnnmvQSeSM181jIKFaVtnr9551eHJUa/rUTr9ajZjnAp+aYQCeK5DMTmkbpxSnimNyMdqTBDcnI6nPFFNHU8Hjue9FVGVhnzxZahoupeILFb+GdNPnt0Rp3cF7UKWHG0cDdnr1yCc03RWddT1GCG4vruKOB1KrhZJIDIDuAP8WOWHpmqXia3/ALI1i/jjaT7HcBXtJp4yUmiAHykn6D8euK1PDMttq3iS4tmU/YJoTbLHFu8x3fknODxw+CccYHWvrnZU+dXtZf16/wCRvGWur1/r+vmWtVvG1DTo9LN5BHosRkhgmjOPtKqqsCxPdWHI46/jVK1uNYvbWz0m1tSLWwVWQzRhZGXq/PRuW+UdcFQK2I9GMEVh58Ed1ptqMCxhZmUo3/LZR/f/ALw7j6Cp9EjjvNQ1jSrl50jhXy7S6hfZKkg6qvABXOQGIzjHTtmqkYR0V7a/jv8A5/gXazu9yl4e0aW1023upbST9+0zBRIdoXKCNtnUnlgT/Dt56irVr5GpySxm0kvri2ne1ltnIglSJgQcjI3qFJx1Py5461f0/Rby3cSRztdSXEfl3cIcIt0wON5zkAhDyBwSM9azf7Igs7Oaz1+6K+S0lx9humy8cSnh0ZW+7jJ4AYc44NR7RTu+bX+v66foNtpcvQREntrRo7SVPtEMkkVvvbaAoODHjquMYIPYg9DmqVvLbawl6NTubTTbuJXEPmTEyRpgq+1Rlg3TgDn2rY1V/D10qGWdD9nhN1F9olJademd/wDy0Py8EHoADjBNGp2Vwi3N1fwaXPNJKpVY4URocc7w6/NyCCPmPTjjGKhUTS6N/wBfMavOyRz+iWXm6hAy6ibiWOANaTxAoHReCMEBTgcFc565rt/D89pNqen2F0kdzfpcNJH57AqImX5lCkcHjsPTJ4FcRDqWpvq+n2c1tNZT3g/s953RjhmJKMAeBywOcZwWroItM+z+KobwA2epwFBNCnz7ApHmBA3Tfxg9g1PEe9eMnrbT8vuEnzJwjrb/ACNS6UvqDuzPl7lgzMdxIDHPP9affBoxdywLEsvlkxiRgqZxkAk1bhXfcJwAEkPQcZwSce1Z+u6gNLs1nn086gs7+X5RcIoJHys7EYC8dfpURk21FHVKfKr+RXOo3Vx4Y8y31LypTbSNPG6CMyzBCcEYzuGGGzoRzzxmxpOpPeXFtqsA3xRSLbzspO2SWIKVfnn5kIP4nk4zXH+IPsipp0PntJdp8nmEOrhvlDEgADr36noM4zXbaVHdPp8IvZ0uLhmXzZoUCrIVbgY9QCo55OK1qU4whddbnNTj735/gb728FtbSQKwEcMhCnHGHOVHp3wKzJntotQWzQ7ZMBxGo5yfXHTrj3PFSTHdeQteODHEwuHgYcSsEZY8+ysd3vxWdrqyxaNdXtjhtRmZYrcKMs0hwuQep2A/ga56UXeze/5jV4XvsRm4g1HV3txJ5kE1sGj3na8MsLPG+1e5JYfTGeCBTrOLbq6LHb+WkUDNcXDDDsR8qxr7BQCT7gDpTbPRotIFrPHJ9vm023mNqxj2szscksMnJLdP97mpNDkdtKN5qMgkugP3zoPlJzkqPoflyOuCa3vo+Xbb+v63JpJv4ty/NCodHkACgEge3+ePwqvqVhFfalZ3UY2z26srbVyJN+Bgn2xVb54Y8tJmSaQvKT656flgVZtPPitdR8xgwuLm2a3hwd6R7GVyD0+ZmXj2JptOOqZ0TvFRlLuU9GtdStbyZNNtIpvMvJIjHKxzAijO5uMEy5cAnoSK2J7e70r/AIRjSUKXAu3ZjcTYM8cSIWKqF+Ug5wTjPH4jmIBbWz28bSai9zp2rrC04OGduvlBc4MeDz3wDxjFXY7A/wBmyL4o1i5uY0STdNFJhUgXeJI48Dcdy4DL0ONtKquaXM3p6avc4ZuUndf1Ydq2rW72vhy9vPLtory5ElylziO4j8o4j3qPm8vzRnOcZHPWt/RL+aCxv9WvIRB9mf8AeiTgyRs3zD3x2/GuZhPh65sZr1tKupxqflNM19KEnS2RyXuYwc/u1OMqD0GegrR8QTQWmpRafJN9qs9UXZ9rhfcEj3ZBx0ODg44OM9KhxUv3dtf06/hp8h07SupPt93/AAxonU9QGsKujW0T6FeaZLdfblQp9ndQ23k8AE7F2kdDkVnDTbcXGkasY5LS6eeV7mJZxsE8kagyKrHnJUZIPORn1FbRNQ1zRbibTdd0mdoNPnRoJLP5naNiMkZOWU4BwCO/pina61vDqXiW11O5FzZ21o0MGnSoRHN5jB0dWzuyMbRjJHr1FTGDjO0fw6rb9ULl1ute35f8E1I2uVmWZJRO0TkLIibQOcEHr0wffI7Gua8QWCXVldziC5vP30huEtY1LRq7EiRkx+8AP8XXPU03Zoum6npLRxz+ZcvJPbBGcxrvUbiy9iCMY469PTqSs8NzbXOn3KRpC8nnhXPmLhAU2AD5snhlPYgjvi3L2TUl/kbNXV2cnZ+K7ia9tW1DSGxKNjXfmbTv2hWYg9uDx1I/Kuusby6gSOWMgwlt0EgO5WHfA9OxB/pXCahobpcQzag73azbmeZ7go0UYB6k87gd3HI9OtaOlz2l/wCIZ7KystW1C+hiW4T7OTD5hCrsVzkjaM+hz1weRWlenTkrxX9fNhzcqs/xO3v7+3vIisYeyusiN/JH32VSRsVeThcn3A74rFuf7J8UQ2xu7WO7jiHmW97DlSmT0LKRsYHqjfXHcZ1prOjzQwyakZftqTJDHI0TIUulOWGMZXBYjHH3uR2rf0eCyWa5u4rcwXt2wEssanErgZ+YEcMM88DPfNcbh7JXSem39b/1sEUntqjIGm6bqsK2sn2JpFWSA29wzGeX5shFDNwwzkAZ4K4XFZ194c1OztxbWGoSpp0dj5FvKZC0kEglDbsAj75yuew46AZ6Oa3sGgmGqQxvazKdzPGG8nHUjHO336jtUEEYs9esNMsLDT7XSJ7fy4bXzCZZM7iJI8kl0PPzZz1pqrJO6e2uu3/D/wBbBUjHm1Keiarc3qSfYLeSdmiO67hmWPZc5IZPLPzZ7jH5EGq3jrR9L1HVtUvbO6e7vWiifUI7YhltozgLz1zuUZz6jgVe0vU1v9SutHulujqMcPmCGeARXAdTyXHKAgYYFe2KW+tIr2Nr7U7C/tHn2XN2dIUCQrHnCzKSVcN1II+UgHBBpczp1edafrf9NOlg10ktTkYtOubfQZleeadZ5MR21ixdtigLyP73HQ+mTRbaVqdneGGN0stPjw6ZYSSSjAJJHY+oPTtnFblpoVvr1jY67Z6tb6Pc3d87Pp+TH8ztiKML16L6EHt3rGnsJYLh31S1+w3lk8kKN95GA5DL25Jxnp9K7IV+ZuN9eqt/V/xNaU1L4QTU3tx9qsppYrjJZACMsv8ACWAPQ8/KRnj6GvUfAHidtfguILpGS9tVV5G7Mrf1B4rzl3hnvrn7Zc7re5YLZuuDIkeBk5PHJOfqOtW/DWNK8caXK7zRhgbZ4icblYEBm9eefwHpXNiqUa1Jpr3krr/L9DSrD21Nu2qPZTz7Gm55460ucgYppzjivmTyxD0FNJzQaQmkA3PFFA68nA70VUaM6msWl6tL82h3PF7q3jn0ua0ivkOoRxq0yzqu5Ap3I7IeCACASODmsm6gtNHjiu7pvPuI7pCtzaBUYAryxGOoYjCkYII9asaXLFd6KL23htYrqSBEleVjlwPkZZOdxQxgcZ7HvzTriTSZbyGVwqyXMAhljjBGyM4wuw5IUnGCc7TtHoR9RByTcXt/X9L7jtbbQ6EXOr2d0txcXmlXAZXARMbMg5ZWHLq390nArT02x+zNcCNgYwYmVixXAjUqE+hz69Rmmw2+kXV+WlliN/ZQI0QiVlLhlHPHBJzz1GfStGe3m0zUraO6tYrg+WJnQ9wdy7G4447VnOp9lfd92w0tfP8AMqz+Zq2jtcQWMKTYdEt7ok7mVtuwkcqT1APGBxii3tTBp0Uw0+K0uCSPsr3AlKMDn7wydpxkH6ipdOkXTxNbWcbeRGPJeMybyN3O0ew6c9BxVRoftepLJPJmO1iKoFbJMj8M2e+FwB7mnG+q6b/1qaxpyVmzIi1GTM1pG7ab98tpxiV4bhj/ABAAgHJAB67hxzVBIr2eOwvklOoAmNbe1R/JWOQAgAIfvqpB4BBAGOldtd2H261W2+xQzMrrzuKSRDuVbnkdcHrWObK00yGznuIIgIHLxTFPlJLZLg4P8WOmcZOK3jVi/hWvb+tSZU0/hNKO+1ixi+zXLzapqDLvlls1aQq24bCQQMKFIG7tz61Do8cr3dhqcotorI2/nuLaYyM1wkhDkuSSQwwSCe4A4rN0mc6jqtyJrJo9JslY+fcLsJ3McqcjJycgLjoD06VW0bTPsEurxW9872jWf7ppo9ixGVlUllzwRtBGMgjmodOKutnp+P8ASMLbOK02OpuLwW2lRPIDunufKUdwXK4z6CpPFXFlpxzIsM90luZFIyjhCckHqMjHr9eBVK9kmtdElFvFHKzRmEbgCWYKSjAfUVX8YzRw+GLKaeRhbWt+gZs4Y7dvIPUMeeR2zSjH3otd2a1W0mxdXtdO1bUruK9i1BLm3t1MkcEap58JJ4RiDg7+vAJxitLw6s8Oh6Zb3UytLBv3mN1LJkfKhUcgjYM5H8q5/wAZz3MzNbXFzCElSO7vEsdxZFDsxLqeT94cj6cCrVtd2ll4uC29rJNFf2UV48yyg7UdQThcZwTz7E1o4uVNL5/dp+plFqLV92b0itql9M32iW3HVJY5PLMfOVG70zn8M1n67bXgGlQFh9iYS210HQs0vnS7lSNVBZXCn5SRxjnHSku7X/iW3sd156QyWznMSbiVz1A7gZycdMU3SNWiFh9stgkeoySh4knnx9s8r5VH+0pAPY9uvWlytax2RpWtflT2Nm1tLSHVrLw1pBmvbe3tm3XhdWjTkkRkj+MA4xnuKpW0kN/bCKwRvsyyGNB/CwjyM/8AfWfyqtpmn6t4eSyk0G/0uGK9SSRLdot8QBb5iXPzBwOx/u4GcU/SdXSO8vLHTdPEukWNvsacEDy5WIO7ryGOcd+OlSotXcHe3+bvf57fMypTcTQ1GGRCpis/tMcCl9ikBpXVTkBj6nAqhqIuNVkvYZIp4bVL2KxuY4pPnRZkH7xtuQNu/HTGSKhl8V2q6pJqK3KP4fUi1jmEZytyQM5Xhvugk8Y9M9KsXN0uk/EG+l/eNbT2ZR2gjJcqQuS4HDEEEg/7IB7VUVNdNbX/ACv8wnV57WKGmyeVo/htrtEe8t73EqKx8xpVDbMk4+baqBy3YAelWb6e6g025biC3v8AdqAkEXmrYyKoEuW6YddrAd/Tk1q6vf6a2mLrNjNDwf3aOVQyOBgplsFXYAdfWsayLXmuXTaq0+ltD5DvbMUaCM7mRY5XyDskyoG0Nt6H1pqafvNWt/nt9/8AkYvljZlvw5eaUuyC105HtbEme1vISZDcmVCJioOSh3IBtzj6d6b2Vsnhea68F3QvrQRGe3tLgb3tgz4kIGNwUEEbeRk5yepxLOw1LS9eOm3t1bw3V0/mSqpEQIjwwAAGAABnAxW9dyWNrqUc0ktrElpbSRWKxZMf2cDPzvxlt3PdcHkd6uVPkmnB3vr3/q/l5+hcYuNmvn8zXOuS6pZ2tzpMFvdOypFc2k2QxMf3eAw2jkgkZwQCAa5+f7RdXOmweIhA6yyqqJawyK0EpL7AWJ5UgHdwQCRnHUWJ9QttNu9LbUwbibUILe8hSCAbrYyRDfGHB+ZN3IAJIxzW3HL9lllRZbi5s9haeW4JARMgsWJ5AA4xg81kkqa92O+39eXyKjb4o3Obm1Gw1Hw9qAuGkiK3ag/aFcRR5GBETC3+qPGCGA561pzQ2t7cx/2ReGxWyJeGMlmXlR94PycepJ9DnrWbolrDDLcWV5LHcPsd7GIYBeBiWaPaT8y7sHaQcHkVUbTryw/skDSLlb6OSSULJOHFtFnLDjAZcHheSc4zyK1ajdpP+rdn/S/OnFxlZ/1/X9eWtMtp4ngntL2wWHULP90V3AtuZRhkP8PTOcAEenIrBh1HUfDOrQXEWuw+fJiKUTRhvKTod6Dg5xwR+ODW7d65ZTWWlXKNdxWVzAzC+SNY9qhtuyR+q4YHHP0zmr7fZrrVm0yaaCZo42le2X5yZMKQwLDG4BslcE8jB61Clyq0l7rvp+e4NRkjn9TvmvdWv4NRuNPuxfSyRR3WmyMCrkAoz4GcZ78EjIziptC8SNJpNvZ20Mk97CCjIjMu7acYDMMAELnr1JBzxW3ZaPAt1NHY27R7lZ2CfL5rkYG5+/X6deOTTbrTkfRjawPPZwRK0kpgDNJwOdh28qOuBUupSaUbdv6t/kNQs/6+RBNafb1hktpZtOuXjIMgIkwmV3Kpzw3ygkjjAwQasvZW50mx1C1iE91p7K0dxbLh4gjEjEYbG35nBT0Y9Kks7/yPOXVJVgjEIaW/dkVFLKoDKh5CncOcYB4OMg1HYLd6I0thq8treanBOkyG2LRPFCWIUhSPn43Y4JPC+lc85S2/p/15v5Cnyt2aI59R2mHS7K1fSYoLVU03WLfFxHKhIIQFssgPIwWzwAcVauxpMvhuC81pbl7RWzcSROYmGGwZPlA3LjB24zg+tUrfV7X7DaXkGnXTiWR5pGMPlLAqguzSAHcAe+Mg9j0zDBK8+p6m99ZywWM9uZDdSzK9okIyVliUZEm7eMj+HB56iocbbaW131/z/rQUeWKsnv8A19w/+w7nTfEuo+IJLCx/smEi6N5byl3m3JujkjeXJj2cEkepAPSsDS9Fn8+91CECXQDOq+dPKxAJUEkqOqHfwMHPH0rqdIjvI7C/WDWIdXllsyILeWdWjZJMBItrH5lBOFYgdSuO1UtJ8VRpr9je6sPsml6Wslolv8kbQSuqo8exf9Z8oyB2AHQ1cJ1Upcutlbrf/h2+v56IVNuCuv6/r/hznIrkvdXsmhpJcRWVsI/sUUQDNIx4xnJ9+OePepfKgs7KSG2spo5UYyPPcuTKC21iq9htIIyOtS+I9Wgu7bw3I2mBPDNtcbZDZEBpJc527eMttAPPqai0XUDq2nXE86smydlVs5VlzlcHjlc4wR02+9dS5muZr+vO33/M6qUk6mv9f19x7Fol80vhy2vLiOTIhDMANzMAOoH0rUbjP9K5r4dTed4XhkDcGWQqg6IN3QV0dfMYmPLVlHzZwVVyza82NPvimmnnOKY3T0rAzQnVhjqaKQnmitqVSEF7yv8ANr8kOz6HisayW8NlK8aiaJ98hUD99hdj4H+2vU9ASara3Y2s7WaJZiSCWdIGG4lxGQT99ey9dp64x1qjfXyvBfNHK7wSSyAIJwGjKjhV4PLD5gR3Bq1azQB9O1ObeZndFspAzFstkOJAflzgqfYE9a+l5ZRXN11O2TUly/1+RqRPqNzeQpagwypILf7XmM4hPU5PJ+6Pl68it1LS10+aO0jeSecEhXOXdvcgnoo96xdOJtZ40wuzBbaPmwBwMn9aLvU/skwEa+fPO2yNEGDISOV9lA6ntWM4OUrR2NnBrqWY44bOC5jZ8Sztu656dcn+tZs1+bHYlqjtLJyrkY2Y/i/w/Ote4jJlUXQV9sayuFG0bR0A+p6VleJPOgsLiUxqt46guigk7CeVXaCQcAr+fNa0pKTs9bmrqJRblqMTW7mTzNIhNlaXMmWScv5zmMYIYgcKGPPJzjtzmqNxq1yq6rHHcTWdpblXknaTzkiuSCQVUDKxyBSvA4JGasarp99d21ve2Rn025iG6bKeXJbDsr4GSq4HPvyBUF9eW+5YNZ0xdQiuYrfyr22UhXZQciUjHO4n0OGFaxUXqlf/AD+fkcFSUnt9/wDX/ANDWLi3vorhtNujJJGIJpLi5JLHcuY1BAycb+lWotHj1CfV0LxmFIvMjMQ2B4gyYHI6Y5A+uD3rMuoobT+0oZ9O+yma7W3Rw2VnBjzvXHG1SgPXo2CQQa1vDupXS2UKXbttuA1ssaQhWtFjUFlY943JBU846VnLmjBOH9bP9P6Zsqr5VFdSQXZudQ1SOIbbSBoo4wepYqS34DIFXreEapZ28d9BGsNtI1ysbAHfyyqzA9fYfSqFoGmuX+0AQJEDIYt255mZiqjI6fdZj+ArTto0uJAiXMhaMbvJjXKysMhdw74JJA9QKmpaKst1/X4lTfu28/6+45SGK3vrm2lS7j0u/WIWkMspbdMIQI3B9C+CAp/E81reIrW+trCPUI5ILK5hhSdYQgeOBMfMi7RhsBc4xjJP1rQ8dWiXMsd5paie7jxJGjEEJkcMRznnjB7isXT9cvrXRZrrxCzQx2VzFEtxbxBhJjGVKcAnkFj/APqraMnUjGpH7nv6HNzWjfyL2pX8l54aur2aG4XT1sv9HJJVgkpbeAvqDtOM5I74qa0vTbRvpiwWv9oWm6HTizK0ssKkL/wFsDnpz0yKfpeuzT6/aXOn3sMWg26yNeyyopRCASAAc8kYI+v51raCytb+DxBPdM1zeeb9m+3MMRKcvsQY+UFWPHQAnkdKhq3utea/yf3a+oJ3kZFhpuozeNrOTUPNs3t12N5pG1wMndGD/rFwckDoT2rotRFrqWoTaBaSWj6leQkOkcTRFMAlTuA2swyDn2+tWrhtP8nSdR1T7EYrTeyRs2JoZmYeWEwcEHBUk9CFNcdNrl5BbRLpFs8NzqeovKguH+QFSCY1lXacZIyvGfx5pSnWfMla2nlf8/P9e8u8U2a/iaxu28OeHvD9vp+JoIvtmqXUcWyILv2FcjhmbbyeTwPfEV7A+pXsv2A3NverZxoBGWMNzCxUZRR/EDgMpySBuHQip9JTxEuiW2oaQEuP7Ru9+oW9zLtVJWbYdoG3y8rjIOTgjrjnT8GaPdRvrVrPp32C5gupGsp4LkecpJO8Bj1U8enccZOV7T2SbbWjfXu9dP60Ii7KxkTaP4jstAjg0o6VFtjYXdtIN8M0Qb5N28FSzHcTg4GR07R3Unhm8lT+0JLO11Cx8pJRCzNAJFyQIj1KKB0OR9eK6bw9LpVjp82nxaiLhLOZ7aaa6bKK0kgPlhiMNhuMgnGfepBe2rprElvBptxd2UU6mK2WLzHUDLg+h4wTjgYPbifbO7uvmtN+4Ri/iOftbOLVIwdcitrs3ETXFxepKyRYcfu/LJ/jHIOAFIOB7rpq6JFZ39vYxNHqFsyQTLcMfJkhkQhQpOSMjrgZPJ561XtrbSbtrC3vpJYNEAY27y3KRmNp1Em2Ip/rArEqcEYOc8VqRtFPYXmgXum2174g1e3S7tFt32xs8eQNs/VdqpuHQZyM4Oauc7Ld2/S/+W+1tPUcZpK5Ss78Pr9v/bdw9tJYwNbCz2AMm1S7TJgnau1WC9ePrir+vacL7Q21e21O9vrC8hN1CYIA7QqnDAAnBGARtIGCKlS3i06Z9WuLUJMokW5IjMrSkL5S7M5PpkDjAJx2NXUtZsreG3t9FttQsdV0u6lhs9LljdY5llDAn5QQ0ZKM3bnPPNZuTc4un+lv6vbXtuW7waSM+21VbzxC8lnZWwtbWMtHdXBCKrzgGJcsNwVwwGRk89gK3LPX0g8PfY9ZmsLO6vkZ0Esp8qNtoMceXxsOVAyxIGB9ayJmgvLePTru9s9NtUjhuLqdhza3LMuxFU5CxnoNwGOuAo5t+ModauZkheZHsyVe6W2tFnunkZiBhGwu0joR/hTnGM5KL0+/+v6XcTvd33Rh3M8VnZaJo+rXe+5lfzLqO5iKiUkZjixs5i3YYNzx0PC4v6HqVtrus3kWoaVbprFqAs17p2+Mq6kIpfeOWxuyMAfLyR26rSfCtimnRWl28M+qW0QWK6tndY7GNWyFQscsMkk7h824jkAAamu6PD4qK21wUFtKZHnjs1MUTybRtaVlKmQA9B+uKwniqd7a9df67md5b9vX+v62KNpP5EtvZT6hpyXxiE6yh9y3Cc4ZsAJjI/h9OlM1O8NjfWNvd27xNK2+2urRv3bkDJAbqH6naeCOB6VZgt7AwR2kumpNBbyIqO/ytsQjbuXpjI7nBzWFZ3Gox6rYW3iZbPUNNmkkuPMhH3GVm2B+MKMY+6BnGTkisIpTbfr/AEv8n/w2zv2NSKCz12/tVF9G1ykGZIIrhHW7tzkfvIydrrkfeHIOMjpWbqGmtd61Y3U0kUu2JbWOBsRsjB95YSAEbeBx7Hp3fo1lbadqj6bYafBZyRFvNu4cKrPnKAt16H2B9Kt+JdNXVrK6tJoxiMfMgxGWIBBIxgcHkAcH86E+SaSen9f1uOMddTN1S9TUtbTTjBNc3t5GBO6SsI7cxbXDhiPmBPyk57Lkc1PptlYQanZ20NoYL6FGjidbfy45YwxcxseUCk54OPvA81n6hqNhpfhua41yO3guJI44oTJlZLqOPYT8i8YZ+uPp0FWI00+40nUo5LORLW6zPPAxztX+IIQPu45UDGeOOlW4vksrpbfP+tLeW9ylZtpHN6laS3F/d6nZW0msWOpTiwgnjjw0HlsrNuYYUDeUCnoQp6d9vV7Tw/Bc61A+owypcTQSW0Utv+7tnBIaUMMs3O4HjIHrxjHsNPvb3UYbTU4zFoOozLZy4eSN5IQd8e0Z25Gw7sjIxz2rTt3t73xELJJBrtprlyGth9nKCzs4hJEzxPxl0xgDkHbk5JGNZtppX0Xb5fJOyfbqQ58sve2vf+u5gWc0eq28/h7xMFgzfbLG+RDst53B2lRgFo2K4yeOAexFUdKsfsWtXtv4gaWx1qCNdllCiiORduGeQLgKT8p45yckVdu4dR8NSQNc6dOGtGWGO7JD+Y0bExqD/ERnrxwOKv67bRW/ijVYHgQW4dPKY8SEuu9g2fc//rrojLW0Ho1fT5bevX9HvtTi3UUm/wCrnpvgeF4PCunxyKFfy88ADgnj68VuHqa4XwFfyW19Lo0txbSRCMSQCKTeUAzlCR3xg4+tdyetfOYuDjWk311+85a6tUY04pppzUw9Me9cpkho9s0UBgSSpBIOD9aK1pyilrJr0/4cZ8+WFlb6ffaNp8dj53nSiZi5O5f4QfTGM9eDiraRf8TfWdHlijaCK+N6t1E4kERAOFA7cDB57e1M0vXraOTStQ8S3PkTW0RgjCQlt0avkBQvbcDljg9ucUj30Nn4xup5NPmn+0EG3eIYWVM7iZMgFflK89R0I5r6eTk201rb8bnSnG6S+5ee39fib7ahFPoxvYUhkWWZVeSNv3SZbaFLY4A/UkVPPbW0GtebdKZpvKG8oAqQoBxGo6/M3U9SPYGsfR9EKWUN3YWYuH1AuksYYJEbdTnzNp+UkMDjkEHjk9C6vIrKTzkHmSOASyEsTjjBU8g44yeBislBNuMH3/r8Doi76PobtrMZrqe7uXDTqm9Ax6sCAB+v6VmeI5tV+3wy6ZFb3jlizwMQOEwDt5BwBwTnvVrQ/MilTUJI0W2mCu4kf59+45yM4A2bfy5rMsJ7u6025tmGn6nD9omjlmckxSxswfyyU+dWz0YcDCj0oiuWbaW2hNWT+yiTxHe3MkNvcaha3TBjsmdJSBb4AHz4U5XtyO1U7fzLO6+3ma8t7BLMyvp0ZCsikeWJo853x5KsGxiqB0efyNTNrd3gghd/mWNzMSACM7iAcfMvykE8ZrYvdYUxWqSXDX14sCqMAn+AN5bnB8vtkdj9MjoSslCOv9f1/VzFXk9dP68mZusaZPZ3trZXMiX9rJAkIVz5coXAbeFPO8Ak45I5610VlPptp4K0fWptxezZ4Y1kwpuVDcx88cgZA9sd65LU9T/tDSrazlkCNdWyTXKJEC6yFjtaMkZz5eOAejnmug1q8iuPh/eWOyWWG2AhZbiJwVcEYb6jgk9cfWicZSjBPv8A8D8bjlfl5o7W01/q3zL2nxWxn1m6s7pLoEs92+3a0KmMGIKp78n6EEVJq32w+H9UvrdJPNuLa1NuYwA9s6SL1AzwTuyD079apWsqzWVrFpU+mSeTbxRX0aJxNGqhGIbALFc4Gcnn6Vp6hdTab4je1sJrBYbmJJ7TzIyu6NRhlbYDtwqnGO45rJ3vrq99fK39enzI5uaNn1Of0m11m10hpLKWHTrBzJiCVA7LgBXYuo+Utzgg8H061razrEC+Ef7I1K4treYlprOeYNMGjjdcC4XByxBOGwc7D9TPLp11qHiC6g0+1FpbwK0EEcUyypLIyFmV4z8vyZB7HPPOeMuyskLanpniCeznuL8JAGwRI2zOwIgxhlbt9R0rS8alpPdWem/9dyXG8bIr/wDCM6vaf23YRana3DzRR3wjgjdQQr5BdWUYVhkZ57Z4Nbfi20uUl07VxbxyWdtsL2bRh3ijePY4Qcb85J9tua1LmDUYdBuorC+X+1GjDPKVCIQowysSM7ccqBwDVKK0h1i7h8P6pc/a/tgMsiQyZTyliyJFfA25fhV71HtW/fbWl7+llf8A4A1FJO7/AK3/ADH3WjxaDb2dndWWoXssUMgiuFVTDdRmXzY1fJ4kUnqcY/KofDmqQaHf6vo89zYym8meS3jnWWM2hCbjubaQflA4HXbyegp+q6xot7Pp2n3UV82oafcjTIWSJwefkLCQkKThRnODWz4RuIINKdJ7Gzs9Wc/Y7q2WRWUYJG47ifmI64PNZybVN+0Tbfy67+n/AAxKfu8qexzwVJZo9UsJ7S/S0spA+l2UhRJXkBcsm4YHUy7mycLjBOKZZa1rOr6/ex3N+0Vlb2yX0YsEEscqswO5nHOQGOe25T2qheRTaVfxWtppNnEt3byme3CiUxKEZVw3ALtnmMdMqB1qzNY2sWlXNlEjR2NtpysWYB7xEc72DqGGAh5A65TAzzXRyx3et9tu/wDX+egNWleJ095c6VeadGgi0y60+S4MNtHFskUSMd+xXQ4ySC2DyCfWuV1aW0kmS/8ADumIkMVxuuLu2+WW3nTPyyHG5UIzyflb3IqSVbIW93DptnAk+mzQy3rrGNlsEJKTtCBiRQCQ+3DAcnOKq2llc3GtC71C1udHXUI5biWWzZbmG6QHggqTu+ZhjA64OfRUYqGrf9en9fiVGUb8mn5mrf6a3iKw8PrYMunaZDJNPLp0MizJEGzsliGOM88HHI9Tituw1G91GSBfDE1odTu4keKbUbbBkaIbJQT1iLAlvf8A4FWL4X1CPTQmoKNYIsJW+2QhdqyN02iA87cFCQD1BIxRI50TxSt1odklrDFcyL5WoFke9MjhGKE89iR2JHSs5Qcrwtte3bvZ9e3y+8nlSbiivcz3TaHHd6bp98+nXrzSXqzyB3tpG/dl4wSMFX2sfw6c1rNYiGWH+y5bia8e2IkaGNpZbl4YyDMP9rAx23MfU1WksdXsrS5ur/R0fW1imkt7ZZs7IvM3Yfac7s87c8nHFR+FhbfZdV+waldXF81rPfRzSxPDLFFlQUjblT8x+YdmC8cHFSa5XKL/AF3777d+pfNazT/pm7bWsN61pcwWyaSWK3N9GyLPJdsDwG5wHzyT/Dz1xV28iW2VbWOQ7Ed7iZTJkGR23HLHqBnp0GaydDRry78OXMCyx6XbWhe8uLiYtM0p3bIm5AYFiHPHPfHSrlzYW0syStO8scUhlcSOR5rdsj2OT+XpXNLSdm9vn3/r7i6Ss/QW6WEW2zcSG6qejn29v61p6I89qxtC0kcsyqYt4OduDuZscLjAAzzVWDUVtrmWGK1E16SoaUxlvLDcKATwPoMnHNX9ZvBp1obJXeSSVNzsoy7Dvx79BWFRylaFt/6/ruXNudoI5q3vDqV3NBLK/kACaRN+3KKflB9c9cenNaMhhE8Mtqm+BiQsyrt+ox3HpWJawSObq4u0VZbh+YUfIijHCoSOuO5HUk46Cr1vqFxYsVuQGyPXAROwx0H0rpqQ/k+46pU1LWC+RflVF1+wvDLFMLvdaXCSuxadAuV2YzgoRnB49D2qJrrV47dpdStllkWeSC1aNTieBVzGzEZxkgk+npTrG+P2yKCCXZPdqwhJXOG7nkEDAySfapLnUJ7m1vrR4JLW4sJ0iQCbKzYQMJUPGCTnj2wa5Wmmk1/w1/6RxuPLNL+v6/rscx4h1CO0n0G2XT9Na9uY2XypQJY3iaTc8TEfKHDAHHXp04zgeGdYubzbaakoDTTyS290rLsuNoyu9cjCjIAZQR6j5TUFnY2F9uaxvjcWsAkaOOWI5t5WdikjnHDAjnqCq4z2pdG1G4soo2u9PF5DZxL9gSyO1gjsRLKoYZKs30x2wDXpKkowcVv929+/9dRJyupLby6/mXGvLzVtJvUsTcSzx26NLaPKYLm1j3j94hJ5+UAE88PjHNbvw4fdNptleSGznsoXuJE8kRGKYzbfLJ/2kTJwMYc5rm9Nvjcataz39npOp2N3K8sMjYimkMYJjV8/NgEYI74PXAq/4V1mXR9T1fTY7V5r69tm+zzTyhi8mNyR7h22kjnHIHTOBnXg/ZyjFefT0/DXovzJack5X8j2TTr2K+giuoBgBiBuwSjZIPQnH17ivPPGPhpLXWlu7a6uGk1Dz5rlrqQFFVFB2oAM55/IVd0Gxnt/COoa9p8FlB4lu7Vone2u0NtK0TbVfklFbAyffOcZNdJr+ota+ELnUFWG6lW0374eYyzKAWU9dvJOR1FeLTcsPV/du+tv68r/AHmdGbjP3e553p15DFFp8FjZMk9vcKBcL8xO5hkYHJJ7+gr1qQhCVz3wPevOo7XSdI1zw/bzPfSrIyql3FIBEsu35Y36nkk56YyO2a9EYDPTkeo6VWPkpOLiu5WIcW04jc7lyPyprGnMabx+PtXnGKGYAJCgAE84opxB5xjNFRJJ7xuUf//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Photomicrograph demonstrating an inflammatory response surrounding the airway.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of L Kobzik, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_56_9093=[""].join("\n");
var outline_f8_56_9093=null;
var title_f8_56_9094="Diphenoxylate and atropine: Drug information";
var content_f8_56_9094=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Diphenoxylate and atropine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?11/39/11892?source=see_link\">",
"    see \"Diphenoxylate and atropine: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?36/33/37397?source=see_link\">",
"    see \"Diphenoxylate and atropine: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F161161\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Lomotil&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F161162\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Lomotil&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F161176\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antidiarrheal",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F161164\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Diarrhea: Oral: Diphenoxylate 5 mg 4 times/day until control achieved (maximum: 20 mg/day), then reduce dose as needed; some patients may be controlled on doses of 5 mg/day",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F161171\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?36/33/37397?source=see_link\">",
"      see \"Diphenoxylate and atropine: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Diarrhea: Oral: Children 2-12 years (use with caution in young children due to variable responses): Liquid: Diphenoxylate 0.3-0.4 mg/kg/day in 4 divided doses until control achieved (maximum: 10 mg/day), then reduce dose as needed; some patients may be controlled on doses as low as 25% of the initial daily dose",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F161165\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F15796182\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No specific adjustment provided in the manufacturer&rsquo;s labeling. Use with extreme caution in patients with advanced hepatorenal disease.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15796183\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No specific adjustment provided in the manufacturer&rsquo;s labeling. Use with extreme caution in patients with advanced hepatorenal disease or abnormal liver function tests.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F161140\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, oral: Diphenoxylate hydrochloride 2.5 mg and atropine sulfate 0.025 mg per 5 mL (5 mL, 10 mL, 60 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Lomotil&reg;: Diphenoxylate hydrochloride 2.5 mg and atropine sulfate 0.025 mg per 5 mL (60 mL) [contains alcohol 15%; cherry flavor] [DSC]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: Diphenoxylate hydrochloride 2.5 mg and atropine sulfate 0.025 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Lomotil&reg;: Diphenoxylate hydrochloride 2.5 mg and atropine sulfate 0.025 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F161124\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block csi drugH1Div\" id=\"F161178\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Controlled Substance",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C-V",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F2999118\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     If there is no response within 48 hours of continuous therapy, this medication is unlikely to be effective and should be discontinued; if chronic diarrhea is not improved symptomatically within 10 days at maximum dosage, control is unlikely with further use. Use of the liquid preparation is recommended in children &lt;13 years of age; use plastic dropper provided when measuring liquid.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F161143\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of diarrhea",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F161185\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Lomotil&reg; may be confused with LaMICtal&reg;, LamISIL&reg;, lamoTRIgine, Lanoxin&reg;, Lasix&reg;, loperamide",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      International issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Lomotil [U.S., Canada, and multiple international markets] may be confused with Ludiomil brand name for maprotiline [multiple international markets]",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Lomotil: Brand name for diphenoxylate [U.S., Canada, and multiple international markets], but also the brand name for loperamide [Mexico, Philippines]",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F161174\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Tachycardia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Confusion, depression, dizziness, drowsiness, euphoria, flushing, headache, hyperthermia, lethargy, malaise, restlessness, sedation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Angioneurotic edema, dry skin, pruritus, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal discomfort, anorexia, gum swelling, nausea, pancreatitis, paralytic ileus, toxic megacolon, vomiting, xerostomia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Urinary retention",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Numbness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Anaphylaxis",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F161146\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to diphenoxylate, atropine, or any component of the formulation; obstructive jaundice; diarrhea associated with pseudomembranous enterocolitis or enterotoxin-producing bacteria; not for use in children &lt;2 years of age",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F161128\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Dehydration/electrolyte imbalance: In case of severe dehydration or electrolyte imbalance, withhold diphenoxylate/atropine treatment until corrective therapy has been initiated. Use in conjunction with fluid and electrolyte therapy when appropriate. Inhibiting peristalsis may lead to fluid retention in the intestine aggravating dehydration and electrolyte imbalance.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Ulcerative colitis: Use with caution in patients with acute ulcerative colitis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Use with caution in children. Younger children may be predisposed to toxicity; signs of atropinism may occur even at recommended doses, especially in patients with Down syndrome. Overdose in children may result in severe respiratory depression, coma, and possibly permanent brain damage.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: If there is no response within 48 hours, this medication is unlikely to be effective and should be discontinued; if chronic diarrhea is not improved symptomatically within 10 days at maximum dosage, control is unlikely with further use. Reduction of intestinal motility may be deleterious in diarrhea resulting from",
"     <i>",
"      Shigella, Salmonella",
"     </i>",
"     , toxigenic strains of",
"     <i>",
"      E. coli",
"     </i>",
"     , and pseudomembranous enterocolitis associated with broad-spectrum antibiotics; use is not recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Dependence: Physical and psychological dependence have been reported with higher than recommended dosing.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299213\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F161133\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AbobotulinumtoxinA: Anticholinergic Agents may enhance the anticholinergic effect of AbobotulinumtoxinA.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetylcholinesterase Inhibitors (Central): Anticholinergics may diminish the therapeutic effect of Acetylcholinesterase Inhibitors (Central). Acetylcholinesterase Inhibitors (Central) may diminish the therapeutic effect of Anticholinergics. If the anticholinergic action is a side effect of the agent, the result may be beneficial.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aclidinium: May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticholinergics: May enhance the adverse/toxic effect of other Anticholinergics.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of CNS depressants used in combination with buprenorphine.  Consider avoiding other CNS depressants in patients thought to be at high risk of buprenorphine overuse or self-injection.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cannabinoids: Anticholinergic Agents may enhance the tachycardic effect of Cannabinoids.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ipratropium (Oral Inhalation): May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce adult dose of CNS depressant agents by 50% with initiation of concomitant methotrimeprazine therapy. Further CNS depressant dosage adjustments should be initiated only after clinically effective methotrimeprazine dose is established.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: CNS Depressants may enhance the sedative effect of Metyrosine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirabegron: Anticholinergic Agents may enhance the therapeutic effect of Mirabegron. This may result in acute urinary retention.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirtazapine: CNS Depressants may enhance the CNS depressant effect of Mirtazapine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     OnabotulinumtoxinA: Anticholinergic Agents may enhance the anticholinergic effect of OnabotulinumtoxinA.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Potassium Chloride: Anticholinergic Agents may enhance the ulcerogenic effect of Potassium Chloride.  Management: Patients on drugs with substantial anticholinergic effects should avoid using any solid oral dosage form of potassium chloride.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramlintide: May enhance the anticholinergic effect of Anticholinergics. These effects are specific to the GI tract.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RimabotulinumtoxinB: Anticholinergic Agents may enhance the anticholinergic effect of RimabotulinumtoxinB.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Secretin: Anticholinergic Agents may diminish the therapeutic effect of Secretin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: CNS Depressants may enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tiotropium: Anticholinergics may enhance the anticholinergic effect of Tiotropium.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Topiramate: Anticholinergic Agents may enhance the adverse/toxic effect of Topiramate. Specifically, the risk of oligohidrosis and hyperthermia may be enhanced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem dose to 1.75 mg for men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F161158\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ethanol: May increase CNS depression; monitor for increased effects with coadministration. Caution patients about effects.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F161135\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F2999114\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Teratogenic effects were not noted in animal studies; decreased maternal weight, fertility and litter sizes were observed. There are no adequate and well-controlled studies in pregnant women.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F161167\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F2999116\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Atropine is excreted in breast milk (refer to Atropine monograph); the manufacturer states that diphenoxylic acid may be excreted in breast milk.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F161148\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Liquid",
"     </b>",
"     (Diphenoxylate-Atropine Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2.5-0.025 mg/5 mL (60 mL): $9.26",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Diphenoxylate-Atropine Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2.5-0.025 mg (100): $53.33",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Lomotil Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2.5-0.025 mg (100): $157.10",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Lonox Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2.5-0.025 mg (100): $47.90",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F161137\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Watch for signs of atropinism (dryness of skin and mucous membranes, tachycardia, thirst, flushing); monitor number and consistency of stools; observe for signs of toxicity, fluid and electrolyte loss, hypotension, and respiratory depression",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F161149\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Beamotil (MY, SG);",
"     </li>",
"     <li>",
"      Dhamotil (HK, MY);",
"     </li>",
"     <li>",
"      Diarase (MY);",
"     </li>",
"     <li>",
"      Diarsed (FR);",
"     </li>",
"     <li>",
"      Diastop (NZ);",
"     </li>",
"     <li>",
"      Dimotil (HK);",
"     </li>",
"     <li>",
"      Diphenoxylate A (MY);",
"     </li>",
"     <li>",
"      Lofenoxal (AU);",
"     </li>",
"     <li>",
"      Lomotil (AU, BB, BF, BJ, BR, CI, CO, EG, ET, GB, GH, GM, GN, HK, IN, JM, KE, LR, MA, ML, MR, MU, MW, NE, NG, NL, PE, PT, SC, SD, SL, SN, TH, TN, TR, TT, TZ, UG, ZA, ZM, ZW);",
"     </li>",
"     <li>",
"      Lomotine (AE, BH, CY, EG, IL, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Reasec (CH, CZ, DE, HN)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F161127\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Diphenoxylate inhibits excessive GI motility and GI propulsion; commercial preparations contain a subtherapeutic amount of atropine to discourage abuse",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F161145\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Atropine:",
"     </b>",
"     See Atropine monograph.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Diphenoxylate:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Onset of action: Antidiarrheal: 45-60 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Duration: Antidiarrheal: 3-4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Absorption: Well absorbed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Metabolism: Extensively hepatic via ester hydrolysis to diphenoxylic acid (active)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Half-life elimination: Diphenoxylate: 2.5 hours; Diphenoxylic acid: 12-14 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Time to peak, serum: 2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Excretion: Primarily feces (49% as unchanged drug and metabolites); urine (~14%, &lt;1% as unchanged drug)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Cutler EA, Barrett GA, Craven PW, et al, &ldquo;Delayed Cardiopulmonary Arrest After Lomotil&reg; Ingestion,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 1980, 65(1):157-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/56/9094/abstract-text/7355016/pubmed\" id=\"7355016\" target=\"_blank\">",
"        7355016",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ginsburg GM, &ldquo;Lomotil&reg; (Diphenoxylate and Atropine) Intoxication,&rdquo;",
"      <i>",
"       Am J Dis Child",
"      </i>",
"      , 1973, 125(2):241-2.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/56/9094/abstract-text/4685838/pubmed\" id=\"4685838\" target=\"_blank\">",
"        4685838",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Karim A, Ranney RE, Evernsen KL, et al, &ldquo;Pharmacokinetics and Metabolism of Diphenoxylate in Man,&rdquo;",
"      <i>",
"       Clin Pharmacol Ther",
"      </i>",
"      , 1972, 13(3):407-19.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/56/9094/abstract-text/5026379/pubmed\" id=\"5026379\" target=\"_blank\">",
"        5026379",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      McCarron MM, Challoner KR, and Thompson GA, &ldquo;Diphenoxylate-Atropine (Lomotil&reg;) Overdose in Children: An Update (Report of Eight Cases and Review of the Literature),&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 1991, 87(5):694-700.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/56/9094/abstract-text/2020516/pubmed\" id=\"2020516\" target=\"_blank\">",
"        2020516",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9370 Version 44.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-1.234.2.38-35693F307E-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_56_9094=[""].join("\n");
var outline_f8_56_9094=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F161161\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F161162\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F161176\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F161164\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F161171\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F161165\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15796182\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15796183\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F161140\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F161124\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F161178\">",
"      Controlled Substance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2999118\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F161143\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F161185\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F161174\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F161146\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F161128\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299213\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F161133\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F161158\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F161135\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2999114\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F161167\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2999116\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F161148\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F161137\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F161149\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F161127\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F161145\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9370\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9370|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?11/39/11892?source=related_link\">",
"      Diphenoxylate and atropine: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?36/33/37397?source=related_link\">",
"      Diphenoxylate and atropine: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f8_56_9095="Pitavastatin: Drug information";
var content_f8_56_9095=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Pitavastatin: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?16/61/17365?source=see_link\">",
"    see \"Pitavastatin: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F8101006\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Livalo&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F8101007\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antilipemic Agent, HMG-CoA Reductase Inhibitor",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F8119990\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Primary hyperlipidemia and mixed dyslipidemia:",
"     </b>",
"     Oral: Initial: 2 mg once daily; may be increased to maximum 4 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Note:",
"     </b>",
"     Doses should be individualized according to the baseline LDL-cholesterol levels, the recommended goal of therapy, and patient response; adjustments should be made at intervals of 4 weeks.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     <i>",
"      Dosage adjustment with concomitant medications:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Erythromycin: Pitavastatin dose should not exceed 1 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Rifampin: Pitavastatin dose should not exceed 2 mg once daily",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F8119991\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F8119992\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     15-60 mL/minute/1.73 m",
"     <sup>",
"      2",
"     </sup>",
"     (not receiving hemodialysis): Initial: 1 mg once daily; maximum:  2 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     ESRD: Initial: 1 mg once daily; maximum: 2 mg once daily",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F8119993\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Contraindicated in active liver disease or in patients with unexplained persistent elevations of serum transaminases.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F8120023\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Livalo&reg;: 1 mg, 2 mg, 4 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F8119911\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F8119995\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be administered with or without food; may take without regard to time of day.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F8100960\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adjunct to dietary therapy to reduce elevations in total cholesterol (TC), LDL-C, apolipoprotein B (Apo B), and triglycerides (TG), and to increase low HDL-C in patients with primary hyperlipidemia and mixed dyslipidemia",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F8101005\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Pitavastatin may be confused with atorvaSTATin, fluvastatin, lovastatin, nystatin, pravastatin, rosuvastatin, simvastatin",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F8119923\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     2% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Constipation (2% to 4%), diarrhea (2% to 3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Neuromuscular &amp; skeletal: Back pain (1% to 4%), myalgia (2% to 3%), pain in extremities (1% to 2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &lt;2% (Limited to important or life-threatening): Alkaline phosphatase increased, amnesia (reversible),  arthralgia, bilirubin increased, blood glucose increased, cognitive impairment (reversible), confusion (reversible), CPK increased, glycosylated hemoglobin (Hb A",
"     <sub>",
"      1c",
"     </sub>",
"     ) increased, headache, hyperglycemia, influenza, memory disturbance (reversible), memory impairment (reversible), nasopharyngitis, pruritus, rash, transaminases increased, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Additional class-related events or case reports (not necessarily reported with pitavastatin therapy): Cataracts, cirrhosis, dermatomyositis, eosinophilia, extraocular muscle movement impaired, fulminant hepatic necrosis, gynecomastia,  hypersensitivity syndrome (symptoms may include anaphylaxis, angioedema, arthralgia, erythema multiforme, eosinophilia, hemolytic anemia, immune-mediated necrotizing myopathy (IMNM), interstitial lung disease, lupus syndrome, photosensitivity, polymyalgia rheumatica, positive ANA, purpura, Stevens-Johnson syndrome, toxic epidermal necrolysis, urticaria, vasculitis), ophthalmoplegia, peripheral nerve palsy, rhabdomyolysis, renal failure (secondary to rhabdomyolysis), thyroid dysfunction, tremor, vertigo",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F8119917\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to pitavastatin or any component of the formulation; active liver disease including unexplained persistent elevations of hepatic transaminases; concurrent use with cyclosporine; pregnancy; breast-feeding",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F8119918\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Diabetes mellitus: Increases in Hb A",
"     <sub>",
"      1c",
"     </sub>",
"     and fasting blood glucose have been reported with HMG-CoA reductase inhibitors; however, the benefits of statin therapy far outweigh the risk of dysglycemia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatotoxicity: Postmarketing reports of fatal and nonfatal hepatic failure are rare. If serious hepatotoxicity with clinical symptoms and/or hyperbilirubinemia or jaundice occurs during treatment, interrupt therapy.  If an alternate etiology is not identified, do not restart pitavastatin.  Liver enzyme tests should be obtained at baseline and as clinically indicated; routine periodic monitoring of liver enzymes is not necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Immune-mediated necrotizing myopathy (IMNM): IMNM, an autoimmune-mediated myopathy, has been reported (rarely) with HMG-CoA reductase inhibitor therapy.  IMNM presents as proximal muscle weakness with elevated CPK levels, which persists despite discontinuation of HMG-CoA reductase inhibitor therapy; additionally, muscle biopsy may show necrotizing myopathy with limited inflammation.  Immunosuppressive therapy (eg, corticosteroids, azathioprine) may be used for treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Myopathy/rhabdomyolysis: Patients receiving HMG-CoA reductase inhibitors have developed rhabdomyolysis with acute renal failure and/or myopathy; patients should be monitored closely. This risk is dose-related and is increased with concurrent use of erythromycin, protease inhibitors, fibric acid derivatives (eg, gemfibrozil), or niacin (doses &ge;1 g/day) (see Drug Interactions). If concurrent use of erythromycin is warranted, dose adjustment of pitavastatin may be required. Ensure patient is on the lowest effective pitavastatin dose in all circumstances. Discontinue use with marked elevations of creatine kinase levels or diagnosis/suspicion of myopathy. The manufacturer recommends temporary discontinuation for elective major surgery, acute medical or surgical conditions, or in any patient experiencing an acute or serious condition predisposing to renal failure (eg, sepsis, hypotension, trauma, uncontrolled seizures). However, based upon current evidence, HMG-CoA reductase inhibitor therapy should be continued in the perioperative period unless risk outweighs cardioprotective benefit. Use caution in patients with renal impairment, inadequately treated hypothyroidism, and those taking other drugs associated with myopathy (eg, colchicine); these patients are predisposed to myopathy. Patients should be instructed to report unexplained muscle pain, tenderness, weakness, or brown urine.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment and/or ethanol use: Use is contraindicated in patients with active liver disease or unexplained persistent elevations of serum transaminases; use with caution in patients who consume large amounts of ethanol or have a history of liver disease. May cause hepatic dysfunction. In all patients, liver function must be monitored prior to initiation of therapy; repeat LFTs if clinically indicated thereafter.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Dosage adjustment required in patients with a Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;60 mL/minute/1.73 m",
"     <sup>",
"      2",
"     </sup>",
"     including end-stage renal disease receiving hemodialysis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cyclosporine: Cyclosporine significantly increases pitavastatin levels and exposure. Concomitant use of cyclosporine is contraindicated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special Populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Use with caution in patients with advanced age, these patients are predisposed to myopathy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: Secondary causes of hyperlipidemia should be ruled out prior to therapy. Pitavastatin has not been studied when the primary lipid abnormality is chylomicron elevation (Fredrickson types I and V) or in familial dysbetalipoproteinemia (Fredrickson type III).",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F8119945\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of SLCO1B1, UGT1A3, UGT2B7",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F8119946\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antacids: May decrease the serum concentration of HMG-CoA Reductase Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Atazanavir: May increase the serum concentration of Pitavastatin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bezafibrate: May enhance the myopathic (rhabdomyolysis) effect of HMG-CoA Reductase Inhibitors. Bezafibrate may increase the serum concentration of HMG-CoA Reductase Inhibitors. More specifically, bezafibrate may increase the serum concentration of fluvastatin Management: Monitor patients closely for myopathy with concomitant use of bezafibrate and HMG-CoA reductase inhibitors. Concomitant use is contraindicated in patients predisposed to myopathy and alternative therapy should be considered.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Boceprevir: May increase the serum concentration of Pitavastatin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bosentan: May increase the metabolism of HMG-CoA Reductase Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Colchicine: May enhance the myopathic (rhabdomyolysis) effect of HMG-CoA Reductase Inhibitors. Colchicine may increase the serum concentration of HMG-CoA Reductase Inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): May increase the serum concentration of Pitavastatin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Danazol: May increase the serum concentration of HMG-CoA Reductase Inhibitors. Management: Concurrent use of simvastatin with danazol is contraindicated.  Initiate lovastatin at an adult maximum dose of 10 mg/day, and do not exceed 20 mg/day, when danazol is given concomitantly.  Fluvastatin, pravastatin and rosuvastatin may pose lower risk.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     DAPTOmycin: HMG-CoA Reductase Inhibitors may enhance the adverse/toxic effect of DAPTOmycin. Specifically, the risk of skeletal muscle toxicity may be increased.  Management: Consider temporarily stopping HMG-CoA reductase inhibitor therapy prior to daptomycin.  If used together, regular (i.e., at least weekly) monitoring of CPK concentrations is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eltrombopag: May increase the serum concentration of OATP1B1/SLCO1B1 Substrates. Management: According to eltrombopag prescribing information, consideration of a preventative dose reduction may be warranted.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fenofibrate: May enhance the adverse/toxic effect of HMG-CoA Reductase Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fenofibric Acid: May enhance the adverse/toxic effect of HMG-CoA Reductase Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fusidic Acid: May enhance the adverse/toxic effect of HMG-CoA Reductase Inhibitors. Specifically, the risk for muscle toxicities, including rhabdomyolysis may be significantly increased. Management: Avoid concurrent use of HMG-CoA reductase inhibitors (statins) with fusidic acid if possible.  If treatment with fusidic acid is necessary, consider temporarily stopping the statin.  With any concurrent use monitor patients closely for statin toxicity.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gemfibrozil: May enhance the myopathic (rhabdomyolysis) effect of Pitavastatin. Gemfibrozil may increase the serum concentration of Pitavastatin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lanthanum: HMG-CoA Reductase Inhibitors may decrease the serum concentration of Lanthanum.  Management: Administer HMG-CoA reductase inhibitors at least two hours before or after lanthanum.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Macrolide Antibiotics: May decrease the metabolism of HMG-CoA Reductase Inhibitors. Management: Avoid lovastatin or simvastatin with erythro-, clarithro-, or telithromycin. Limit pitavastatin to a 1 mg/day maximum adult dose with erythromycin.  Atorvastatin dose adjustments may be required. Increase monitoring for toxicity with any such combination.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Azithromycin (Systemic); Fidaxomicin; Spiramycin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Niacin: May enhance the adverse/toxic effect of HMG-CoA Reductase Inhibitors. Management: This is of greatest concern with niacin doses of 1 g or greater daily.  Avoid simvastatin 80 mg in combination with niacin 1 g or greater in Chinese patients. Canadian labeling contraindicates use of niacin with rosuvastatin 40 mg.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Niacinamide: May enhance the adverse/toxic effect of HMG-CoA Reductase Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pazopanib: HMG-CoA Reductase Inhibitors may enhance the hepatotoxic effect of Pazopanib. Specifically, the risk for increased serum transaminase concentrations may be increased.  Management: Simvastatin is specifically implicated in this interaction.  There is a lack of data regarding the risk with other statins, but caution appears warranted with any statins.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Red Yeast Rice: May enhance the adverse/toxic effect of HMG-CoA Reductase Inhibitors.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifamycin Derivatives: May increase the serum concentration of Pitavastatin. Management: Limit pitavastatin dose to a maximum of 2 mg/day with concurrent rifampin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sildenafil: May decrease the metabolism of HMG-CoA Reductase Inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     St Johns Wort: May increase the metabolism of HMG-CoA Reductase Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Telaprevir: May increase the serum concentration of Pitavastatin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trabectedin: HMG-CoA Reductase Inhibitors may enhance the myopathic (rhabdomyolysis) effect of Trabectedin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): HMG-CoA Reductase Inhibitors may enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F8119949\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ethanol: Avoid excessive ethanol consumption (due to potential hepatic effects).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Food: Red yeast rice contains an estimated 2.4 mg lovastatin per 600 mg rice.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F8119913\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     X (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F8119914\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Cholesterol biosynthesis may be important in fetal development. Contraindicated in pregnancy. Administer to women of childbearing potential only when conception is highly unlikely and patients have been informed of potential hazards.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F8119916\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/contraindicated",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F8119994\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be taken with or without food; may take without regard to time of day. Red yeast rice contains an estimated 2.4 mg lovastatin per 600 mg rice.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16322688\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Livalo Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1 mg (90): $456.19",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2 mg (90): $456.19",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     4 mg (90): $456.19",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F8119997\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Baseline CPK (recheck CPK in any patient with symptoms suggestive of myopathy; discontinue therapy if markedly elevated); renal function; baseline liver function tests (LFTs) and repeat when clinically indicated thereafter. Patients with elevated transaminase levels should have a second (confirmatory) test and frequent monitoring until values normalize; discontinue if increase in ALT/AST is persistently &gt;3 times ULN (NCEP, 2002).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     <b>",
"      Lipid panel (total cholesterol, HDL, LDL, triglycerides):",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      ATP III recommendations (NCEP, 2002):",
"     </i>",
"     Baseline; 6-8 weeks after initiation of drug therapy; if dose increased, then at 6-8 weeks until final dose determined. Once treatment goal achieved, follow up intervals may be reduced to every 4-6 months. Lipid panel should be assessed at least annually, and preferably at each clinic visit.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     <i>",
"      Manufacturer recommendation:",
"     </i>",
"     Upon initiation or titration, lipid panel should be analyzed after 4 weeks of therapy.",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F12992814\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Flovas (IN);",
"     </li>",
"     <li>",
"      Livalo (CL, KP, TH, TW);",
"     </li>",
"     <li>",
"      Livazo (NL)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F8119952\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, the rate-limiting enzyme in cholesterol synthesis (reduces the production of mevalonic acid from HMG-CoA); this then results in a compensatory increase in the expression of LDL receptors on hepatocyte membranes and a stimulation of LDL catabolism",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F8119957\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : ~148 L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protein binding: &gt;99%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metabolism: Hepatic, via UGT1A3 and UGT 2B7; minimal metabolism via CYP2C9 and CYP2C8",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bioavailability: 51%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Half-life elimination: ~12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Time to peak, plasma: ~1 hour",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Excretion: Feces (79%); urine (15%)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Diabetes Association, &ldquo;Standards of Medical Care in Diabetes Mellitus -- 2012,&rdquo;",
"      <i>",
"       Diabetes Care",
"      </i>",
"      , 2012, 35(Suppl ):11-63.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/56/9095/abstract-text/22187469/pubmed\" id=\"22187469\" target=\"_blank\">",
"        22187469",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Berglund L, Brunzell JD, Goldberg AC, et al, &ldquo;Evaluation and Treatment of Hypertriglyceridemia: An Endocrine Society Clinical Practice Guideline,&rdquo;",
"      <i>",
"       J Clin Endocrinol Metab",
"      </i>",
"      , 2012, 97(9):2969-89.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/56/9095/abstract-text/22962670/pubmed\" id=\"22962670\" target=\"_blank\">",
"        22962670",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cannon CP, Braunwald E, McCabe CH, et al, &ldquo;Intensive Versus Moderate Lipid Lowering With Statins After Acute Coronary Syndromes. Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2004, 350(15):1495-504.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/56/9095/abstract-text/15007110/pubmed\" id=\"15007110\" target=\"_blank\">",
"        15007110",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Castro C and Gourley M, \"Diagnosis and Treatment of Inflammatory Myopathy: Issues and Management,\"",
"      <i>",
"       Ther Adv Musculoskelet Dis",
"      </i>",
"      , 2012, 4(2):111-20.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/56/9095/abstract-text/22870499/pubmed\" id=\"22870499\" target=\"_blank\">",
"        22870499",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      de Denus S and Spinler SA, &ldquo;Early Statin Therapy for Acute Coronary Syndromes,&rdquo;",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 2002, 36(11):1749-58.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/56/9095/abstract-text/12398573/pubmed\" id=\"12398573\" target=\"_blank\">",
"        12398573",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III),&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2001, 285(19):2486-97.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/56/9095/abstract-text/11368702/pubmed\" id=\"11368702\" target=\"_blank\">",
"        11368702",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fernandez AB, Karas RH, Alsheikh-Ali AA, et al, &ldquo;Statins and Interstitial Lung Disease: A Systematic Review of the Literature and of Food and Drug Administration Adverse Event Reports,&rdquo;",
"      <i>",
"       Chest",
"      </i>",
"      , 2008, 134(4):824-30.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/56/9095/abstract-text/18689579/pubmed\" id=\"18689579\" target=\"_blank\">",
"        18689579",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fihn SD, Gardin JM, Abrams J, et al, &ldquo;2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2012, 126(25):3097-137.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/56/9095/abstract-text/23166211/pubmed\" id=\"23166211\" target=\"_blank\">",
"        23166211",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fleisher LA, Beckman JA, Brown KA, et al, &ldquo;2009 ACCF/AHA Focused Update on Perioperative Beta Blockade Incorporated Into the ACC/AHA 2007 Guidelines on Perioperative Cardiovascular Evaluation and Care for Noncardiac Surgery. A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines,&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 2009, 54(22):e13-118.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/56/9095/abstract-text/19926002/pubmed\" id=\"19926002\" target=\"_blank\">",
"        19926002",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Grundy SM, Cleeman JI, Merz CN, et al, &ldquo;Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines,&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 2004, 44(3):720-32.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/56/9095/abstract-text/15358046/pubmed\" id=\"15358046\" target=\"_blank\">",
"        15358046",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Heeschen C, Hamm CW, Laufs U, et al, &ldquo;Withdrawal of Statins Increases Event Rates in Patients With Acute Coronary Syndromes,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2002, 105(12):1446-52.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/56/9095/abstract-text/11914253/pubmed\" id=\"11914253\" target=\"_blank\">",
"        11914253",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hillis LD, Smith PK, Anderson JL, et al, &ldquo;2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2011, 124(23):2610-42.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/56/9095/abstract-text/22064600/pubmed\" id=\"22064600\" target=\"_blank\">",
"        22064600",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      LaRosa JC, Grundy SM, Waters DD, et al, &ldquo;Intensive Lipid Lowering With Atorvastatin in Patients With Stable Coronary Disease,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2005, 352(14):1425-35.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/56/9095/abstract-text/15755765/pubmed\" id=\"15755765\" target=\"_blank\">",
"        15755765",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      LeManach Y, Godet G, Coriat P, et al, &ldquo;The Impact of Postoperative Discontinuation or Continuation of Chronic Statin Therapy on Cardiac Outcome After Major Vascular Surgery,&rdquo;",
"      <i>",
"       Anesth Analg",
"      </i>",
"      , 2007, 104(6):1326-33.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/56/9095/abstract-text/17513620/pubmed\" id=\"17513620\" target=\"_blank\">",
"        17513620",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;MRC/BHF Heart Protection Study of Cholesterol Lowering With Simvastatin in 20,536 High-Risk Individuals: A Randomised Placebo-Controlled Trial. Heart Protection Study Collaborative Group,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 2002, 360(9326):7-22.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/56/9095/abstract-text/12114036/pubmed\" id=\"12114036\" target=\"_blank\">",
"        12114036",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Neuvonen PJ, Niemi M, and Backman JT, &ldquo;Drug Interactions with Lipid-lowering Drugs: Mechanisms and Clinical Relevance,&rdquo;",
"      <i>",
"       Clin Pharmacol Ther",
"      </i>",
"      , 2006, 80(6):565-81.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/56/9095/abstract-text/17178259/pubmed\" id=\"17178259\" target=\"_blank\">",
"        17178259",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pasternak RC, Smith SC Jr, Bairey-Merz CN, et al, &ldquo;ACC/AHA/NHLBI Clinical Advisory on the Use and Safety of Statins,&rdquo;",
"      <i>",
"       Stroke",
"      </i>",
"      , 2002, 33(9):2337-41. Available at file://stroke.ahajournals.org/cgi/content/short/33/9/2337",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/56/9095/abstract-text/12215610/pubmed\" id=\"12215610\" target=\"_blank\">",
"        12215610",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Poldermans D, Bax JJ, Kertai MD, et al, &ldquo;Statins Are Associated With a Reduced Incidence of Perioperative Mortality in Patients Undergoing Major Noncardiac Vascular Surgery,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2003, 107(14):1848-51.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/56/9095/abstract-text/12695283/pubmed\" id=\"12695283\" target=\"_blank\">",
"        12695283",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ridker PM, Danielson E, Fonseca FAH, et al, &ldquo;Rosuvastatin to Prevent Vascular Events in Men and Women With Elevated C-Reactive Protein,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2008, 359(21):2195-207.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/56/9095/abstract-text/18997196/pubmed\" id=\"18997196\" target=\"_blank\">",
"        18997196",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sever PS, Dahlof B, Poulter NR, et al, &ldquo;Prevention of Coronary and Stroke Events With Atorvastatin in Hypertensive Patients Who Have Average or Lower-Than-Average Cholesterol Concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial - Lipid-Lowering Arm (ASCOT-LLA): A Multicentre Randomised Controlled Trial,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 2003, 361(9364):1149-58.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/56/9095/abstract-text/12686036/pubmed\" id=\"12686036\" target=\"_blank\">",
"        12686036",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Shepherd J, Cobbe SM, Ford I, et al, &ldquo;Prevention of Coronary Heart Disease With Pravastatin in Men With Hypercholesterolemia. West of Scotland Coronary Prevention Study Group,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1995, 333(20):1301-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/56/9095/abstract-text/7566020/pubmed\" id=\"7566020\" target=\"_blank\">",
"        7566020",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Smith SC Jr, Benjamin EJ, Bonow RO, et al, &ldquo;AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients With Coronary and Other Atherosclerotic Vascular Disease: 2011 Update: A Guideline From the American Heart Association and American College of Cardiology Foundation,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2011, 124(22):2458-73.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/56/9095/abstract-text/22052934/pubmed\" id=\"22052934\" target=\"_blank\">",
"        22052934",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9532 Version 43.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-122.72.76.133-E4AAF914B2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_56_9095=[""].join("\n");
var outline_f8_56_9095=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8101006\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8101007\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8119990\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8119991\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8119992\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8119993\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8120023\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8119911\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8119995\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8100960\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8101005\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8119923\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8119917\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8119918\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8119945\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8119946\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8119949\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8119913\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8119914\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8119916\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8119994\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16322688\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8119997\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12992814\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8119952\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8119957\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9532\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9532|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?16/61/17365?source=related_link\">",
"      Pitavastatin: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f8_56_9096="Poorly differentiated cancer from an unknown primary site";
var content_f8_56_9096=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Poorly differentiated cancer from an unknown primary site",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/56/9096/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/56/9096/contributors\">",
"     John D Hainsworth, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/56/9096/contributors\">",
"     F Anthony Greco, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/56/9096/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/56/9096/contributors\">",
"     George P Canellos, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/56/9096/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/56/9096/contributors\">",
"     Michael E Ross, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?8/56/9096/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 3, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cancer of unknown primary site (CUP) is a relatively common clinical entity, with about 4 to 5 percent of all invasive cancers not having an apparent primary at presentation [",
"    <a class=\"abstract\" href=\"UTD.htm?8/56/9096/abstract/1\">",
"     1",
"    </a>",
"    ]. Within this category, tumors from many primary sites with varying biology are represented. Most cancers of unknown primary site are adenocarcinomas, and can be recognized by routine histologic examination. However, 20 to 25 percent of CUPs are poorly differentiated, and cannot be precisely characterized by histologic examination. About 80 percent of these poorly differentiated tumors have features of carcinoma, and are termed &ldquo;poorly differentiated carcinoma&rdquo; after initial pathologic examination. In the remainder, histologic examination results in the diagnosis of &ldquo;poorly differentiated neoplasm&rdquo;, signifying the inability to distinguish between carcinoma, melanoma, lymphoma, sarcoma, or germ cell tumor.",
"   </p>",
"   <p>",
"    As accurate a diagnosis as possible is essential since the therapy for various tumors can be quite different and may be curative in some patients. The diagnostic approach to poorly differentiated cancers of unknown primary site will be reviewed here, along with the prognostic and therapeutic implications.",
"   </p>",
"   <p>",
"    Other relevant topics include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/26/14758?source=see_link\">",
"       \"Overview of the classification and management of cancers of unknown primary site\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/29/28121?source=see_link\">",
"       \"Adenocarcinoma of unknown primary site\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/6/15459?source=see_link\">",
"       \"Squamous cell carcinoma of unknown primary site\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/28/19911?source=see_link\">",
"       \"Head and neck squamous cell carcinoma of unknown primary\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/13/41174?source=see_link\">",
"       \"Neuroendocrine cancer of unknown primary site\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/21/43352?source=see_link\">",
"       \"Axillary node metastases with occult primary breast cancer\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DIAGNOSTIC EVALUATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1568144326\">",
"    <span class=\"h2\">",
"     Initial approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;The approach to the patient with a cancer of unknown origin requires obtaining an adequate biopsy sample or cytologic specimen. (See",
"    <a class=\"local\" href=\"#H1568144418\">",
"     'Pathologic studies'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Once a diagnosis of malignancy has been established, a thorough history, physical examination, and routine laboratory testing should be obtained in all patients with poorly differentiated neoplasm in an effort to identify the primary site.",
"     </li>",
"     <li>",
"      Computerized tomography (CT) or magnetic resonance imaging (MRI) of the chest and abdomen should be performed because of the high frequency of mediastinal and retroperitoneal lymphadenopathy in these patients. Positron emission tomography (PET) and",
"      <span class=\"nowrap\">",
"       PET/CT",
"      </span>",
"      are often useful in detecting the primary tumor",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      identifying additional sites of metastatic disease [",
"      <a class=\"abstract\" href=\"UTD.htm?8/56/9096/abstract/2,3\">",
"       2,3",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Serum levels of human chorionic gonadotropin (hCG) and alpha-fetoprotein (AFP) should be obtained in all patients with poorly differentiated tumors of unknown primary site, since significant elevations of these tumor markers suggest the diagnosis of extragonadal germ cell tumor. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/52/10058?source=see_link\">",
"       \"Extragonadal germ cell tumors involving the mediastinum and retroperitoneum\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Other serum tumor markers, such as carcinoembryonic antigen (CEA), CA-125, CA19-9, and CA15-3, are not useful in identifying the primary site or tissue of origin. However, these markers are often elevated and serial measurement may be useful in subsequently following the response to therapy in and individual patient.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1568144418\">",
"    <span class=\"h2\">",
"     Pathologic studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;The first step in the diagnostic evaluation of a patient with poorly differentiated cancer of unknown primary site is review of the biopsy material.",
"   </p>",
"   <p>",
"    A nonspecific light microscopic diagnosis can be due to a biopsy specimen that is very small or poorly preserved. In particular, tissue obtained by fine needle aspiration (FNA) often provides inadequate diagnostic material in patients with poorly differentiated tumors, because histologic detail is poorly preserved and the ability to perform special studies is limited by the small amount of tissue available.",
"   </p>",
"   <p>",
"    Examination of poorly differentiated malignancies using routine light microscopy alone is inadequate. There are no light microscopic features that can reliably definitively distinguish between these different tumor groups and between chemosensitive tumors and those that are resistant to standard chemotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?8/56/9096/abstract/4\">",
"     4",
"    </a>",
"    ]. Even with careful retrospective review of these cases, some tumors that are highly responsive to specific treatment regimens (germ cell tumor, lymphoma) cannot be readily distinguished morphologically.",
"   </p>",
"   <p>",
"    Thus, tumor biopsies from these patients should undergo additional pathologic evaluation using immunohistochemistry (IHC). If the immunohistochemistry results are inconclusive, molecular tumor profiling should be performed. In selected cases, electron microscopy (EM) and chromosomal analysis should be considered if other results are inconclusive.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h3\">",
"     Immunohistochemistry",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immunohistochemistry (IHC) is particularly valuable in identifying the tumor lineage (carcinoma versus lymphoma versus sarcoma, etc.) in patients with poorly differentiated neoplasm (",
"    <a class=\"graphic graphic_table graphicRef62750 \" href=\"UTD.htm?23/26/23980\">",
"     table 1",
"    </a>",
"    ). Once a poorly differentiated carcinoma has been identified, IHC can sometimes suggest a specific tumor type",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    primary site (",
"    <a class=\"graphic graphic_table graphicRef56518 \" href=\"UTD.htm?29/14/29932\">",
"     table 2",
"    </a>",
"    ). IHC uses antibodies that are directed at specific cell components or products including enzymes, normal tissue components, hormones and tumor markers. Such staining can be performed on formalin-fixed, paraffin-embedded tissue. Considerable technical expertise is required to perform these tests and proper interpretation requires an experienced pathologist.",
"   </p>",
"   <p>",
"    No IHC staining pattern is completely specific. However, a specific diagnosis is often suggested by the IHC results. Certain stains, (eg, LCA and PSA) rarely yield false positive results, while false positive and false negative IHC results are frequent with the others. Some carcinomas stain positively for vimentin and some sarcomas stain for keratin. Conversely, some poorly differentiated carcinomas lose all specific markers and are negative for keratin markers.",
"   </p>",
"   <p>",
"    Examples of the potential utility of IHC in the evaluation of poorly differentiated neoplasms include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Monoclonal antibodies that react with antigens present on human white blood cells can reliably differentiate hematologic from nonhematologic neoplasms in formalin-fixed sections [",
"      <a class=\"abstract\" href=\"UTD.htm?8/56/9096/abstract/5-9\">",
"       5-9",
"      </a>",
"      ]. In one study, immunostaining for leukocyte common antigen (LCA, CD45) was applied to 315 lymphomas and 420 nonhematologic tumors [",
"      <a class=\"abstract\" href=\"UTD.htm?8/56/9096/abstract/10\">",
"       10",
"      </a>",
"      ]. All of the non-Hodgkin lymphomas, 12 of 25 Hodgkin lymphomas, and none of the non-hematologic tumors were LCA positive.",
"     </li>",
"     <li>",
"      Antibodies to intermediate filament proteins (vimentin, keratin, and desmin) are useful to distinguish between lymphoma and other neoplasms. Lymphomas can be positive for vimentin but are negative for keratin and desmin, which are characteristic markers for benign and malignant epithelial or muscular tissues, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?8/56/9096/abstract/11-13\">",
"       11-13",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Positive staining for S100 protein, HMB-45 antigen, and vimentin supports the diagnosis of amelanotic melanoma [",
"      <a class=\"abstract\" href=\"UTD.htm?8/56/9096/abstract/14,15\">",
"       14,15",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Positive staining for factor VIII-related antigen is a specific but not sensitive marker for angiosarcoma [",
"      <a class=\"abstract\" href=\"UTD.htm?8/56/9096/abstract/16,17\">",
"       16,17",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Positive staining for c-kit (CD117) supports the diagnosis of a gastrointestinal stromal tumor [",
"      <a class=\"abstract\" href=\"UTD.htm?8/56/9096/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    After a poorly differentiated cancer is recognized to be a carcinoma, IHC staining can sometimes provide further characterization:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A neuroendocrine carcinoma (eg, small cell lung cancer, carcinoid, islet cell tumor) is suggested by positive immunostaining for chromogranin A or synaptophysin [",
"      <a class=\"abstract\" href=\"UTD.htm?8/56/9096/abstract/19\">",
"       19",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The IHC detection of prostate specific antigen (PSA) may indicate prostate cancer in a man [",
"      <a class=\"abstract\" href=\"UTD.htm?8/56/9096/abstract/20\">",
"       20",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      IHC staining for octamer binding transcription factor 4 (OCT4, also called POU domain class 5 transcription factor 1) establishes a germ cell origin for a tumor [",
"      <a class=\"abstract\" href=\"UTD.htm?8/56/9096/abstract/21\">",
"       21",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A substantial percentage of unknown primary cancers over express p53, bcl-2, c-myc, Ras, and HER2 (c-erbB-2) oncoproteins, which may narrow the differential diagnosis [",
"      <a class=\"abstract\" href=\"UTD.htm?8/56/9096/abstract/22-25\">",
"       22-25",
"      </a>",
"      ]. As an example, in one study of 371 adenocarcinomas of breast, lung, and stomach, a large proportion (79 percent) of invasive breast carcinomas expressed bcl-2 compared to only 6 and 8 percent of pulmonary and gastric carcinomas [",
"      <a class=\"abstract\" href=\"UTD.htm?8/56/9096/abstract/25\">",
"       25",
"      </a>",
"      ]. Furthermore, the intensity of staining was moderate to intense in 70 percent of the breast cancers, compared with only 1 to 2 percent of gastric and lung carcinomas.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1568146501\">",
"    <span class=\"h3\">",
"     Molecular tumor profiling",
"    </span>",
"    &nbsp;&mdash;&nbsp;Molecular tumor profiling is a valuable new addition to the diagnosis and management of patients with cancer of unknown primary site. To date, most of the development of these techniques has focused on predicting the tissue of origin in patients with carcinoma (usually adenocarcinoma) of unknown primary site. The role of molecular tumor profiling in identifying the lineage of poorly differentiated neoplasms of unknown primary site (ie, carcinoma versus sarcoma versus lymphoma, etc.) has not been investigated. Until supporting evidence is available, routine use of molecular tumor profiling should be restricted to patients in whom pathologic evaluation has narrowed the diagnostic spectrum by identifying a carcinoma. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/29/28121?source=see_link&amp;anchor=H7#H7\">",
"     \"Adenocarcinoma of unknown primary site\", section on 'Molecular tumor profiling'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Electron microscopy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Electron microscopy requires special tissue cutting and fixation, and is relatively expensive. For these reasons, electron microscopy usually is reserved for neoplasms whose lineage remains unclear after light microscopy and IHC.",
"   </p>",
"   <p>",
"    Electron microscopy is extremely reliable in distinguishing lymphoma from carcinoma and is probably superior to IHC for the identification of poorly differentiated sarcomas. The presence of structures such as neurosecretory granules in neuroendocrine tumors and premelanosomes in melanoma can help identify these neoplasms.",
"   </p>",
"   <p>",
"    Electron microscopy can also provide evidence for adenocarcinoma or squamous cell carcinoma in cases in which light microscopy is not distinctive. However, it is usually impossible to pinpoint the origin of poorly differentiated adenocarcinomas or squamous cell carcinomas by electron microscopic studies, since few ultrastructural features are specific for any site of origin [",
"    <a class=\"abstract\" href=\"UTD.htm?8/56/9096/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Undifferentiated tumors often lose specific ultrastructural features as well as typical histology. For this reason, the absence of a particular ultrastructural finding cannot be used to rule out a specific diagnosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Chromosome analysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The identification of tumor-specific chromosome abnormalities has allowed the application of cytogenetic analysis to the evaluation of poorly differentiated neoplasms of unknown primary site in selected cases.",
"   </p>",
"   <p>",
"    The utility of cytogenetic analysis can be illustrated by the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The majority of B cell lymphomas contain immunoglobulin (Ig) gene rearrangements, and they usually express a unique clonal surface Ig that provides a specific tumor marker [",
"      <a class=\"abstract\" href=\"UTD.htm?8/56/9096/abstract/27-29\">",
"       27-29",
"      </a>",
"      ]. In lymphomas that lack detectable surface or cytoplasmic Ig, diagnostic clonal gene rearrangements are often demonstrable. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/23/31098?source=see_link\">",
"       \"Normal B and T lymphocyte development\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/55/28536?source=see_link\">",
"       \"Cytogenetic and molecular genetic diagnostic tools\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A specific chromosomal translocation (t[11;22] [q24;q12]) is found in all peripheral primitive neuroectodermal tumors and is also frequent in Ewing sarcoma [",
"      <a class=\"abstract\" href=\"UTD.htm?8/56/9096/abstract/30,31\">",
"       30,31",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/18/32042?source=see_link\">",
"       \"Pathogenetic factors in soft tissue and bone sarcomas\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/37/7770?source=see_link&amp;anchor=H8#H8\">",
"       \"Epidemiology, pathology, and molecular genetics of the Ewing sarcoma family of tumors\", section on 'Molecular genetics'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      An isochromosome of the short arm of chromosome 12 (i12p) can be detected in a large percentage of testicular and extragonadal germ cell tumors in men [",
"      <a class=\"abstract\" href=\"UTD.htm?8/56/9096/abstract/32\">",
"       32",
"      </a>",
"      ]. The identification of germ cell tumors has important therapeutic and prognostic implications because of the responsiveness of these tumors to cisplatin-based chemotherapy. The development of a genomic hybridization technique that can detect extra 12p material using paraffin-embedded tissue specimens may make this procedure more clinically applicable by avoiding the need to obtain fresh tissue by biopsy, but this procedure is not widely available [",
"      <a class=\"abstract\" href=\"UTD.htm?8/56/9096/abstract/33\">",
"       33",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A chromosomal translocation NUT gene is associated with aggressive, refractory midline carcinoma in children and young adults [",
"      <a class=\"abstract\" href=\"UTD.htm?8/56/9096/abstract/34\">",
"       34",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H1568146612\">",
"       'NUT midline carcinoma'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Detection of the Epstein-Barr virus genome can be an indicator of nasopharyngeal carcinoma in patients with metastatic disease in cervical lymph nodes and an undetermined primary site. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/36/26184?source=see_link&amp;anchor=H8#H8\">",
"       \"Epidemiology, etiology, and diagnosis of nasopharyngeal carcinoma\", section on 'Epstein-Barr virus'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     TREATMENT AND PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with poorly differentiated neoplasms of unknown primary site, the ability to distinguish between different tumor types can have very important prognostic",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    therapeutic implications.",
"   </p>",
"   <p>",
"    When specialized diagnostic studies identify a treatable neoplasm, therapy should follow guidelines established for that tumor. Examples of treatable tumor types occasionally identified in these patients include neuroendocrine carcinoma, Ewing sarcoma, and a variety of primitive sarcomas. Other important tumor groups that may be identified are discussed in this section.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Lymphomas",
"    </span>",
"    &nbsp;&mdash;&nbsp;Undifferentiated neoplasms that are identified as lymphoma respond well to the same combination chemotherapy regimens that are used for aggressive non-Hodgkin lymphoma. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/45/26330?source=see_link\">",
"     \"Initial treatment of advanced stage diffuse large B cell lymphoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/18/33065?source=see_link\">",
"     \"Initial treatment of peripheral T cell lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This was illustrated in a report of 35 patients, all of whom presented with histologically unclassified neoplasms that expressed LCA (CD45) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/56/9096/abstract/35\">",
"     35",
"    </a>",
"    ]. Treatment with standard antilymphoma regimens resulted in an actuarial disease-free survival of 45 percent at 30 months. This outcome was similar to that for a group of concurrently treated patients with aggressive lymphoma and typical histology on light microscopy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1568145737\">",
"    <span class=\"h2\">",
"     Extragonadal germ cell tumors",
"    </span>",
"    &nbsp;&mdash;&nbsp;A few patients with poorly differentiated carcinoma of unknown primary site have extragonadal germ cell tumors that are unrecognizable by standard histologic criteria. These patients typically have some but not all of the following characteristics:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Young age",
"     </li>",
"     <li>",
"      Male gender",
"     </li>",
"     <li>",
"      Predominant tumor location in the mediastinum or retroperitoneum",
"     </li>",
"     <li>",
"      Marked elevation of the serum hCG or AFP levels",
"     </li>",
"     <li>",
"      Presence of 12p chromosomal gain (isochromosome 12p)",
"     </li>",
"     <li>",
"      Immunohistochemical staining for octamer binding transcription factor 4 (also called POU domain class 5 transcription factor 1) [",
"      <a class=\"abstract\" href=\"UTD.htm?8/56/9096/abstract/21\">",
"       21",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Most young men with poorly differentiated carcinoma and features of extragonadal germ cell tumor have an excellent response to chemotherapy, and some are cured with cisplatin-based regimens. For this reason, all patients with poorly differentiated carcinoma or poorly differentiated adenocarcinoma of unknown primary site who have these characteristics should be treated according to the guidelines established for poor prognosis germ cell tumors. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/63/24568?source=see_link\">",
"     \"Initial risk-stratified treatment for advanced testicular germ cell tumors\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1568145977\">",
"    <span class=\"h2\">",
"     Poorly differentiated carcinoma without characteristics of germ cell tumor",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients with poorly differentiated carcinoma of unknown primary site do not have features typical of extragonadal germ cell tumor, and an empiric trial of chemotherapy has been recommended. Several investigators have reported higher overall response rates in this group when compared to patients with adenocarcinoma of unknown primary site, particularly when platinum-based regimens are used [",
"    <a class=\"abstract\" href=\"UTD.htm?8/56/9096/abstract/36-39\">",
"     36-39",
"    </a>",
"    ]. In addition, some investigators have reported a minority (15 percent) of patients with complete response and long-term survival [",
"    <a class=\"abstract\" href=\"UTD.htm?8/56/9096/abstract/36\">",
"     36",
"    </a>",
"    ], while others have not observed such a subset [",
"    <a class=\"abstract\" href=\"UTD.htm?8/56/9096/abstract/40\">",
"     40",
"    </a>",
"    ]. Unfortunately, most patients with poorly differentiated carcinoma of unknown primary site have short survival (median 8 to 10 months) when treated with empiric platinum-based regimens [",
"    <a class=\"abstract\" href=\"UTD.htm?8/56/9096/abstract/36,38,39\">",
"     36,38,39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although data remain incomplete, support for site-specific therapy directed by the results of molecular tumor profiling, rather than empiric treatment, is becoming increasingly compelling. At present, most data exist for patients with adenocarcinoma of unknown primary site. However, it seems likely that molecular tumor profiling will also be effective in patients with poorly differentiated carcinoma. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/29/28121?source=see_link\">",
"     \"Adenocarcinoma of unknown primary site\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Validation of the available molecular profiling assays was performed in patients with known primary tumors, including both adenocarcinoma and poorly differentiated carcinoma histology. Accuracy was similar regardless of histology.",
"     </li>",
"     <li>",
"      In the single prospective study to date, 18 percent of patients had poorly differentiated carcinoma, and an additional 24 percent had poorly differentiated adenocarcinoma [",
"      <a class=\"abstract\" href=\"UTD.htm?8/56/9096/abstract/41\">",
"       41",
"      </a>",
"      ]. In this study, site-specific treatment directed by molecular profiling results led to a median survival of 12.5 months in the entire group of 194 patients. Those predicted to have more responsive tumor types had longer median survival than did those with less responsive types (13.4 versus 7.6 months, respectively).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Occasionally, a patient with poorly differentiated carcinoma of unknown primary site has clinical features that fit one of the treatable subsets described for adenocarcinoma of unknown primary site. These patients should receive the same treatment as described for those with adenocarcinoma. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/29/28121?source=see_link&amp;anchor=H9#H9\">",
"     \"Adenocarcinoma of unknown primary site\", section on 'Specific patient subgroups'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Molecular tumor profiling should be included in the diagnostic evaluation of patients with poorly differentiated carcinoma of unknown primary site. If a tissue of origin is predicted, site-specific therapy is appropriate. Until further experience with molecular assay-directed therapy in patients with poorly differentiated carcinoma of unknown primary site accumulates, empiric therapy is also an acceptable option. Although the optimum empiric chemotherapy regimen is not well defined, we favor a platinum-based combination [",
"    <a class=\"abstract\" href=\"UTD.htm?8/56/9096/abstract/36-39,42-45\">",
"     36-39,42-45",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/29/28121?source=see_link&amp;anchor=H19#H19\">",
"     \"Adenocarcinoma of unknown primary site\", section on 'Empiric therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The use of high-dose chemotherapy with stem cell or hematopoietic growth factor support does not appear to improve the outcome of these patients [",
"    <a class=\"abstract\" href=\"UTD.htm?8/56/9096/abstract/46,47\">",
"     46,47",
"    </a>",
"    ]. In one report, 20 patients less than 61 years of age with poorly differentiated adenocarcinoma or poorly differentiated carcinoma were treated with high-dose chemotherapy, hematopoietic progenitor cells and growth factor support [",
"    <a class=\"abstract\" href=\"UTD.htm?8/56/9096/abstract/46\">",
"     46",
"    </a>",
"    ]. There was only one complete response and overall median survival was 11 months.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1568146612\">",
"    <span class=\"h2\">",
"     NUT midline carcinoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;NUT midline carcinomas are defined by the presence of a chromosomal rearrangement of the NUT gene [",
"    <a class=\"abstract\" href=\"UTD.htm?8/56/9096/abstract/34,48\">",
"     34,48",
"    </a>",
"    ]. The molecular translocation involves the BRD4 gene in 70 percent of cases but has also been described with other genes. NUT midline carcinomas are aggressive, poorly differentiated tumors that include variable degrees of squamous differentiation in approximately one-half of cases.",
"   </p>",
"   <p>",
"    The largest experience with NUT midline carcinomas was a retrospective analysis of 63 cases that included 59 cases from a single institution combined with 4 cases from the literature over a 22 year period [",
"    <a class=\"abstract\" href=\"UTD.htm?8/56/9096/abstract/34\">",
"     34",
"    </a>",
"    ]. Approximately one-half of the cases arose in patients less than 18 years of age, and there was an equal distribution in males and females. Of 54 cases with adequate information, 31 (57 percent) arose in the thorax, 19 (35 percent) in the head and neck, and 4 (7 percent) at other sites.",
"   </p>",
"   <p>",
"    Metastases were present at diagnosis in 60 percent of cases. Despite aggressive treatment (surgery, radiation therapy,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    chemotherapy), the prognosis was poor. The two-year progression-free survival and overall survival rates were 9 and 19 percent, respectively. No systemic therapeutic approach has been shown to have significant activity in NUT midline carcinoma.",
"   </p>",
"   <p>",
"    Most of the cases of NUT midline carcinoma have been diagnosed in recent years, presumably due to increased awareness of this entity and better diagnostic capabilities. The commercially available C52 monoclonal antibody can be used for immunohistochemical testing of poorly differentiated carcinomas without glandular differentiation that arise in the chest or head and neck [",
"    <a class=\"abstract\" href=\"UTD.htm?8/56/9096/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Light microscopy generally cannot establish a diagnosis in patients with poorly differentiated cancers of unknown primary site. Specialized studies, including immunohistochemistry, molecular tumor profiling, and in selected cases electron microscopy (EM)",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      chromosomal analysis can usually distinguish between a diagnosis of carcinoma, germ cell tumor, lymphoma, melanoma, or sarcoma. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Diagnostic evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      When specialized pathologic studies are consistent with a diagnosis of poorly differentiated lymphoma, extragonadal germ cell tumor, melanoma, or sarcoma, treatment should be based upon that diagnostic category. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Treatment and prognosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For other patients whose evaluation is consistent with a poorly differentiated carcinoma, the information derived from immunohistochemistry and molecular tumor profiling will often suggest the site of origin. In this setting, treatment should be based upon those results. For patients with a good performance status in whom the complete pathologic evaluation does not allow classification beyond poorly differentiated carcinoma, a trial of empiric chemotherapy is indicated. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/29/28121?source=see_link&amp;anchor=H315626628#H315626628\">",
"       \"Adenocarcinoma of unknown primary site\", section on 'Treatment for patients not included in specific subgroups'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/56/9096/abstract/1\">",
"      Greco FA, Hainsworth JD. Introduction: unknown primary cancer. Semin Oncol 2009; 36:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/56/9096/abstract/2\">",
"      S&egrave;ve P, Billotey C, Broussolle C, et al. The role of 2-deoxy-2-[F-18]fluoro-D-glucose positron emission tomography in disseminated carcinoma of unknown primary site. Cancer 2007; 109:292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/56/9096/abstract/3\">",
"      Podoloff DA. PET/CT and occult primary tumors. J Natl Compr Canc Netw 2009; 7:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/56/9096/abstract/4\">",
"      Hainsworth JD, Wright EP, Gray GF Jr, Greco FA. Poorly differentiated carcinoma of unknown primary site: correlation of light microscopic findings with response to cisplatin-based combination chemotherapy. J Clin Oncol 1987; 5:1275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/56/9096/abstract/5\">",
"      Battifora H, Trowbridge IS. A monoclonal antibody useful for the differential diagnosis between malignant lymphoma and nonhematopoietic neoplasms. Cancer 1983; 51:816.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/56/9096/abstract/6\">",
"      Gabbiani G, Kapanci Y, Barazzone P, Franke WW. Immunochemical identification of intermediate-sized filaments in human neoplastic cells. A diagnostic aid for the surgical pathologist. Am J Pathol 1981; 104:206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/56/9096/abstract/7\">",
"      Nagle RB, McDaniel KM, Clark VA, Payne CM. The use of antikeratin antibodies in the diagnosis of human neoplasms. Am J Clin Pathol 1983; 79:458.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/56/9096/abstract/8\">",
"      Schlegel R, Banks-Schlegel S, McLeod JA, Pinkus GS. Immunoperoxidase localization of keratin in human neoplasms: a preliminary survey. Am J Pathol 1980; 101:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/56/9096/abstract/9\">",
"      Warnke RA, Gatter KC, Falini B, et al. Diagnosis of human lymphoma with monoclonal antileukocyte antibodies. N Engl J Med 1983; 309:1275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/56/9096/abstract/10\">",
"      Michels S, Swanson PE, Frizzera G, Wick MR. Immunostaining for leukocyte common antigen using an amplified avidin-biotin-peroxidase complex method and paraffin sections. A study of 735 hematopoietic and nonhematopoietic human neoplasms. Arch Pathol Lab Med 1987; 111:1035.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/56/9096/abstract/11\">",
"      Denk H, Krepler R, Artlieb U, et al. Proteins of intermediate filaments. An immunohistochemical and biochemical approach to the classification of soft tissue tumors. Am J Pathol 1983; 110:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/56/9096/abstract/12\">",
"      Osborn M, Weber K. Tumor diagnosis by intermediate filament typing: a novel tool for surgical pathology. Lab Invest 1983; 48:372.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/56/9096/abstract/13\">",
"      Ramaekers FC, Vroom TM, Moesker O, et al. The use of antibodies to intermediate filament proteins in the differential diagnosis of lymphoma versus metastatic carcinoma. Histochem J 1985; 17:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/56/9096/abstract/14\">",
"      Kahn HJ, Marks A, Thom H, Baumal R. Role of antibody to S100 protein in diagnostic pathology. Am J Clin Pathol 1983; 79:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/56/9096/abstract/15\">",
"      Mottolese M, Venturo I, Benevolo M, et al. Immunocytochemical diagnosis of amelanotic metastatic melanoma using monoclonal antibodies HMB-45 and Ep1-3. Melanoma Res 1994; 4:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/56/9096/abstract/16\">",
"      Ohsawa M, Naka N, Tomita Y, et al. Use of immunohistochemical procedures in diagnosing angiosarcoma. Evaluation of 98 cases. Cancer 1995; 75:2867.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/56/9096/abstract/17\">",
"      Leader M, Collins M, Patel J, Henry K. Staining for factor VIII related antigen and Ulex europaeus agglutinin I (UEA-I) in 230 tumours. An assessment of their specificity for angiosarcoma and Kaposi's sarcoma. Histopathology 1986; 10:1153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/56/9096/abstract/18\">",
"      Miettinen M, Lasota J. Gastrointestinal stromal tumors--definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis. Virchows Arch 2001; 438:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/56/9096/abstract/19\">",
"      O'Connor DT, Burton D, Deftos LJ. Immunoreactive human chromogranin A in diverse polypeptide hormone producing human tumors and normal endocrine tissues. J Clin Endocrinol Metab 1983; 57:1084.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/56/9096/abstract/20\">",
"      Allhoff EP, Proppe KH, Chapman CM, et al. Evaluation of prostate specific acid phosphatase and prostate specific antigen in identification of prostatic cancer. J Urol 1983; 129:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/56/9096/abstract/21\">",
"      Cheng L. Establishing a germ cell origin for metastatic tumors using OCT4 immunohistochemistry. Cancer 2004; 101:2006.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/56/9096/abstract/22\">",
"      Bar-Eli M, Abbruzzese JL, Lee-Jackson D, Frost P. p53 gene mutation spectrum in human unknown primary tumors. Anticancer Res 1993; 13:1619.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/56/9096/abstract/23\">",
"      Briasoulis E, Tsokos M, Fountzilas G, et al. Bcl2 and p53 protein expression in metastatic carcinoma of unknown primary origin: biological and clinical implications. A Hellenic Co-operative Oncology Group study. Anticancer Res 1998; 18:1907.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/56/9096/abstract/24\">",
"      Pavlidis N, Briassoulis E, Bai M, et al. Overexpression of C-myc, Ras and C-erbB-2 oncoproteins in carcinoma of unknown primary origin. Anticancer Res 1995; 15:2563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/56/9096/abstract/25\">",
"      Alsabeh R, Wilson CS, Ahn CW, et al. Expression of bcl-2 by breast cancer: a possible diagnostic application. Mod Pathol 1996; 9:439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/56/9096/abstract/26\">",
"      Hammar SP. Metastatic adenocarcinoma of unknown primary origin. Hum Pathol 1998; 29:1393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/56/9096/abstract/27\">",
"      Arnold A, Cossman J, Bakhshi A, et al. Immunoglobulin-gene rearrangements as unique clonal markers in human lymphoid neoplasms. N Engl J Med 1983; 309:1593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/56/9096/abstract/28\">",
"      Cleary ML, Chao J, Warnke R, Sklar J. Immunoglobulin gene rearrangement as a diagnostic criterion of B-cell lymphoma. Proc Natl Acad Sci U S A 1984; 81:593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/56/9096/abstract/29\">",
"      Lossos IS, Okada CY, Tibshirani R, et al. Molecular analysis of immunoglobulin genes in diffuse large B-cell lymphomas. Blood 2000; 95:1797.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/56/9096/abstract/30\">",
"      Turc-Carel C, Aurias A, Mugneret F, et al. Chromosomes in Ewing's sarcoma. I. An evaluation of 85 cases of remarkable consistency of t(11;22)(q24;q12). Cancer Genet Cytogenet 1988; 32:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/56/9096/abstract/31\">",
"      Whang-Peng J, Triche TJ, Knutsen T, et al. Chromosome translocation in peripheral neuroepithelioma. N Engl J Med 1984; 311:584.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/56/9096/abstract/32\">",
"      Bosl GJ, Ilson DH, Rodriguez E, et al. Clinical relevance of the i(12p) marker chromosome in germ cell tumors. J Natl Cancer Inst 1994; 86:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/56/9096/abstract/33\">",
"      Summersgill B, Goker H, Osin P, et al. Establishing germ cell origin of undifferentiated tumors by identifying gain of 12p material using comparative genomic hybridization analysis of paraffin-embedded samples. Diagn Mol Pathol 1998; 7:260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/56/9096/abstract/34\">",
"      Bauer DE, Mitchell CM, Strait KM, et al. Clinicopathologic features and long-term outcomes of NUT midline carcinoma. Clin Cancer Res 2012; 18:5773.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/56/9096/abstract/35\">",
"      Horning SJ, Carrier EK, Rouse RV, et al. Lymphomas presenting as histologically unclassified neoplasms: characteristics and response to treatment. J Clin Oncol 1989; 7:1281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/56/9096/abstract/36\">",
"      Pouessel D, Culine S, Becht C, et al. Gemcitabine and docetaxel as front-line chemotherapy in patients with carcinoma of an unknown primary site. Cancer 2004; 100:1257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/56/9096/abstract/37\">",
"      Greco FA, Burris HA 3rd, Erland JB, et al. Carcinoma of unknown primary site. Cancer 2000; 89:2655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/56/9096/abstract/38\">",
"      Greco FA, Erland JB, Morrissey LH, et al. Carcinoma of unknown primary site: phase II trials with docetaxel plus cisplatin or carboplatin. Ann Oncol 2000; 11:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/56/9096/abstract/39\">",
"      Briasoulis E, Kalofonos H, Bafaloukos D, et al. Carboplatin plus paclitaxel in unknown primary carcinoma: a phase II Hellenic Cooperative Oncology Group Study. J Clin Oncol 2000; 18:3101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/56/9096/abstract/40\">",
"      Hainsworth JD, Johnson DH, Greco FA. Cisplatin-based combination chemotherapy in the treatment of poorly differentiated carcinoma and poorly differentiated adenocarcinoma of unknown primary site: results of a 12-year experience. J Clin Oncol 1992; 10:912.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/56/9096/abstract/41\">",
"      Hainsworth JD, Rubin MS, Spigel DR, et al. Molecular gene expression profiling to predict the tissue of origin and direct site-specific therapy in patients with carcinoma of unknown primary site: a prospective trial of the Sarah Cannon research institute. J Clin Oncol 2013; 31:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/56/9096/abstract/42\">",
"      Culine S, Lortholary A, Voigt JJ, et al. Cisplatin in combination with either gemcitabine or irinotecan in carcinomas of unknown primary site: results of a randomized phase II study--trial for the French Study Group on Carcinomas of Unknown Primary (GEFCAPI 01). J Clin Oncol 2003; 21:3479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/56/9096/abstract/43\">",
"      Hainsworth JD, Erland JB, Kalman LA, et al. Carcinoma of unknown primary site: treatment with 1-hour paclitaxel, carboplatin, and extended-schedule etoposide. J Clin Oncol 1997; 15:2385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/56/9096/abstract/44\">",
"      Greco FA, Burris HA 3rd, Litchy S, et al. Gemcitabine, carboplatin, and paclitaxel for patients with carcinoma of unknown primary site: a Minnie Pearl Cancer Research Network study. J Clin Oncol 2002; 20:1651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/56/9096/abstract/45\">",
"      Greco FA, Rodriguez GI, Shaffer DW, et al. Carcinoma of unknown primary site: sequential treatment with paclitaxel/carboplatin/etoposide and gemcitabine/irinotecan: a Minnie Pearl Cancer Research Network phase II trial. Oncologist 2004; 9:644.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/56/9096/abstract/46\">",
"      Culine S, Fabbro M, Ychou M, et al. Chemotherapy in carcinomas of unknown primary site: a high-dose intensity policy. Ann Oncol 1999; 10:569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/56/9096/abstract/47\">",
"      Culine S, Fabbro M, Ychou M, et al. Alternative bimonthly cycles of doxorubicin, cyclophosphamide, and etoposide, cisplatin with hematopoietic growth factor support in patients with carcinoma of unknown primary site. Cancer 2002; 94:840.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/56/9096/abstract/48\">",
"      French CA. Pathogenesis of NUT midline carcinoma. Annu Rev Pathol 2012; 7:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/56/9096/abstract/49\">",
"      Haack H, Johnson LA, Fry CJ, et al. Diagnosis of NUT midline carcinoma using a NUT-specific monoclonal antibody. Am J Surg Pathol 2009; 33:984.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4875 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.248-4F64B2DDF4-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_56_9096=[""].join("\n");
var outline_f8_56_9096=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H11\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DIAGNOSTIC EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1568144326\">",
"      Initial approach",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1568144418\">",
"      Pathologic studies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      - Immunohistochemistry",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1568146501\">",
"      - Molecular tumor profiling",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Electron microscopy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Chromosome analysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      TREATMENT AND PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Lymphomas",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1568145737\">",
"      Extragonadal germ cell tumors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1568145977\">",
"      Poorly differentiated carcinoma without characteristics of germ cell tumor",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1568146612\">",
"      NUT midline carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/4875\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/4875|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/26/23980\" title=\"table 1\">",
"      CUP immunostaining",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?29/14/29932\" title=\"table 2\">",
"      Immunohistochemistry CUP",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/29/28121?source=related_link\">",
"      Adenocarcinoma of unknown primary site",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/21/43352?source=related_link\">",
"      Axillary node metastases with occult primary breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/55/28536?source=related_link\">",
"      Cytogenetic and molecular genetic diagnostic tools",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/36/26184?source=related_link\">",
"      Epidemiology, etiology, and diagnosis of nasopharyngeal carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/37/7770?source=related_link\">",
"      Epidemiology, pathology, and molecular genetics of the Ewing sarcoma family of tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/52/10058?source=related_link\">",
"      Extragonadal germ cell tumors involving the mediastinum and retroperitoneum",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/28/19911?source=related_link\">",
"      Head and neck squamous cell carcinoma of unknown primary",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/63/24568?source=related_link\">",
"      Initial risk-stratified treatment for advanced testicular germ cell tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/45/26330?source=related_link\">",
"      Initial treatment of advanced stage diffuse large B cell lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/18/33065?source=related_link\">",
"      Initial treatment of peripheral T cell lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/13/41174?source=related_link\">",
"      Neuroendocrine cancer of unknown primary site",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/23/31098?source=related_link\">",
"      Normal B and T lymphocyte development",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/26/14758?source=related_link\">",
"      Overview of the classification and management of cancers of unknown primary site",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/18/32042?source=related_link\">",
"      Pathogenetic factors in soft tissue and bone sarcomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/6/15459?source=related_link\">",
"      Squamous cell carcinoma of unknown primary site",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f8_56_9097="Fecal incontinence related to pregnancy and vaginal delivery";
var content_f8_56_9097=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Fecal incontinence related to pregnancy and vaginal delivery",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/56/9097/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/56/9097/contributors\">",
"     Christina Lewicky-Gaupp, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/56/9097/contributors\">",
"     Dee E Fenner, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/56/9097/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/56/9097/contributors\">",
"     Linda Brubaker, MD, FACS, FACOG",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/56/9097/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/56/9097/contributors\">",
"     Sandy J Falk, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?8/56/9097/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 12, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fecal incontinence has a significant impact on quality of life [",
"    <a class=\"abstract\" href=\"UTD.htm?8/56/9097/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. Although disorders of stool consistency and a wide variety of anorectal conditions can cause fecal incontinence, the association between fecal incontinence and pregnancy, vaginal delivery, and anal sphincter laceration will be discussed here. Other etiologies of fecal incontinence and the effects of childbirth on the pelvic floor are reviewed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/59/22458?source=see_link\">",
"     \"Fecal incontinence in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/18/19753?source=see_link\">",
"     \"Pelvic floor disorders associated with pregnancy and childbirth\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFINITIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fecal incontinence refers to the involuntary loss of solid or liquid stool, while the term anal incontinence also includes involuntary release of flatus. Fecal incontinence will be the focus of this topic review.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PREVALENCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prevalence of fecal incontinence varies depending on the population studied, the definition of type of stool loss, and the frequency of episodes.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one population-based, age-stratified postal survey of women aged 30 to 90 years (n = 6000), the prevalence of fecal incontinence (defined as at least monthly loss of liquid or solid stool) was 7.7 percent (range 3 to 15.7 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?8/56/9097/abstract/4\">",
"       4",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      At three to six months after vaginal or cesarean delivery, as many as 13 to 25 percent of women report fecal incontinence [",
"      <a class=\"abstract\" href=\"UTD.htm?8/56/9097/abstract/5,6\">",
"       5,6",
"      </a>",
"      ]. However, the prevalence falls to 1 to 6 percent by 12 months [",
"      <a class=\"abstract\" href=\"UTD.htm?8/56/9097/abstract/7,8\">",
"       7,8",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     PREGNANCY AND FECAL INCONTINENCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pregnancy appears to be a risk factor for fecal incontinence. In studies of nulliparous women, the prevalence of fecal incontinence increased from 1 percent prior to pregnancy to 7 percent during pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?8/56/9097/abstract/7,9,10\">",
"     7,9,10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     LABOR AND FECAL INCONTINENCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of fecal incontinence associated with second stage of labor appears to be similar to the risk of vaginal delivery [",
"    <a class=\"abstract\" href=\"UTD.htm?8/56/9097/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. In small case control studies, similar incidence of fecal incontinence has been reported for women who underwent cesarean delivery after laboring compared with those who had an instrumented vaginal delivery.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     VAGINAL DELIVERY AND FECAL INCONTINENCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The role that vaginal delivery plays in symptoms of fecal incontinence is controversial [",
"    <a class=\"abstract\" href=\"UTD.htm?8/56/9097/abstract/5,13,14\">",
"     5,13,14",
"    </a>",
"    ]. In a systematic review of comparative studies with short-term follow-up, risk of anal incontinence (ie, fecal or flatal incontinence) was significantly increased after spontaneous vaginal delivery compared to cesarean delivery (OR 1.32, 95% CI 1.04-1.68) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/56/9097/abstract/15\">",
"     15",
"    </a>",
"    ]. However, the risk of fecal incontinence alone (ie, liquid or solid stool) was not significantly increased. Similarly, in a population-based study of 6152 women, vaginal delivery was associated with a greater risk of fecal incontinence compared with cesarean delivery (76 versus 24 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/56/9097/abstract/16\">",
"     16",
"    </a>",
"    ] if the delivery conferred a laceration or required instrumentation. In a longitudinal cohort study of women 5 to 10 years after their first delivery, there was no significant difference in anal incontinence symptoms in women who had a cesarean delivery (either prior to reaching complete dilation or after complete dilation) compared with those who delivered via spontaneous or instrumented vaginal delivery [",
"    <a class=\"abstract\" href=\"UTD.htm?8/56/9097/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Anal sphincter laceration is the most established and potentially most modifiable risk factor for developing fecal incontinence after vaginal delivery. Other risk factors include operative vaginal delivery (eg, vacuum or forceps-assisted delivery), increasing maternal age, vaginal parity, and depression [",
"    <a class=\"abstract\" href=\"UTD.htm?8/56/9097/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Role of anal sphincter laceration",
"    </span>",
"    &nbsp;&mdash;&nbsp;In women with obstetric anal sphincter injuries (OASIS), the risk of subsequent fecal incontinence is estimated to be 9 to 28 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?8/56/9097/abstract/18-21\">",
"     18-21",
"    </a>",
"    ]. Women with clinically evident sphincter tears are significantly more likely to report fecal incontinence, fecal urgency, and flatal incontinence, compared to women without sphincter tears [",
"    <a class=\"abstract\" href=\"UTD.htm?8/56/9097/abstract/13\">",
"     13",
"    </a>",
"    ]. Risk of fecal incontinence is increased with laceration of the internal anal sphincter as compared to the external anal sphincter [",
"    <a class=\"abstract\" href=\"UTD.htm?8/56/9097/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Risk factors for OASIS include operative vaginal delivery, median episiotomy, fetal macrosomia, and increasing maternal age [",
"    <a class=\"abstract\" href=\"UTD.htm?8/56/9097/abstract/23\">",
"     23",
"    </a>",
"    ]. Because of the strong association between sphincter laceration and fecal incontinence, these risk factors are discussed in detail below:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Operative vaginal delivery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Operative vaginal delivery is a well-documented risk factor for anal sphincter laceration and other pelvic floor disorders. This risk is further increased if the fetus is in the occiput posterior position. The risk of OASIS appears to be higher in forceps deliveries than in vacuum-assisted delivery [",
"    <a class=\"abstract\" href=\"UTD.htm?8/56/9097/abstract/24-26\">",
"     24-26",
"    </a>",
"    ], although some studies have reached the opposite conclusion [",
"    <a class=\"abstract\" href=\"UTD.htm?8/56/9097/abstract/27\">",
"     27",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/18/19753?source=see_link\">",
"     \"Pelvic floor disorders associated with pregnancy and childbirth\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/39/15994?source=see_link\">",
"     \"Operative vaginal delivery\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Median episiotomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Extension of a median episiotomy which creates a third or fourth degree laceration or deep vaginal tear is one of the more common complications of episiotomy. Median episiotomy incurs a higher risk of anal sphincter laceration than mediolateral episiotomy. Episiotomy may increase the average perineal tear length; increased tear length appears to be associated with the severity of the laceration [",
"    <a class=\"abstract\" href=\"UTD.htm?8/56/9097/abstract/28\">",
"     28",
"    </a>",
"    ]. Risk factors for severe lacerations include macrosomia, previous third or fourth degree laceration (in multiparous women), median episiotomy, instrumented vaginal delivery, Asian ancestry, and nulliparity. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/42/13992?source=see_link&amp;anchor=H16#H16\">",
"     \"Approach to episiotomy\", section on 'Complications'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Birth weight",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple studies have shown that larger birth weights are associated with anal sphincter lacerations [",
"    <a class=\"abstract\" href=\"UTD.htm?8/56/9097/abstract/19,27,29,30\">",
"     19,27,29,30",
"    </a>",
"    ]. As an example, a population-based study (n = 284,783) reported an odds ratio of 1.47 for a sphincter laceration with each 500 g increase in fetal birth weight [",
"    <a class=\"abstract\" href=\"UTD.htm?8/56/9097/abstract/31\">",
"     31",
"    </a>",
"    ]. While the majority of published reports support the association between birth weight and anal sphincter laceration, conflicting data exist [",
"    <a class=\"abstract\" href=\"UTD.htm?8/56/9097/abstract/32\">",
"     32",
"    </a>",
"    ]. Increasing birth weight is associated with operative vaginal delivery [",
"    <a class=\"abstract\" href=\"UTD.htm?8/56/9097/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Prolonged second stage of labor",
"    </span>",
"    &nbsp;&mdash;&nbsp;Second stage of labor that exceeds 60 minutes appears to be associated with anal sphincter lacerations [",
"    <a class=\"abstract\" href=\"UTD.htm?8/56/9097/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Maternal birth position",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is some suggestion that women who give birth in the standing, squatting or lithotomy positions may have an increased risk of anal sphincter laceration [",
"    <a class=\"abstract\" href=\"UTD.htm?8/56/9097/abstract/34,35\">",
"     34,35",
"    </a>",
"    ]. In a large population-based study, women who underwent vaginal, noninstrumented deliveries had a significantly increased risk of anal sphincter tear if the delivery occurred in squatting or lithotomy position as compared to other positions, including supine, semirecumbent, or lateral recumbent (OR 2.02, 95% CI 1.58-2.59 and OR 2.05, 95% CI 1.09-3.82, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/56/9097/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Maternal age",
"    </span>",
"    &nbsp;&mdash;&nbsp;Increasing maternal age at delivery has been associated with significantly higher rates of OASIS and postpartum fecal incontinence [",
"    <a class=\"abstract\" href=\"UTD.htm?8/56/9097/abstract/36-38\">",
"     36-38",
"    </a>",
"    ]. As an example, an observational study of women reported an increase in odds ratio of 1.09 per year of maternal age (95% CI 1.06-1.12) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/56/9097/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Role of neural injury",
"    </span>",
"    &nbsp;&mdash;&nbsp;Labor and vaginal delivery are associated with partial denervation of the pelvic floor in most women. Studies suggest that neuromuscular injury resolves during the first year after delivery for the majority of women. This may account for the spontaneous resolution of incontinence over that same period. However, in some cases, electrophysiologic evidence of denervation injury can be seen five to six years after delivery, and denervation injury may accumulate with increasing parity.",
"   </p>",
"   <p>",
"    Major risk factors for nerve damage associated with childbirth are forceps delivery, length of second stage of labor, and increasing birth weight. This topic is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/18/19753?source=see_link\">",
"     \"Pelvic floor disorders associated with pregnancy and childbirth\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Studies of pudendal nerve function after labor and delivery have not found a significant effect of neuropathy on subsequent fecal incontinence [",
"    <a class=\"abstract\" href=\"UTD.htm?8/56/9097/abstract/39-41\">",
"     39-41",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Role of time since delivery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies of women in their 50s to 60s suggest that, by that age, causes other than pregnancy and delivery history are more important in correlating with fecal incontinence. This was illustrated by the following studies, which evaluated women at 5, 18, and 30 years after delivery:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one prospective cohort study, at five years after vaginal delivery, fecal incontinence occurred in 6.4 percent of women; 31 percent of women who had sustained a sphincter tear versus 2.2 percent of those without a tear. Predictors of incontinence included anal incontinence symptoms at both five and nine months postpartum [",
"      <a class=\"abstract\" href=\"UTD.htm?8/56/9097/abstract/20\">",
"       20",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a study conducted 18 years after vaginal delivery in women with a history of OASIS, the overall rate of severe fecal incontinence was 10 percent; 13.1 percent in women who sustained a sphincter tear versus 7.8 percent in those who did not (RR 1.7, 95% CI 1.0-2.8). Interestingly, however, only 6.4 percent of the fecal incontinence in the study subjects could be attributed to the original sphincter laceration [",
"      <a class=\"abstract\" href=\"UTD.htm?8/56/9097/abstract/42\">",
"       42",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A 30-year retrospective cohort study reported no difference in fecal incontinence among three groups of women: those who delivered vaginally and had a sphincter laceration; those who delivered vaginally with episiotomy and no sphincter laceration; and those who delivered by cesarean delivery [",
"      <a class=\"abstract\" href=\"UTD.htm?8/56/9097/abstract/21\">",
"       21",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Similarly, in a study of over 2600 women in their 50s, the prevalence of fecal incontinence was similar for nulliparous, primiparous and multiparous women; 11, 9, and 9 percent, respectively. Prevalence was also similar among the parous women, irrespective of mode of delivery [",
"    <a class=\"abstract\" href=\"UTD.htm?8/56/9097/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS AND DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fecal and anal incontinence are clinical diagnoses.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Medical history",
"    </span>",
"    &nbsp;&mdash;&nbsp;The history should initially focus on determining whether fecal incontinence is present, and its severity. True incontinence must be differentiated from frequency and urgency without loss of bowel contents.",
"   </p>",
"   <p>",
"    Women suffering from anovaginal or rectovaginal fistulas present with complaints of uncontrollable passage of gas or feces from the vagina. A malodorous vaginal discharge and fecal soiling of the undergarments are also common complaints. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/11/32951?source=see_link&amp;anchor=H2#H2\">",
"     \"Rectovaginal, anovaginal, and colovesical fistulas\", section on 'Clinical manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Occult anal sphincter laceration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anal sphincter lacerations are not always recognized at the time of delivery and occult injuries to the sphincter may contribute to postpartum fecal incontinence. In observational studies, occult anal sphincter lacerations have been detected with endoanal ultrasound in large numbers in women after spontaneous (9 to 36 percent), vacuum (0 to 21 percent), and forceps deliveries (80 to 83 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/56/9097/abstract/39,44,45\">",
"     39,44,45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Occult anal sphincter lacerations are not always symptomatic; anal incontinence was reported by up to 23 percent of women with sonographic diagnoses of anal sphincter injury [",
"    <a class=\"abstract\" href=\"UTD.htm?8/56/9097/abstract/39,44,45\">",
"     39,44,45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The clinical usefulness and feasibility of screening for occult anal sphincter laceration in women after childbirth is controversial [",
"    <a class=\"abstract\" href=\"UTD.htm?8/56/9097/abstract/46,47\">",
"     46,47",
"    </a>",
"    ]. In asymptomatic women, it appears that occult sphincter lacerations have no long term effect on anal continence [",
"    <a class=\"abstract\" href=\"UTD.htm?8/56/9097/abstract/46\">",
"     46",
"    </a>",
"    ]. In a prospective cohort study of primiparas with occult anal sphincter lacerations, at 10-year follow-up, only women who were symptomatic in the immediate postpartum period had deterioration over time of anal continence.",
"   </p>",
"   <p>",
"    Conversely, there is some suggestion that sonographic detection and subsequent sphincter repair may decrease the development of severe fecal incontinence [",
"    <a class=\"abstract\" href=\"UTD.htm?8/56/9097/abstract/47\">",
"     47",
"    </a>",
"    ]. In the only randomized trial (n = 752) which addressed this question, primiparas with no clinically recognized anal sphincter laceration were assigned to undergo or not undergo an endoanal ultrasound immediately after delivery; lacerations diagnosed via ultrasound and confirmed via surgical exploration were repaired. Of the 376 women in the ultrasound group, 21 (5.6 percent) had sonographically diagnosed sphincter tears. At 3 and 12 months postpartum, significantly fewer of the women who had anal ultrasound reported severe fecal incontinence (12 and 11 women at 3 and 12 months, respectively), as compared to those who did not undergo anal ultrasound (31 and 23 women) (RR -5.4, 95% CI -8.9 to -2.0 and RR -3.5, 95% CI -6.8 to -0.3, respectively). Using these data, it was estimated that 29 women would have to undergo endoanal ultrasound to prevent one case of severe fecal incontinence.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;The physical examination should include inspection of the perianal area and vagina and a digital rectal examination. Perianal sensation can be assessed by eliciting the anal wink sign (anocutaneous reflex); sphincter muscular function can be tested by instructing patients to bear down and squeeze the examining finger during the rectal examination.",
"   </p>",
"   <p>",
"    Most anovaginal and rectovaginal fistulas of obstetric origin are located in the lower third of the vagina, just inside the introitus. They are readily apparent on physical examination as a red velvety area. There is often thinning of the rectovaginal septum and tenting of the anal mucosa, which are palpable on rectal examination.",
"   </p>",
"   <p>",
"    A full discussion of the approach to physical exam for patients with fecal incontinence can be found separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/59/22458?source=see_link&amp;anchor=H19#H19\">",
"     \"Fecal incontinence in adults\", section on 'Physical examination'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/11/32951?source=see_link&amp;anchor=H3#H3\">",
"     \"Rectovaginal, anovaginal, and colovesical fistulas\", section on 'Evaluation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Diagnostic procedures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most women with fecal incontinence can be treated empirically without specific diagnostic evaluation. Diagnostic procedures available to further evaluate fecal incontinence include endoanal ultrasound, anorectal manometry, pudendal nerve terminal latency measurement, defecography and electromyography. A comprehensive discussion of these procedures can be found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/59/22458?source=see_link\">",
"     \"Fecal incontinence in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The goal of treatment is to improve continence and bowel-related quality of life. Three main approaches are most commonly used for treatment of fecal incontinence: medical therapy, biofeedback, and surgery. A full discussion of the treatment of fecal incontinence can be found separately, major therapeutic measures are briefly summarized below. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/59/22458?source=see_link\">",
"     \"Fecal incontinence in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In cases of episiotomy breakdown, repair can be performed when the wound surface is free from exudate and covered by pink granulation tissue. Women who have chronic third or fourth degree lacerations typically have incontinence to gas and liquid feces, but may not lose solid stool, because the puborectalis mechanism is usually intact. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/22/3433?source=see_link\">",
"     \"Repair of episiotomy and perineal lacerations associated with childbirth\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/29/34263?source=see_link\">",
"     \"Delayed surgical management of the disrupted anal sphincter\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In women with chronic third or fourth degree laceration, it is imperative to begin with good medical management of fecal incontinence prior to pursuing a surgical repair. Supportive measures can be instituted in most patients. This may include avoiding foods (eg, caffeine) or activities (eg, exercise after eating) known to worsen symptoms, optimizing stool consistency with fiber supplements, ritualizing bowel habits, and improving perianal skin hygiene.",
"   </p>",
"   <p>",
"    If the patient continues to have bothersome fecal incontinence despite the optimization of medical and dietary management, as well as pelvic floor exercises, then surgical repair is indicated. It is extremely important, however, to ensure that a patient is adequately counseled and has realistic expectations with regard to her outcome. Most studies cite dismal continence rates of 10 to 51 percent five years after anal sphincteroplasty [",
"    <a class=\"abstract\" href=\"UTD.htm?8/56/9097/abstract/48-50\">",
"     48-50",
"    </a>",
"    ]. Thus, patients need to be aware that while surgery can improve their incontinence, most women will continue to have some difficulty controlling flatus and liquid stools. Women should never be told that \"normal\" pre-injury function can be restored.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     RECURRENCE WITH SUBSEQUENT VAGINAL DELIVERY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Anal sphincter laceration",
"    </span>",
"    &nbsp;&mdash;&nbsp;For women with a history of a prior sphincter laceration, the risk of a subsequent laceration is increased two- to seven-fold after a subsequent vaginal delivery [",
"    <a class=\"abstract\" href=\"UTD.htm?8/56/9097/abstract/51-54\">",
"     51-54",
"    </a>",
"    ]. Despite this increased overall risk of recurrent laceration, the absolute risk remains low. Most studies cite risks of recurrent laceration which range from 3.6 to 7.2 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?8/56/9097/abstract/55-57\">",
"     55-57",
"    </a>",
"    ]. The recurrence risk is highest if the subsequent delivery is operative (OR 6.5, 95% CI 1.5-9.4), and when a median episiotomy is performed (OR 17.4, 95% CI 7.5-51.0) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/56/9097/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Fecal incontinence",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a woman with a history of anal sphincter laceration, it is controversial whether subsequent vaginal delivery affects fecal continence [",
"    <a class=\"abstract\" href=\"UTD.htm?8/56/9097/abstract/31,42,58-61\">",
"     31,42,58-61",
"    </a>",
"    ]. In general, it appears that in women with previous OASIS, vaginal delivery increases the short-term risk of persistent fecal incontinence [",
"    <a class=\"abstract\" href=\"UTD.htm?8/56/9097/abstract/58-60\">",
"     58-60",
"    </a>",
"    ]. The presence of transient incontinence after sphincter laceration and repair is also predictive of the likelihood of developing persistent incontinence with a subsequent delivery. However, this increased risk was not found in studies in which women were followed for five or more years [",
"    <a class=\"abstract\" href=\"UTD.htm?8/56/9097/abstract/31,42,61\">",
"     31,42,61",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     APPROACH TO OBSTETRIC MANAGEMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Primary patient choice cesarean delivery to prevent fecal incontinence",
"    </span>",
"    &nbsp;&mdash;&nbsp;The role of primary patient choice cesarean delivery for the prevention of fecal incontinence is a topic of debate. There is insufficient evidence to support primary cesarean delivery for this indication. Research findings, while controversial, suggests no difference in long-term rates of fecal incontinence when cesarean delivery is performed [",
"    <a class=\"abstract\" href=\"UTD.htm?8/56/9097/abstract/14,39,62\">",
"     14,39,62",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The Term Breech Trial is the only large (n = 2000) randomized trial comparing outcomes of women assigned to planned cesarean or planned vaginal delivery of a singleton breech fetus. The overall prevalence of fecal incontinence was 2.2 percent and planned cesarean delivery conferred no protection against fecal incontinence compared to planned vaginal delivery (RR 1.10, 95% CI 0.47-2.58) [",
"      <a class=\"abstract\" href=\"UTD.htm?8/56/9097/abstract/62\">",
"       62",
"      </a>",
"      ]. Limitations of this trial were that only 21 women developed fecal incontinence and almost one-half of the women in the planned vaginal delivery group underwent cesarean birth. Additionally, the incidence of fecal incontinence in this study was lower than is generally reported. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Prevalence'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In a large population-based survey that included over 1500 women, the prevalence of fecal incontinence did not differ among women who had a cesarean, instrumental, or spontaneous vaginal delivery. In fact, pregnancy itself seemed to contribute to the development of incontinence and other pelvic floor disorders rather than mode of delivery [",
"      <a class=\"abstract\" href=\"UTD.htm?8/56/9097/abstract/14\">",
"       14",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A meta-analysis of randomized trial and observational studies including 31,698 women (6028 of whom had a cesarean delivery) found no benefit of cesarean delivery in the preservation of anal continence [",
"      <a class=\"abstract\" href=\"UTD.htm?8/56/9097/abstract/63\">",
"       63",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a 12-year longitudinal study, the prevalence of fecal incontinence among women who delivered by cesarean section was no different than that of women who had spontaneous vaginal deliveries [",
"      <a class=\"abstract\" href=\"UTD.htm?8/56/9097/abstract/64\">",
"       64",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Perineal massage",
"    </span>",
"    &nbsp;&mdash;&nbsp;Perineal massage in the weeks immediately preceding vaginal delivery does not prevent fecal incontinence. A systematic review including three randomized trials of antenatal perineal massage (for at least the last four weeks of pregnancy) revealed no difference in postpartum fecal or flatal incontinence compared to no antenatal perineal massage [",
"    <a class=\"abstract\" href=\"UTD.htm?8/56/9097/abstract/65\">",
"     65",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Mode of delivery in women with a history of anal sphincter laceration or fecal incontinence",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are insufficient high quality data to provide guidance regarding the delivery mode of a woman with a history of a sphincter laceration. Women with transient anal incontinence symptoms following an initial delivery have a 1 in 6 chance of developing permanent symptoms following a subsequent vaginal delivery. It is estimated that 2 to 23 cesarean deliveries would need to be performed in women with prior OASIS to prevent a single recurrent anal sphincter laceration [",
"    <a class=\"abstract\" href=\"UTD.htm?8/56/9097/abstract/54,66\">",
"     54,66",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H22\">",
"     'Recurrence with subsequent vaginal delivery'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Experts recommend that a woman with persistent fecal incontinence and a poorly functioning anal sphincter be offered a planned cesarean for subsequent deliveries. In counseling a woman with a history of OASIS, it is important to explain the uncertainties regarding risk of recurrent or persistent anal incontinence, as well as operative risks associated with cesarean delivery. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/21/344?source=see_link\">",
"     \"Cesarean delivery on maternal request\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Operative vaginal delivery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Current evidence supports use of vacuum rather than forceps delivery to minimize maternal morbidity when the gestational age is greater than 34 weeks and the likelihood of success is very high. However, there is inadequate evidence upon which to base a recommendation for use of either vacuum or forceps for all circumstances when operative vaginal delivery is attempted. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/39/15994?source=see_link&amp;anchor=H20#H20\">",
"     \"Operative vaginal delivery\", section on 'Risks'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Episiotomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Avoidance of routine use of episiotomy is known to reduce both perineal trauma and healing complications after vaginal delivery. Similar to operative vaginal delivery, median episiotomy is a known and modifiable risk factor for anal sphincter tear. Mediolateral episiotomy may also extend into an anal sphincter laceration; however, this occurs frequently with extension of a mediolateral episiotomy, but less frequently than with median episiotomy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/42/13992?source=see_link&amp;anchor=H6#H6\">",
"     \"Approach to episiotomy\", section on 'Routine versus restricted use'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Repair of anal sphincter laceration",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h3\">",
"     Primary sphincter repair technique",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary sphincter repair (immediately after delivery) is important to minimize the risk of fecal incontinence [",
"    <a class=\"abstract\" href=\"UTD.htm?8/56/9097/abstract/47\">",
"     47",
"    </a>",
"    ]. Anal sphincter repair should be performed by an experienced surgeon with proper lighting, anesthesia, and instrumentation. However, even with immediate repair, 40 to 50 percent of women will still develop anal incontinence, clearly demonstrating the importance of primary prevention of OASIS [",
"    <a class=\"abstract\" href=\"UTD.htm?8/56/9097/abstract/67,68\">",
"     67,68",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/22/3433?source=see_link\">",
"     \"Repair of episiotomy and perineal lacerations associated with childbirth\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Repair can be accomplished with either an end-to-end approximation or an overlapping repair of the torn sphincter. A systematic review of three randomized trials reported that the overlap technique was associated with lower risk of anal incontinence (weighted mean difference -1.70, 95% CI -3.03 to -0.37) and a reduced risk of worsening incontinence symptoms over 12 months (RR 0.26, 95% CI 0.09 to 0.79, one trial, 41 women) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/56/9097/abstract/69\">",
"     69",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h3\">",
"     Secondary sphincter repair",
"    </span>",
"    &nbsp;&mdash;&nbsp;In women with clinically recognized OASIS and primary sphincter repair (immediately after delivery), 35 percent may still have sonographically detectable defects of the internal anal sphincter 6 to 12 months postpartum [",
"    <a class=\"abstract\" href=\"UTD.htm?8/56/9097/abstract/70\">",
"     70",
"    </a>",
"    ]. The risk of sphincter gaps after primary repair was reported as greater in women who had a fourth- versus third-degree perineal laceration (OR 15.4, 95% CI 4.8-50).",
"   </p>",
"   <p>",
"    Treatment of fecal incontinence by secondary sphincteroplasty (remote from delivery) is successful in approximately 66 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?8/56/9097/abstract/71\">",
"     71",
"    </a>",
"    ]. Improvement in fecal incontinence after secondary sphincteroplasty appears to be similar in women who have and have not had previous primary sphincter repair [",
"    <a class=\"abstract\" href=\"UTD.htm?8/56/9097/abstract/72,73\">",
"     72,73",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/29/34263?source=see_link\">",
"     \"Delayed surgical management of the disrupted anal sphincter\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?5/55/6006?source=see_link\">",
"       \"Patient information: Fecal incontinence (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The prevalence of fecal incontinence in women is approximately 8 percent. Thirteen to 25 percent of parous women experience fecal incontinence within the first six months postpartum (see",
"      <a class=\"local\" href=\"#H3\">",
"       'Prevalence'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      New onset fecal incontinence may be associated with either pregnancy or delivery. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Pregnancy and fecal incontinence'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H6\">",
"       'Vaginal delivery and fecal incontinence'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Anal sphincter laceration is a well-documented risk factor for fecal incontinence after vaginal delivery. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Role of anal sphincter laceration'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      As women age, the impact of obstetric anal sphincter injury on fecal incontinence is superseded by the impact of aging on the continence mechanism. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Role of time since delivery'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Perineal massage is not protective against the development of postpartum fecal incontinence. (See",
"      <a class=\"local\" href=\"#H27\">",
"       'Perineal massage'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Operative delivery and median episiotomy are risk factors for anal sphincter laceration. Modifying obstetrical practices could potentially decrease the incidence of this debilitating condition. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Operative vaginal delivery'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H9\">",
"       'Median episiotomy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We do not suggest primary elective cesarean delivery for prevention of fecal incontinence (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H26\">",
"       'Primary patient choice cesarean delivery to prevent fecal incontinence'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In women with a history of fecal incontinence or obstetric anal sphincter injury, the optimal mode of delivery for subsequent pregnancies is uncertain. Many experts advise that a woman with persistent fecal incontinence and a poorly functioning anal sphincter be offered a planned cesarean for subsequent deliveries. The patient and her clinician must weigh the pros and cons of both delivery methods. (See",
"      <a class=\"local\" href=\"#H28\">",
"       'Mode of delivery in women with a history of anal sphincter laceration or fecal incontinence'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Choice of repair technique of anal sphincter laceration (end-to-end versus overlap) should depend upon surgical experience. There is insufficient evidence showing that either method affects subsequent fecal incontinence. (See",
"      <a class=\"local\" href=\"#H32\">",
"       'Primary sphincter repair technique'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/56/9097/abstract/1\">",
"      Fialkow MF, Melville JL, Lentz GM, et al. The functional and psychosocial impact of fecal incontinence on women with urinary incontinence. Am J Obstet Gynecol 2003; 189:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/56/9097/abstract/2\">",
"      Handa VL, Zyczynski HM, Burgio KL, et al. The impact of fecal and urinary incontinence on quality of life 6 months after childbirth. Am J Obstet Gynecol 2007; 197:636.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/56/9097/abstract/3\">",
"      Lo J, Osterweil P, Li H, et al. Quality of life in women with postpartum anal incontinence. Obstet Gynecol 2010; 115:809.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/56/9097/abstract/4\">",
"      Melville JL, Fan MY, Newton K, Fenner D. Fecal incontinence in US women: a population-based study. Am J Obstet Gynecol 2005; 193:2071.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/56/9097/abstract/5\">",
"      Donnelly V, Fynes M, Campbell D, et al. Obstetric events leading to anal sphincter damage. Obstet Gynecol 1998; 92:955.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/56/9097/abstract/6\">",
"      Guise JM, Morris C, Osterweil P, et al. Incidence of fecal incontinence after childbirth. Obstet Gynecol 2007; 109:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/56/9097/abstract/7\">",
"      Chaliha C, Kalia V, Stanton SL, et al. Antenatal prediction of postpartum urinary and fecal incontinence. Obstet Gynecol 1999; 94:689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/56/9097/abstract/8\">",
"      Hall W, McCracken K, Osterweil P, Guise JM. Frequency and predictors for postpartum fecal incontinence. Am J Obstet Gynecol 2003; 188:1205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/56/9097/abstract/9\">",
"      Chaliha C, Sultan AH, Bland JM, et al. Anal function: effect of pregnancy and delivery. Am J Obstet Gynecol 2001; 185:427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/56/9097/abstract/10\">",
"      Solans-Dom&egrave;nech M, S&aacute;nchez E, Espu&ntilde;a-Pons M, Pelvic Floor Research Group (Grup de Recerca del S&ograve;l Pelvi&agrave;; GRESP). Urinary and anal incontinence during pregnancy and postpartum: incidence, severity, and risk factors. Obstet Gynecol 2010; 115:618.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/56/9097/abstract/11\">",
"      Bahl R, Strachan B, Murphy DJ. Pelvic floor morbidity at 3 years after instrumental delivery and cesarean delivery in the second stage of labor and the impact of a subsequent delivery. Am J Obstet Gynecol 2005; 192:789.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/56/9097/abstract/12\">",
"      Liebling RE, Swingler R, Patel RR, et al. Pelvic floor morbidity up to one year after difficult instrumental delivery and cesarean section in the second stage of labor: a cohort study. Am J Obstet Gynecol 2004; 191:4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/56/9097/abstract/13\">",
"      Borello-France D, Burgio KL, Richter HE, et al. Fecal and urinary incontinence in primiparous women. Obstet Gynecol 2006; 108:863.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/56/9097/abstract/14\">",
"      MacLennan AH, Taylor AW, Wilson DH, Wilson D. The prevalence of pelvic floor disorders and their relationship to gender, age, parity and mode of delivery. BJOG 2000; 107:1460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/56/9097/abstract/15\">",
"      Pretlove SJ, Thompson PJ, Toozs-Hobson PM, et al. Does the mode of delivery predispose women to anal incontinence in the first year postpartum? A comparative systematic review. BJOG 2008; 115:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/56/9097/abstract/16\">",
"      Guise JM, Boyles SH, Osterweil P, et al. Does cesarean protect against fecal incontinence in primiparous women? Int Urogynecol J Pelvic Floor Dysfunct 2009; 20:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/56/9097/abstract/17\">",
"      Handa VL, Blomquist JL, Knoepp LR, et al. Pelvic floor disorders 5-10 years after vaginal or cesarean childbirth. Obstet Gynecol 2011; 118:777.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/56/9097/abstract/18\">",
"      Sangalli MR, Floris L, Faltin D, Weil A. Anal incontinence in women with third or fourth degree perineal tears and subsequent vaginal deliveries. Aust N Z J Obstet Gynaecol 2000; 40:244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/56/9097/abstract/19\">",
"      Zetterstr&ouml;m J, L&oacute;pez A, Anz&eacute;n B, et al. Anal sphincter tears at vaginal delivery: risk factors and clinical outcome of primary repair. Obstet Gynecol 1999; 94:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/56/9097/abstract/20\">",
"      Pollack J, Nordenstam J, Brismar S, et al. Anal incontinence after vaginal delivery: a five-year prospective cohort study. Obstet Gynecol 2004; 104:1397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/56/9097/abstract/21\">",
"      Nygaard IE, Rao SS, Dawson JD. Anal incontinence after anal sphincter disruption: a 30-year retrospective cohort study. Obstet Gynecol 1997; 89:896.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/56/9097/abstract/22\">",
"      Rockwood TH, Church JM, Fleshman JW, et al. Patient and surgeon ranking of the severity of symptoms associated with fecal incontinence: the fecal incontinence severity index. Dis Colon Rectum 1999; 42:1525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/56/9097/abstract/23\">",
"      Fenner DE, Genberg B, Brahma P, et al. Fecal and urinary incontinence after vaginal delivery with anal sphincter disruption in an obstetrics unit in the United States. Am J Obstet Gynecol 2003; 189:1543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/56/9097/abstract/24\">",
"      Baumann P, Hammoud AO, McNeeley SG, et al. Factors associated with anal sphincter laceration in 40,923 primiparous women. Int Urogynecol J Pelvic Floor Dysfunct 2007; 18:985.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/56/9097/abstract/25\">",
"      Fitzgerald MP, Weber AM, Howden N, et al. Risk factors for anal sphincter tear during vaginal delivery. Obstet Gynecol 2007; 109:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/56/9097/abstract/26\">",
"      Minaglia SM, Ozel B, Gatto NM, et al. Decreased rate of obstetrical anal sphincter laceration is associated with change in obstetric practice. Int Urogynecol J Pelvic Floor Dysfunct 2007; 18:1399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/56/9097/abstract/27\">",
"      Handa VL, Danielsen BH, Gilbert WM. Obstetric anal sphincter lacerations. Obstet Gynecol 2001; 98:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/56/9097/abstract/28\">",
"      Nager CW, Helliwell JP. Episiotomy increases perineal laceration length in primiparous women. Am J Obstet Gynecol 2001; 185:444.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/56/9097/abstract/29\">",
"      Parnell C, Langhoff-Roos J, M&oslash;ller H. Conduct of labor and rupture of the sphincter ani. Acta Obstet Gynecol Scand 2001; 80:256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/56/9097/abstract/30\">",
"      Jand&eacute;r C, Lyren&auml;s S. Third and fourth degree perineal tears. Predictor factors in a referral hospital. Acta Obstet Gynecol Scand 2001; 80:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/56/9097/abstract/31\">",
"      De Leeuw JW, Vierhout ME, Struijk PC, et al. Anal sphincter damage after vaginal delivery: functional outcome and risk factors for fecal incontinence. Acta Obstet Gynecol Scand 2001; 80:830.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/56/9097/abstract/32\">",
"      MacArthur C, Glazener CM, Wilson PD, et al. Obstetric practice and faecal incontinence three months after delivery. BJOG 2001; 108:678.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/56/9097/abstract/33\">",
"      Assimakopoulos E, Zafrakas M, Garmiris P, et al. Fetal abdominal subcutaneous tissue thickness measured by ultrasound at term is associated with birth weight and mode of delivery. Clin Exp Obstet Gynecol 2007; 34:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/56/9097/abstract/34\">",
"      Gottvall K, Allebeck P, Ek&eacute;us C. Risk factors for anal sphincter tears: the importance of maternal position at birth. BJOG 2007; 114:1266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/56/9097/abstract/35\">",
"      G&aring;reberg B, Magnusson B, Sultan B, et al. Birth in standing position: a high frequency of third degree tears. Acta Obstet Gynecol Scand 1994; 73:630.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/56/9097/abstract/36\">",
"      Chiarelli P, Murphy B, Cockburn J. Fecal incontinence after high-risk delivery. Obstet Gynecol 2003; 102:1299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/56/9097/abstract/37\">",
"      Lewis C, Williams AM, Rogers RG. Postpartum anal sphincter lacerations in a population with minimal exposure to episiotomy and operative vaginal delivery. Int Urogynecol J Pelvic Floor Dysfunct 2008; 19:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/56/9097/abstract/38\">",
"      Burgio KL, Borello-France D, Richter HE, et al. Risk factors for fecal and urinary incontinence after childbirth: the childbirth and pelvic symptoms study. Am J Gastroenterol 2007; 102:1998.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/56/9097/abstract/39\">",
"      Sultan AH, Kamm MA, Hudson CN, et al. Anal-sphincter disruption during vaginal delivery. N Engl J Med 1993; 329:1905.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/56/9097/abstract/40\">",
"      Sultan AH, Kamm MA, Hudson CN. Pudendal nerve damage during labour: prospective study before and after childbirth. Br J Obstet Gynaecol 1994; 101:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/56/9097/abstract/41\">",
"      Zetterstr&ouml;m J, L&oacute;pez A, Holmstr&ouml;m B, et al. Obstetric sphincter tears and anal incontinence: an observational follow-up study. Acta Obstet Gynecol Scand 2003; 82:921.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/56/9097/abstract/42\">",
"      Faltin DL, Otero M, Petignat P, et al. Women's health 18 years after rupture of the anal sphincter during childbirth: I. Fecal incontinence. Am J Obstet Gynecol 2006; 194:1255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/56/9097/abstract/43\">",
"      Fritel X, Ringa V, Varnoux N, et al. Mode of delivery and fecal incontinence at midlife: a study of 2,640 women in the Gazel cohort. Obstet Gynecol 2007; 110:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/56/9097/abstract/44\">",
"      Varma A, Gunn J, Gardiner A, et al. Obstetric anal sphincter injury: prospective evaluation of incidence. Dis Colon Rectum 1999; 42:1537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/56/9097/abstract/45\">",
"      Sultan AH, Kamm MA, Bartram CI, Hudson CN. Anal sphincter trauma during instrumental delivery. Int J Gynaecol Obstet 1993; 43:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/56/9097/abstract/46\">",
"      Frudinger A, Ballon M, Taylor SA, Halligan S. The natural history of clinically unrecognized anal sphincter tears over 10 years after first vaginal delivery. Obstet Gynecol 2008; 111:1058.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/56/9097/abstract/47\">",
"      Faltin DL, Boulvain M, Floris LA, Irion O. Diagnosis of anal sphincter tears to prevent fecal incontinence: a randomized controlled trial. Obstet Gynecol 2005; 106:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/56/9097/abstract/48\">",
"      Halverson AL, Hull TL. Long-term outcome of overlapping anal sphincter repair. Dis Colon Rectum 2002; 45:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/56/9097/abstract/49\">",
"      Bravo Gutierrez A, Madoff RD, Lowry AC, et al. Long-term results of anterior sphincteroplasty. Dis Colon Rectum 2004; 47:727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/56/9097/abstract/50\">",
"      Trowbridge ER, Morgan D, Trowbridge MJ, et al. Sexual function, quality of life, and severity of anal incontinence after anal sphincteroplasty. Am J Obstet Gynecol 2006; 195:1753.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/56/9097/abstract/51\">",
"      Peleg D, Kennedy CM, Merrill D, Zlatnik FJ. Risk of repetition of a severe perineal laceration. Obstet Gynecol 1999; 93:1021.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/56/9097/abstract/52\">",
"      Payne TN, Carey JC, Rayburn WF. Prior third- or fourth-degree perineal tears and recurrence risks. Int J Gynaecol Obstet 1999; 64:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/56/9097/abstract/53\">",
"      Harkin R, Fitzpatrick M, O'Connell PR, O'Herlihy C. Anal sphincter disruption at vaginal delivery: is recurrence predictable? Eur J Obstet Gynecol Reprod Biol 2003; 109:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/56/9097/abstract/54\">",
"      Elfaghi I, Johansson-Ernste B, Rydhstroem H. Rupture of the sphincter ani: the recurrence rate in second delivery. BJOG 2004; 111:1361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/56/9097/abstract/55\">",
"      Dandolu V, Chatwani A, Harmanli O, et al. Risk factors for obstetrical anal sphincter lacerations. Int Urogynecol J Pelvic Floor Dysfunct 2005; 16:304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/56/9097/abstract/56\">",
"      Lowder JL, Burrows LJ, Krohn MA, Weber AM. Risk factors for primary and subsequent anal sphincter lacerations: a comparison of cohorts by parity and prior mode of delivery. Am J Obstet Gynecol 2007; 196:344.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/56/9097/abstract/57\">",
"      Spydslaug A, Trogstad LI, Skrondal A, Eskild A. Recurrent risk of anal sphincter laceration among women with vaginal deliveries. Obstet Gynecol 2005; 105:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/56/9097/abstract/58\">",
"      Bek KM, Laurberg S. Risks of anal incontinence from subsequent vaginal delivery after a complete obstetric anal sphincter tear. Br J Obstet Gynaecol 1992; 99:724.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/56/9097/abstract/59\">",
"      Poen AC, Felt-Bersma RJ, Strijers RL, et al. Third-degree obstetric perineal tear: long-term clinical and functional results after primary repair. Br J Surg 1998; 85:1433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/56/9097/abstract/60\">",
"      Fynes M, Donnelly V, Behan M, et al. Effect of second vaginal delivery on anorectal physiology and faecal continence: a prospective study. Lancet 1999; 354:983.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/56/9097/abstract/61\">",
"      Sze EH. Anal incontinence among women with one versus two complete third-degree perineal lacerations. Int J Gynaecol Obstet 2005; 90:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/56/9097/abstract/62\">",
"      Hannah ME, Whyte H, Hannah WJ, et al. Maternal outcomes at 2 years after planned cesarean section versus planned vaginal birth for breech presentation at term: the international randomized Term Breech Trial. Am J Obstet Gynecol 2004; 191:917.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/56/9097/abstract/63\">",
"      Nelson RL, Furner SE, Westercamp M, Farquhar C. Cesarean delivery for the prevention of anal incontinence. Cochrane Database Syst Rev 2010; :CD006756.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/56/9097/abstract/64\">",
"      MacArthur C, Glazener C, Lancashire R, et al. Exclusive caesarean section delivery and subsequent urinary and faecal incontinence: a 12-year longitudinal study. BJOG 2011; 118:1001.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/56/9097/abstract/65\">",
"      Beckmann MM, Garrett AJ. Antenatal perineal massage for reducing perineal trauma. Cochrane Database Syst Rev 2006; :CD005123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/56/9097/abstract/66\">",
"      McKenna DS, Ester JB, Fischer JR. Elective cesarean delivery for women with a previous anal sphincter rupture. Am J Obstet Gynecol 2003; 189:1251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/56/9097/abstract/67\">",
"      Kammerer-Doak DN, Wesol AB, Rogers RG, et al. A prospective cohort study of women after primary repair of obstetric anal sphincter laceration. Am J Obstet Gynecol 1999; 181:1317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/56/9097/abstract/68\">",
"      Haadem K, Dahlstrom JA, Ling L, Ohrlander S. Anal sphincter function after delivery rupture. Obstet Gynecol 1987; 70:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/56/9097/abstract/69\">",
"      Fernando R, Sultan AH, Kettle C, et al. Methods of repair for obstetric anal sphincter injury. Cochrane Database Syst Rev 2006; :CD002866.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/56/9097/abstract/70\">",
"      Bradley CS, Richter HE, Gutman RE, et al. Risk factors for sonographic internal anal sphincter gaps 6-12 months after delivery complicated by anal sphincter tear. Am J Obstet Gynecol 2007; 197:310.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/56/9097/abstract/71\">",
"      Madoff RD. Surgical treatment options for fecal incontinence. Gastroenterology 2004; 126:S48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/56/9097/abstract/72\">",
"      Giordano P, Renzi A, Efron J, et al. Previous sphincter repair does not affect the outcome of repeat repair. Dis Colon Rectum 2002; 45:635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/56/9097/abstract/73\">",
"      Vaizey CJ, Norton C, Thornton MJ, et al. Long-term results of repeat anterior anal sphincter repair. Dis Colon Rectum 2004; 47:858.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8086 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-61.234.146.186-7705E05A5A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_56_9097=[""].join("\n");
var outline_f8_56_9097=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H35\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFINITIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PREVALENCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      PREGNANCY AND FECAL INCONTINENCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      LABOR AND FECAL INCONTINENCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      VAGINAL DELIVERY AND FECAL INCONTINENCE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Role of anal sphincter laceration",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Operative vaginal delivery",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Median episiotomy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Birth weight",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Prolonged second stage of labor",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Maternal birth position",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Maternal age",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Role of neural injury",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Role of time since delivery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      CLINICAL MANIFESTATIONS AND DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Medical history",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Occult anal sphincter laceration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Diagnostic procedures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      RECURRENCE WITH SUBSEQUENT VAGINAL DELIVERY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Anal sphincter laceration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Fecal incontinence",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      APPROACH TO OBSTETRIC MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Primary patient choice cesarean delivery to prevent fecal incontinence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Perineal massage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Mode of delivery in women with a history of anal sphincter laceration or fecal incontinence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Operative vaginal delivery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Episiotomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Repair of anal sphincter laceration",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      - Primary sphincter repair technique",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      - Secondary sphincter repair",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/42/13992?source=related_link\">",
"      Approach to episiotomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/21/344?source=related_link\">",
"      Cesarean delivery on maternal request",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/29/34263?source=related_link\">",
"      Delayed surgical management of the disrupted anal sphincter",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/59/22458?source=related_link\">",
"      Fecal incontinence in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/39/15994?source=related_link\">",
"      Operative vaginal delivery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?5/55/6006?source=related_link\">",
"      Patient information: Fecal incontinence (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/18/19753?source=related_link\">",
"      Pelvic floor disorders associated with pregnancy and childbirth",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/11/32951?source=related_link\">",
"      Rectovaginal, anovaginal, and colovesical fistulas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/22/3433?source=related_link\">",
"      Repair of episiotomy and perineal lacerations associated with childbirth",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f8_56_9098="Diagnosis of pulmonary tuberculosis in HIV-negative patients";
var content_f8_56_9098=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Diagnosis of pulmonary tuberculosis in HIV-negative patients",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/56/9098/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/56/9098/contributors\">",
"     John Bernardo, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/56/9098/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/56/9098/contributors\">",
"     Sheldon L Kaplan, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/56/9098/contributors\">",
"     C Fordham von Reyn, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/56/9098/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/56/9098/contributors\">",
"     Elinor L Baron, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?8/56/9098/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 7, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Initiation of a diagnostic evaluation for tuberculosis (TB) is usually based on suspicion for TB on epidemiologic, clinical, and radiographic grounds (",
"    <a class=\"graphic graphic_table graphicRef80879 \" href=\"UTD.htm?38/31/39420\">",
"     table 1",
"    </a>",
"    ). Consideration of TB as part of the differential diagnosis of selected patients with respiratory infections is important to avoid delays in diagnosis and inappropriate antibiotic therapy; prompt diagnosis facilitates timely therapeutic intervention and minimizes risk for community transmission.",
"   </p>",
"   <p>",
"    Diagnostic evaluation for TB may be initiated in outpatient settings [",
"    <a class=\"abstract\" href=\"UTD.htm?8/56/9098/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. For circumstances in which clinical circumstances preclude outpatient management or in which there is public health risk for transmission, hospitalization with respiratory isolation is appropriate [",
"    <a class=\"abstract\" href=\"UTD.htm?8/56/9098/abstract/1-5\">",
"     1-5",
"    </a>",
"    ]. Consultation and expert assistance is available at any point during the patient evaluation from state health departments and from United States Centers for Disease Control and Prevention (CDC)-supported Regional Training and Medical Consultation Centers [",
"    <a class=\"abstract\" href=\"UTD.htm?8/56/9098/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The diagnosis of tuberculosis will be reviewed here. The microbiology, epidemiology, clinical manifestations, and treatment of TB are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/13/18649?source=see_link\">",
"     \"Epidemiology of tuberculosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/47/39673?source=see_link\">",
"     \"Clinical manifestations and evaluation of pulmonary tuberculosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/21/19802?source=see_link\">",
"     \"Treatment of pulmonary tuberculosis in HIV-negative patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     GENERAL APPROACH",
"    </span>",
"    &nbsp;&mdash;&nbsp;In general, establishing a clinical diagnosis of tuberculosis (TB) includes assessing the following factors (",
"    <a class=\"graphic graphic_table graphicRef80879 \" href=\"UTD.htm?38/31/39420\">",
"     table 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Clinical manifestations, physical findings (cough generally &gt;2 to 3 weeks duration, lymphadenopathy, fevers, night sweats, weight loss). In general, specific symptoms localize to site(s) of disease.",
"     </li>",
"     <li>",
"      History of prior TB infection or disease. Tuberculin skin testing and interferon-gamma release assays are useful for identifying M. tuberculosis infection, and one of these tests should be performed in a suspected case. A positive test supports a diagnosis of infection, but it cannot be used alone for diagnosis of active disease. A negative test does not exclude disease [",
"      <a class=\"abstract\" href=\"UTD.htm?8/56/9098/abstract/7,8\">",
"       7,8",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Epidemiologic factors (including known or possible exposures, and past or present residence in or travel to an endemic area).",
"     </li>",
"     <li>",
"      Radiographic features,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      laboratory findings consistent with TB (",
"      <a class=\"graphic graphic_table graphicRef80879 \" href=\"UTD.htm?38/31/39420\">",
"       table 1",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The diagnosis of tuberculosis is confirmed by isolation of the organism from secretions or tissue. In some circumstances, establishing a definitive laboratory diagnosis of TB may not be possible. No specific bacteriologic confirmation is ever established in 15 to 20 percent of patients with a clinical diagnosis of TB [",
"    <a class=\"abstract\" href=\"UTD.htm?8/56/9098/abstract/1,9\">",
"     1,9",
"    </a>",
"    ]. In such cases, a presumptive clinical diagnosis is sufficient for initiating therapy. Most individuals diagnosed with TB are begun on specific treatment before the diagnosis is confirmed by the laboratory. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/47/39673?source=see_link\">",
"     \"Clinical manifestations and evaluation of pulmonary tuberculosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/10/20648?source=see_link\">",
"     \"Diagnosis of latent tuberculosis infection in HIV-negative adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Adults and older children",
"    </span>",
"    &nbsp;&mdash;&nbsp;The approach to diagnosis of tuberculosis begins with a history and physical examination to assess the patient&rsquo;s risk for TB (",
"    <a class=\"graphic graphic_table graphicRef80879 \" href=\"UTD.htm?38/31/39420\">",
"     table 1",
"    </a>",
"    ). Patients meeting clinical criteria should undergo chest radiography; if imaging results are suggestive of TB, three sputum specimens are submitted for AFB smears and culture (coughed or induced). These should be obtained at least eight hours apart and should include at least one early morning specimen [",
"    <a class=\"abstract\" href=\"UTD.htm?8/56/9098/abstract/10\">",
"     10",
"    </a>",
"    ]. In patients at moderate to high risk for TB, at least one of these sputum specimens should also be tested using a nucleic acid amplification (NAA) test if available [",
"    <a class=\"abstract\" href=\"UTD.htm?8/56/9098/abstract/11\">",
"     11",
"    </a>",
"    ]. If clinical suspicion for TB is high, initiation of empiric therapy pending laboratory diagnostic confirmation is appropriate.",
"   </p>",
"   <p>",
"    If extrapulmonary TB is suspected, alternative or additional laboratory specimens are warranted as outlined below and in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/21/20826?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and treatment of extrapulmonary and miliary tuberculosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Children under five",
"    </span>",
"    &nbsp;&mdash;&nbsp;Issues related to diagnosis of tuberculosis in children are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/4/23625?source=see_link&amp;anchor=H9#H9\">",
"     \"Tuberculosis disease in children\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     CHEST RADIOGRAPHY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chest radiography is part of the initial approach to a diagnostic evaluation of a patient with suspected tuberculosis (TB) of any organ system; it is a useful tool for evaluating symptomatic patients with appropriate epidemiologic risk factors for TB [",
"    <a class=\"abstract\" href=\"UTD.htm?8/56/9098/abstract/12-14\">",
"     12-14",
"    </a>",
"    ]. Active pulmonary tuberculosis often cannot be distinguished from inactive disease on the basis of radiography alone, and readings of &ldquo;fibrosis&rdquo; or &ldquo;scarring&rdquo; must be viewed in the context of the clinical and epidemiologic presentation.",
"   </p>",
"   <p>",
"    Reactivation pulmonary tuberculosis classically presents with focal infiltration of the upper lobe(s) (usually of the apical",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    posterior segments) or the lower lobe(s) (usually of the apical&mdash;also called superior&mdash;segments) (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef74846 graphicRef70220 graphicRef54807 graphicRef56912 \" href=\"UTD.htm?13/19/13625\">",
"     image 1A-D",
"    </a>",
"    ). Disease may be unilateral or bilateral. Cavitation may be present and inflammation and tissue destruction may result in fibrosis with traction",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    enlargement of hilar and mediastinal lymph nodes.",
"   </p>",
"   <p>",
"    In some cases, pulmonary TB in adults may not present with the &ldquo;classic&rdquo; radiographic appearance described above. Lobar or segmental infiltration may be visualized in other lung regions, with or without hilar adenopathy, lung mass (tuberculoma), small fibronodular lesions (termed &ldquo;miliary&rdquo; because they resemble scattered millet seeds), or pleural effusions [",
"    <a class=\"abstract\" href=\"UTD.htm?8/56/9098/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. This is particularly likely among patients with advanced HIV disease for whom &ldquo;atypical&rdquo; radiographic presentations are common [",
"    <a class=\"abstract\" href=\"UTD.htm?8/56/9098/abstract/17-19\">",
"     17-19",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/10/1194?source=see_link\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of tuberculosis in HIV-infected patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Occasionally specialized views of the chest may be required, such as an apical lordotic projection for careful evaluation of the lung apices or a lateral decubitus series to evaluate for presence of pleural effusion.",
"   </p>",
"   <p>",
"    Chest computed tomography (CT) is more sensitive than plain chest radiography for identifying early or subtle parenchymal and nodal processes. The resolution provided by CT usually is not required for diagnosis or management of pulmonary TB; it may be reserved for circumstances in which more precise resolution of features observed in a chest radiograph is required. Computed",
"    <span class=\"nowrap\">",
"     tomography/positron",
"    </span>",
"    emission tomography",
"    <span class=\"nowrap\">",
"     (CT/PET)",
"    </span>",
"    scanning may be useful for distinguishing active inflammatory (eg, infectious)",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    neoplastic processes from inactive lesions (eg, fibrosis), although its sensitivity in the setting of clinical suspicion for tuberculosis has not been established [",
"    <a class=\"abstract\" href=\"UTD.htm?8/56/9098/abstract/20-22\">",
"     20-22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Radiographic abnormalities are discussed further separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/47/39673?source=see_link\">",
"     \"Clinical manifestations and evaluation of pulmonary tuberculosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     LABORATORY EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;This section describes clinical specimens that may be used for diagnostic purposes. The approach to the initial evaluation of these specimens is summarized below. (See",
"    <a class=\"local\" href=\"#H17\">",
"     'Preliminary results'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Clinical specimens",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Sputum",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sputum may be obtained spontaneously (by coughing) or it may be induced; patients providing sputum samples should understand that nasopharyngeal discharge and saliva are not sputum [",
"    <a class=\"abstract\" href=\"UTD.htm?8/56/9098/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. At least 5 mL is optimal for adequate diagnostic yield [",
"    <a class=\"abstract\" href=\"UTD.htm?8/56/9098/abstract/25\">",
"     25",
"    </a>",
"    ]. A series of at least three single specimens should be collected in 8- to 24-hour intervals (with at least one specimen obtained in the early morning), although the diagnosis often can be made with two specimens [",
"    <a class=\"abstract\" href=\"UTD.htm?8/56/9098/abstract/10,26-30\">",
"     10,26-30",
"    </a>",
"    ]. Obtaining three specimens is useful for culture even if the first or second specimen is smear positive.",
"   </p>",
"   <p>",
"    For patients who have difficulty producing sputum, sputum may be induced by inhalation of aerosolized hypertonic saline generated by a nebulizer [",
"    <a class=\"abstract\" href=\"UTD.htm?8/56/9098/abstract/31-33\">",
"     31-33",
"    </a>",
"    ]. Such specimens may appear thin and watery and should be clearly labeled &ldquo;induced sputum&rdquo; so they will not be discarded by the laboratory as inadequate specimens. This procedure should be administered by qualified, trained personnel using appropriate respiratory protection in an area with appropriate environmental controls. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/52/20294?source=see_link\">",
"     \"Tuberculosis transmission and control\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients who are unable to produce adequate samples of expectorated sputum should undergo serial sputum induction. In general, the yields of induced sputum and bronchoalveolar lavage specimens are comparable, and induced sputum is safer and less costly [",
"    <a class=\"abstract\" href=\"UTD.htm?8/56/9098/abstract/34-36\">",
"     34-36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Bronchoscopy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bronchoscopy with bronchoalveolar lavage",
"    <span class=\"nowrap\">",
"     (and/or",
"    </span>",
"    biopsy) should be reserved for the following circumstances [",
"    <a class=\"abstract\" href=\"UTD.htm?8/56/9098/abstract/34,35,37\">",
"     34,35,37",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Unsuccessful attempts to obtain adequate expectorated or induced sputum samples",
"     </li>",
"     <li>",
"      Negative sputum studies in the setting of a high clinical suspicion for tuberculosis (TB)",
"     </li>",
"     <li>",
"      Potential alternative diagnosis for which diagnostic bronchoscopy is required",
"     </li>",
"     <li>",
"      Urgent diagnostic information needed",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Sputum produced after bronchoscopy (during the immediate period following bronchoscopy and the day following the procedure) should also be collected for laboratory evaluation. Bronchoscopy should be performed by personnel using appropriate respiratory protection in an area with appropriate environmental controls. Careful disinfection and sterilization of the bronchoscope and ancillary equipment such as biopsy forceps is required. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/52/20294?source=see_link\">",
"     \"Tuberculosis transmission and control\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Gastric secretions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gastric aspiration can be useful in children who cannot produce sputum (even with induction). It is discussed in detail separately (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/4/23625?source=see_link&amp;anchor=H18#H18\">",
"     \"Tuberculosis disease in children\", section on 'Gastric aspirate'",
"    </a>",
"    ). In general, gastric aspiration is not used for adults who cannot produce sputum (spontaneous or induced); bronchoscopy is the appropriate next step.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Body fluids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Evaluation of tuberculous pleural effusion is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/35/12856?source=see_link\">",
"     \"Tuberculous pleural effusions in HIV-negative patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/47/22261?source=see_link\">",
"     \"Tuberculous pleural effusions in HIV-infected patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Evaluation of other body fluids is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/21/20826?source=see_link&amp;anchor=H13124464#H13124464\">",
"     \"Clinical manifestations, diagnosis, and treatment of extrapulmonary and miliary tuberculosis\", section on 'Clinical approach'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Tissue biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Maximal diagnostic yield can be obtained by pleural biopsy. The procedure can be performed closed or under thorascopic guidance. Pleural biopsy demonstrates granulomatous inflammation with or without caseation in approximately 60 percent of patients with pleural tuberculosis. AFB staining and culture of three pleural biopsy specimens combined with microscopic examination can establish a diagnosis of TB in up to 90 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?8/56/9098/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Tissue biopsy may establish a definitive diagnosis of tuberculosis when noninvasive techniques are not diagnostic. In the setting of tuberculous peritonitis, organism burden in ascites fluid is typically low. Laparoscopic or open biopsy with culture of tissue may be necessary to establish a diagnosis. Biopsy specimens from the lung, bone marrow, pericardium, lymph nodes, bones, joints, bowel, liver, brain, or other tissues allow for both histopathologic examination and microbiological studies. Biopsy specimens should be collected with and without fixative; specimens without fixative are required for culture.",
"   </p>",
"   <p>",
"    Microscopy of tissue biopsy specimens in the setting of tuberculosis typically demonstrates granulomatous inflammation. Granulomas of tuberculosis characteristically contain epithelioid macrophages, Langhans giant cells, and lymphocytes. The centers of tuberculous granulomas often have characteristic caseation (&ldquo;cheese-like&rdquo;) necrosis; organisms may or may not be seen with acid-fast staining. The demonstration of characteristic caseating granulomas on a tissue section in the appropriate clinical and epidemiologic circumstances strongly supports a diagnosis of active tuberculosis, but it is not pathognomonic; culture is required to establish a laboratory diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?8/56/9098/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Diagnostic microbiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acid fast bacteria observed on stained smears may represent M. tuberculosis or nontuberculous mycobacteria. Thus, acid fast staining should always be supplemented by cultures for species identification and drug susceptibility testing. In some situations, molecular testing also is appropriate.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Stained smears",
"    </span>",
"    &nbsp;&mdash;&nbsp;The detection of acid-fast bacilli (AFB) on microscopic examination of stained smears is the most rapid and inexpensive TB diagnostic tool. In many countries, smears are the only diagnostic test used. Smears may be prepared directly from clinical specimens or from concentrated preparations; concentrated material is preferred.",
"   </p>",
"   <p>",
"    Stained sputum smears are not as sensitive as sputum cultures. At least 5000 to 10,000 bacilli per mL are needed for detection of bacteria in stained smears; in contrast, 10 to 100 organisms are needed for a positive culture [",
"    <a class=\"abstract\" href=\"UTD.htm?8/56/9098/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The sensitivity and positive predictive value of AFB smear microscopy are approximately 45 to 80 percent and 50 to 80 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?8/56/9098/abstract/24\">",
"     24",
"    </a>",
"    ]. Sensitivity increases when multiple specimens are obtained and are subjected to concentration procedures, and can be as high as 90 percent in optimal circumstances. However, the sensitivity of stained smears is lower in patients with a small organism burdens (such as children with primary TB) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/56/9098/abstract/41-44\">",
"     41-44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The acid fast staining procedure is based on the ability of the mycobacteria to retain dye when treated with mineral acid or an acid-alcohol solution. Two common techniques for acid fast staining are the older carbolfuchsin methods (including the Ziehl-Neelsen and the Kinyoun methods) (",
"    <a class=\"graphic graphic_picture graphicRef56964 \" href=\"UTD.htm?36/51/37680\">",
"     picture 1",
"    </a>",
"    ), and the more rapid fluorochrome procedure (using auramine-O or auramine-rhodamine dyes with fluorescence microscopy) (",
"    <a class=\"graphic graphic_picture graphicRef80852 \" href=\"UTD.htm?17/38/18030\">",
"     picture 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/56/9098/abstract/41,45-47\">",
"     41,45-47",
"    </a>",
"    ]. The fluorochrome technique is up to 10-fold more sensitive than the carbolfuchsin methods. Advances in fluorescence microscopy with use of inexpensive, long-lasting light-emitting diodes (LEDs) as the source of light are improving access to fluorescence microscopy in resource-limited settings [",
"    <a class=\"abstract\" href=\"UTD.htm?8/56/9098/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Acid fast bacteria visualized on a slide may represent M. tuberculosis or nontuberculous mycobacteria, so species identification requires culture",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    nucleic acid amplification. In the setting of high clinical suspicion for tuberculosis, initiation of empiric therapy based on preliminary acid fast staining results is appropriate.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4856569\">",
"    <span class=\"h3\">",
"     Culture",
"    </span>",
"    &nbsp;&mdash;&nbsp;All clinical specimens suspected of containing mycobacteria should be cultured. Culture can detect as few as 10",
"    <span class=\"nowrap\">",
"     bacteria/mL.",
"    </span>",
"    Culture is required for drug susceptibility testing and cultures can also be used for species identification. The sensitivity and specificity of sputum culture are about 80 and 98 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?8/56/9098/abstract/49,50\">",
"     49,50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are three types of traditional culture media: egg based (Lowenstein-Jensen), agar based (Middlebrook 7H10 or 7H11), and liquid (Middlebrook 7H12 and other commercially available broths). Growth in liquid media is faster (one to three weeks) than growth on solid media (three to eight weeks) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/56/9098/abstract/49\">",
"     49",
"    </a>",
"    ]. Growth tends to be slightly better on egg-based medium, but growth is more rapid on agar medium. Agar medium permits examination of colony morphology and detection of mixed cultures.",
"   </p>",
"   <p>",
"    Commercially available automated liquid broth culture systems that use colorimetric systems for detection of mycobacteria are important technical advances in the detection of M. tuberculosis.",
"   </p>",
"   <p>",
"    Specimens should be inoculated onto at least one container of solid medium. This culture system should be used in conjunction with a",
"    <span class=\"nowrap\">",
"     liquid/broth",
"    </span>",
"    culture system. Lowenstein-Jensen slants are a useful backup for detection of rare mycobacterial strains that may not grow on other media. Automated liquid systems should be examined for growth at least every two to three days; solid media should be examined for growth once or twice weekly.",
"   </p>",
"   <p>",
"    Once growth is detected, a sample should be processed or forwarded to a reference laboratory for identification and drug susceptibility testing. Species identification can be performed using nucleic acid hybridization with a",
"    <span class=\"nowrap\">",
"     DNA/RNA",
"    </span>",
"    probe, high-pressure liquid chromatography (HPLC), or biochemical methods [",
"    <a class=\"abstract\" href=\"UTD.htm?8/56/9098/abstract/51,52\">",
"     51,52",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H23\">",
"     'Drug susceptibility testing'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Sputum samples should be obtained from patients with pulmonary TB at least monthly until at least two sequential, monthly samples are culture-negative, in order to document response to therapy and to optimize treatment. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/21/19802?source=see_link\">",
"     \"Treatment of pulmonary tuberculosis in HIV-negative patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4856355\">",
"    <span class=\"h3\">",
"     Molecular tests",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h4\">",
"     Nucleic acid amplification",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nucleic acid amplification (NAA) testing can be used for rapid diagnosis of an organism belonging to the M. tuberculosis complex (24 to 48 hours) in patients for whom the suspicion for TB is moderate to high. NAA testing has excellent positive predictive value in the setting of AFB smear positive specimens for distinguishing tuberculous from nontuberculous mycobacteria (&gt;95 percent), and it can rapidly establish the presence of tuberculosis in 50 to 80 percent of AFB smear negative specimens (which would eventually be culture-positive) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/56/9098/abstract/11\">",
"     11",
"    </a>",
"    ]. However, NAA does not replace the roles of routine AFB smear and culture; culture is required for drug susceptibility testing [",
"    <a class=\"abstract\" href=\"UTD.htm?8/56/9098/abstract/53\">",
"     53",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H17\">",
"     'Preliminary results'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    NAA tests permit amplification of a specific target RNA or DNA sequence that can be detected via a nucleic acid probe [",
"    <a class=\"abstract\" href=\"UTD.htm?8/56/9098/abstract/54,55\">",
"     54,55",
"    </a>",
"    ]. As few as 1 to 10",
"    <span class=\"nowrap\">",
"     organisms/mL",
"    </span>",
"    may give a positive result [",
"    <a class=\"abstract\" href=\"UTD.htm?8/56/9098/abstract/53,56-59\">",
"     53,56-59",
"    </a>",
"    ]. In AFB smear positive respiratory specimens, the sensitivity and specificity of amplification methods are 95 and 98 percent, respectively; in smear negative specimens, the sensitivity and specificity are about 75 to 88 percent and 95 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?8/56/9098/abstract/60-62\">",
"     60-62",
"    </a>",
"    ]. A positive NAA result supports the diagnosis of TB in the appropriate clinical and epidemiologic circumstances; smear positivity together with positive NAA is considered sufficient for diagnosis of tuberculosis [",
"    <a class=\"abstract\" href=\"UTD.htm?8/56/9098/abstract/56,63\">",
"     56,63",
"    </a>",
"    ]. A negative NAA result is not sufficient to exclude TB [",
"    <a class=\"abstract\" href=\"UTD.htm?8/56/9098/abstract/25\">",
"     25",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H17\">",
"     'Preliminary results'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    NAA results must be interpreted in the context of clinical and epidemiologic factors; contamination and laboratory errors can cause false-positive results. In addition, NAA can detect nucleic acid from dead and live organisms, so testing can remain positive even after appropriate therapy. Therefore, this method is only appropriate for initial diagnostic purposes.",
"   </p>",
"   <p>",
"    The US Food and Drug Administration (FDA) has approved two NAA tests for detection of M. tuberculosis complex bacteria in respiratory secretions: the Enhanced Amplified Mycobacterium Tuberculosis Direct Test (E-MTD) and the Amplicor Mycobacterium Tuberculosis Test (Amplicor) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/56/9098/abstract/60,61\">",
"     60,61",
"    </a>",
"    ]. The E-MTD test is approved for use in AFB smear positive and smear negative specimens (with fewer than seven days of antimycobacterial therapy), while Amplicor is approved only for smear positive samples.",
"   </p>",
"   <p>",
"    Decisions regarding the use of NAA should be individualized on the basis of available information. A positive NAA may tip the balance in favor of making a decision to initiate antituberculous therapy, but results should be interpreted in a clinical context and on the basis of local laboratory performance [",
"    <a class=\"abstract\" href=\"UTD.htm?8/56/9098/abstract/18,56\">",
"     18,56",
"    </a>",
"    ]. The negative predictive value of the E-MTD test can be useful in deciding to terminate respiratory isolation [",
"    <a class=\"abstract\" href=\"UTD.htm?8/56/9098/abstract/11\">",
"     11",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H17\">",
"     'Preliminary results'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H20\">",
"     'Infection control'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Nucleic acid amplification (NAA) tests may be performed for specimens other than respiratory secretions, although this is an &ldquo;off-label&rdquo; application and is not approved by the FDA [",
"    <a class=\"abstract\" href=\"UTD.htm?8/56/9098/abstract/62\">",
"     62",
"    </a>",
"    ]. Some laboratories develop, validate, and perform &ldquo;in-house&rdquo; NAA testing on these types of samples. NAA tests appear to have high specificity but moderate sensitivity in cerebrospinal fluid (CSF) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/56/9098/abstract/64-66\">",
"     64-66",
"    </a>",
"    ]. In one study, sensitivity and specificity of NAA testing in CSF were 59 and 100 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?8/56/9098/abstract/64\">",
"     64",
"    </a>",
"    ]. This suggests that NAA tests may be used to confirm the diagnosis of tuberculous meningitis when used together with traditional CSF studies, but NAA tests cannot be used to rule out TB meningitis. Further research is needed to establish accuracy of NAA tests in other clinical specimens [",
"    <a class=\"abstract\" href=\"UTD.htm?8/56/9098/abstract/67\">",
"     67",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4856396\">",
"    <span class=\"h4\">",
"     Xpert MTB/RIF assay",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Xpert",
"    <span class=\"nowrap\">",
"     MTB/RIF",
"    </span>",
"    assay is an automated nucleic acid amplification test that can simultaneously identify M. tuberculosis and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    resistance [",
"    <a class=\"abstract\" href=\"UTD.htm?8/56/9098/abstract/68,69\">",
"     68,69",
"    </a>",
"    ]. In a study including 1730 patients with suspected tuberculosis, the test correctly identified 98 percent of patients with smear positive tuberculosis and 72 percent of patients with smear",
"    <span class=\"nowrap\">",
"     negative/culture",
"    </span>",
"    positive tuberculosis [",
"    <a class=\"abstract\" href=\"UTD.htm?8/56/9098/abstract/68\">",
"     68",
"    </a>",
"    ]. The accuracy for identification of rifampin resistance was 98 percent. The assay is simple to perform with minimal training, is not prone to cross-contamination, and requires minimal biosafety facilities. (See",
"    <a class=\"local\" href=\"#H23\">",
"     'Drug susceptibility testing'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The feasibility, diagnostic accuracy, and effectiveness of this assay in resource limited settings have been demonstrated [",
"    <a class=\"abstract\" href=\"UTD.htm?8/56/9098/abstract/69-71\">",
"     69-71",
"    </a>",
"    ]. This test has the potential to dramatically reduce the time to diagnosis and the time to initiation of effective therapy, although it requires a reliable power supply and operating temperatures below 30&deg;C.",
"   </p>",
"   <p>",
"    Molecular based tests for detection of drug resistance are discussed further separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/52/32586?source=see_link&amp;anchor=H6#H6\">",
"     \"Diagnosis, treatment, and prevention of drug-resistant tuberculosis\", section on 'Rapid testing'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Preliminary results",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, the initial diagnostic evaluation for individuals at moderate to high suspicion for pulmonary tuberculosis should include three sputum specimens for AFB smear and culture, as well as at least one specimen for nucleic acid amplification (NAA) testing [",
"    <a class=\"abstract\" href=\"UTD.htm?8/56/9098/abstract/11\">",
"     11",
"    </a>",
"    ]. NAA results must be interpreted in correlation with AFB smear results while culture (the gold standard for laboratory confirmation) is pending [",
"    <a class=\"abstract\" href=\"UTD.htm?8/56/9098/abstract/11\">",
"     11",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If both NAA and AFB smear results are positive, a diagnosis of TB has been established. Therapy should be initiated while awaiting culture results for drug susceptibility testing.",
"     </li>",
"     <li>",
"      If the NAA result is positive and the AFB smear is negative, repeat NAA testing may be warranted. If two or more specimens are NAA positive, TB can be presumed to be present. Clinician judgment should be used when deciding whether empiric TB therapy should be initiated while awaiting culture results.",
"     </li>",
"     <li>",
"      If the NAA result is negative and the AFB smear is positive, a test for inhibitors that may limit amplification should be performed [",
"      <a class=\"abstract\" href=\"UTD.htm?8/56/9098/abstract/72\">",
"       72",
"      </a>",
"      ]. If inhibitors are detected, the effect of inhibitors may be overcome by repeating the assay on a diluted (1:10) sample of the same original specimen [",
"      <a class=\"abstract\" href=\"UTD.htm?8/56/9098/abstract/73,74\">",
"       73,74",
"      </a>",
"      ]. If inhibitors are not detected, and an additional specimen is also found to be AFB smear positive and NAA negative, the presence of a nontuberculous mycobacteria may be presumed. Clinician judgment should be used when deciding whether empiric TB therapy should be initiated while awaiting culture results.",
"     </li>",
"     <li>",
"      TB cannot be definitively excluded in some patients even if both NAA and AFB smear results are negative. Thus, clinician judgment should be used regarding initiation of empiric TB therapy while awaiting culture results.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Presumptive diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;For cases in which it is not possible to establish an immediate laboratory diagnosis, a presumptive clinical diagnosis is sufficient for initiating therapy (based on epidemiologic exposure, positive",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/35/15924?source=see_link\">",
"     tuberculin skin test",
"    </a>",
"    or IGRA, physical findings, radiographic findings,",
"    <span class=\"nowrap\">",
"     sputum/secretions/fluid",
"    </span>",
"    analyses,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    histopathology). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/21/19802?source=see_link&amp;anchor=H21#H21\">",
"     \"Treatment of pulmonary tuberculosis in HIV-negative patients\", section on 'Culture negative TB'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     WHILE LABORATORY DIAGNOSTICS ARE PENDING",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Infection control",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diagnostic evaluation for tuberculosis (TB) may be handled in the outpatient setting if clinical circumstances permit [",
"    <a class=\"abstract\" href=\"UTD.htm?8/56/9098/abstract/24,40\">",
"     24,40",
"    </a>",
"    ]. There is no need to hospitalize on the basis of suspected infectiousness if the patient poses no danger to public health. Outpatients can be instructed to remain at home, without visitors and away from other family members. Individuals particularly susceptible to tuberculosis (such as small children and immunocompromised individuals) should not visit or live with patients who may be infectious. These types of decisions are usually made in conjunction with the local public health authority, which should be notified at the time tuberculosis is suspected. (See",
"    <a class=\"local\" href=\"#H21\">",
"     'Reporting and public health'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Hospitalization with respiratory isolation is appropriate if social or clinical circumstances preclude outpatient management or if there is public health risk for transmission [",
"    <a class=\"abstract\" href=\"UTD.htm?8/56/9098/abstract/1-5\">",
"     1-5",
"    </a>",
"    ]. In these settings, assessments of the patient&rsquo;s social circumstances (eg, living, employment, school, access to health care resources) by public health personnel can be used to determine whether isolation is warranted. Hospitalized patients should be placed in negative pressure respiratory isolation until infectious M. tuberculosis has been ruled out on the basis of the following criteria [",
"    <a class=\"abstract\" href=\"UTD.htm?8/56/9098/abstract/25\">",
"     25",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      An alternative diagnosis explaining the clinical syndrome has been established",
"     </li>",
"     <li>",
"      Demonstration of three negative AFB sputum smear results",
"     </li>",
"     <li>",
"      Demonstration of a negative sputum NAA result and two negative AFB sputum smear results",
"     </li>",
"     <li>",
"      Antimycobacterial therapy initiated with clinical response to treatment (usually four to seven days), with three subsequent negative sputum AFB smears",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Stricter isolation criteria may be required depending on individual circumstances, particularly for settings in which discontinuation of isolation precautions would pose potential risk to other patients.",
"   </p>",
"   <p>",
"    Most extrapulmonary TB (eg, isolated TB lymphadenitis) is not considered infectious. Other issues related to tuberculosis transmission and control are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/52/20294?source=see_link\">",
"     \"Tuberculosis transmission and control\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Reporting and public health",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tuberculosis is a reportable disease in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?8/56/9098/abstract/75\">",
"     75",
"    </a>",
"    ]. Persons with confirmed or suspected tuberculosis must be reported to a state or local public health authority promptly (in many states, this period is 24 hours) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/56/9098/abstract/2,76\">",
"     2,76",
"    </a>",
"    ]. Laboratories that process diagnostic specimens for tuberculosis also are required to report the isolation of M. tuberculosis complex to the provider and to the public health authority.",
"   </p>",
"   <p>",
"    Case and suspect reporting initiates a series of events to assist the clinician and patient with additional diagnostic measures and management of the disease. Public health personnel also initiate activities such as contact notification and investigation to assess and limit the impact of the infection on the community. This includes new case finding and prevention of disease in high risk contacts [",
"    <a class=\"abstract\" href=\"UTD.htm?8/56/9098/abstract/77\">",
"     77",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The public health authority can provide a link to expert medical consultation for diagnosis or management; this may be especially useful in regions with limited local expertise or where TB is not common. In the United States, the Centers for Disease Control and Prevention (CDC) also sponsors regional centers where consultation is available [",
"    <a class=\"abstract\" href=\"UTD.htm?8/56/9098/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Empiric therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;A presumptive clinical diagnosis is sufficient for initiation of treatment pending diagnostic laboratory results when the clinical suspicion for TB is considered likely. The approach to empiric therapy for TB is outlined in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/35/19002?source=see_link\">",
"     \"Treatment of pulmonary tuberculosis in the HIV-infected patient\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/21/19802?source=see_link\">",
"     \"Treatment of pulmonary tuberculosis in HIV-negative patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In a minority of patients with TB, laboratory confirmation is never established. This also is usually the case in children under five years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?8/56/9098/abstract/9\">",
"     9",
"    </a>",
"    ]. In such cases a presumptive diagnosis may be made based on clinical and radiographic presentation and response to empiric treatment.",
"   </p>",
"   <p>",
"    Fluoroquinolones should not be used as a single drug in patients with a presumed diagnosis of community acquired pneumonia who have clinical findings suggesting TB or have",
"    <span class=\"nowrap\">",
"     historical/epidemiologic",
"    </span>",
"    risks for TB. Even transient use of fluoroquinolones may facilitate development of mycobacterial resistance to this drug class and promote continued TB transmission in the community [",
"    <a class=\"abstract\" href=\"UTD.htm?8/56/9098/abstract/78-83\">",
"     78-83",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Drug susceptibility testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Drug susceptibility testing for INH, RIF, and EMB should be performed on initial isolates from each site of disease [",
"    <a class=\"abstract\" href=\"UTD.htm?8/56/9098/abstract/84\">",
"     84",
"    </a>",
"    ]. Susceptibility testing should be repeated and include testing for second-line agents for patients who have had prior therapy, have been in contact with a patient with known drug resistance, or have positive cultures after more than three months of treatment. Such testing should be performed only in reference laboratories.",
"   </p>",
"   <p>",
"    Susceptibility testing should be repeated if the patient remains culture-positive after three months of therapy or positive cultures are detected after negative cultures have been documented.",
"   </p>",
"   <p>",
"    The agar proportion and liquid culture methods are used in the United States for detecting mycobacterial drug resistance. These methods quantify the relative growth of organisms on solid agar or liquid media in the presence or absence of antimycobacterial drugs following growth detection of the parent culture and inoculation into the secondary media [",
"    <a class=\"abstract\" href=\"UTD.htm?8/56/9098/abstract/24\">",
"     24",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H4856569\">",
"     'Culture'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Testing for first-line drug susceptibilities usually requires at least three weeks; turnaround times have been improved by using liquid culture systems. Rapid tests including molecular tests or assays in which decontaminated respiratory samples are inoculated directly into drug-free and drug-containing medium. Rapid tests for tuberculosis drug susceptibility testing include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The microscopic-observation drug-susceptibility (MODS) and thin layer agar (TLA) assays; in these techniques, drug free and drug-containing media (liquid for MODS, solid for TLA) are inoculated with patient specimens, and cultures are microscopically examined for growth [",
"      <a class=\"abstract\" href=\"UTD.htm?8/56/9098/abstract/85-89\">",
"       85-89",
"      </a>",
"      ]. These are relatively rapid, inexpensive tools, although thus far the utility is limited by biosafety concerns and relative labor intensity.",
"      <br/>",
"      <br/>",
"      Comparative sensitivities of MODS, automated mycobacterial culture and Lowenstein-Jensen culture on 3760 sputum samples in Peru were 98, 89, and 84 percent, respectively. Median time to culture positivity was 7, 13, and 26 days, respectively. Agreement between the MODS assay and the reference standards for drug susceptibilities was 92 to 100 percent.",
"      <br/>",
"      <br/>",
"      Strains of M. tuberculosis with variable morphology may not be appropriate for detection with this technique [",
"      <a class=\"abstract\" href=\"UTD.htm?8/56/9098/abstract/85\">",
"       85",
"      </a>",
"      ]. Combining the assay with routine culture on solid medium permits confirmation of organism identification.",
"     </li>",
"     <li>",
"      Molecular beacons are labeled oligonucleotides that fluoresce when hybridized to a target sequence encoding genes for drug resistance [",
"      <a class=\"abstract\" href=\"UTD.htm?8/56/9098/abstract/90\">",
"       90",
"      </a>",
"      ]. About 95 percent of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"       rifampin",
"      </a>",
"      -resistant strains contain mutations within a single locus (rpoB), and rifampin resistance may be a surrogate marker for MDR-TB; approximately 90 percent of rifampin-resistant strains also are resistant to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/21/40279?source=see_link\">",
"       isoniazid",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?8/56/9098/abstract/91-95\">",
"       91-95",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      The GeneXpert",
"      <span class=\"nowrap\">",
"       MTB/RIF",
"      </span>",
"      assay is an RT-PCR-based system for the detection of M. tuberculosis in sputum and simultaneous determination of resistance to rifampicin using molecular beacon technology [",
"      <a class=\"abstract\" href=\"UTD.htm?8/56/9098/abstract/96\">",
"       96",
"      </a>",
"      ]. Its relatively high cost may be a factor in implementing this technology in resource limited TB endemic settings. (See",
"      <a class=\"local\" href=\"#H4856396\">",
"       'Xpert MTB/RIF assay'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The Mycobacteriology Laboratory Branch at CDC-Division of Tuberculosis Elimination has initiated a molecular testing service for the identification of drug resistance in isolates of Mycobacterium tuberculosis complex using PCR and DNA sequence analysis [",
"    <a class=\"abstract\" href=\"UTD.htm?8/56/9098/abstract/97\">",
"     97",
"    </a>",
"    ]. The testing identifies genetic mutations associated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/21/40279?source=see_link\">",
"     isoniazid",
"    </a>",
"    resistance. Genetic loci associated with resistance to second-line drugs including fluoroquinolones, and the injectables",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/16/34056?source=see_link\">",
"     amikacin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/10/40102?source=see_link\">",
"     kanamycin",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/59/11189?source=see_link\">",
"     capreomycin",
"    </a>",
"    are also examined.",
"   </p>",
"   <p>",
"    To be eligible for this service, the case must meet at least one of the following criteria [",
"    <a class=\"abstract\" href=\"UTD.htm?8/56/9098/abstract/97\">",
"     97",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      High risk of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"       rifampin",
"      </a>",
"      resistance or MDR-TB (eg, previous TB, MDR-TB contact, foreign born)",
"     </li>",
"     <li>",
"      Known",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"       rifampin",
"      </a>",
"      resistance",
"     </li>",
"     <li>",
"      High profile patient (eg, daycare worker, nurse)",
"     </li>",
"     <li>",
"      Adverse reaction (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"       rifampin",
"      </a>",
"      allergy)",
"     </li>",
"     <li>",
"      Mixed or non-viable culture",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In general, patients meeting appropriate clinical criteria for tuberculosis should have initiation of tuberculosis (TB) diagnostic evaluation with chest radiography. A positive",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/35/15924?source=see_link\">",
"       tuberculin skin test",
"      </a>",
"      or Interferon-gamma release assay (IGRA) supports a diagnosis of TB infection, although a negative test does not rule out TB. If this evaluation is suggestive of pulmonary TB, three sputum specimens for AFB smear and culture should be obtained (",
"      <a class=\"graphic graphic_table graphicRef80879 \" href=\"UTD.htm?38/31/39420\">",
"       table 1",
"      </a>",
"      ). In patients in whom the suspicion for TB is moderate to high, at least one specimen should also be tested using a nucleic acid amplification (NAA) test if available. Early morning gastric aspiration for mycobacterial culture may be substituted for children under five years of age who are unable to produce expectorated or induced sputum. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'General approach'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H10\">",
"       'Gastric secretions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In the setting of suspected extrapulmonary TB, samples of tissue",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      fluid should be obtained for histopathological, microbiologic, and biochemical analysis. Molecular testing should be performed if validated testing is available. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'General approach'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Reactivation pulmonary tuberculosis classically presents with focal infiltration of the upper lobe(s), usually of the apical",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      posterior segments, or of the superior (apical) segment(s) of the lower lobe(s) (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef74846 graphicRef70220 graphicRef54807 graphicRef56912 \" href=\"UTD.htm?13/19/13625\">",
"       image 1A-D",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Chest radiography'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A series of at least three sputum specimens should be collected in 8- to 24-hour intervals (with at least one specimen obtained in the early morning). Sputum induction may be performed for patients who have difficulty coughing up sputum. Sputum is preferred over bronchoalveolar lavage specimens with respect to safety and cost; the yields are comparable. Other clinical specimens and tissues may be obtained depending on individual patient circumstances. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Clinical specimens'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The detection of acid-fast bacilli (AFB) on microscopic examination of stained smears is the most rapid and inexpensive TB diagnostic tool. Acid-fast bacteria may represent M. tuberculosis or nontuberculous mycobacteria; nucleic acid amplification (NAA) can detect presence of M. tuberculosis complex but culture is needed for species identification and drug susceptibility testing. NAA results must be interpreted in conjunction with AFB smear results while culture is pending. The Xpert",
"      <span class=\"nowrap\">",
"       MTB/RIF",
"      </span>",
"      assay is also an important tool for rapid diagnosis of tuberculosis as well as presence of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"       rifampin",
"      </a>",
"      resistance. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Diagnostic microbiology'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H17\">",
"       'Preliminary results'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      It may not be possible to establish a definitive laboratory diagnosis. In such cases, a presumptive clinical diagnosis is sufficient for initiating therapy. This may be made based on epidemiologic exposure, positive",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/35/15924?source=see_link\">",
"       tuberculin skin test",
"      </a>",
"      or IGRA, physical findings, radiographic findings, analyses of sputum, secretions, or fluids,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      histopathology. Clinical and radiographic response to empiric treatment in the appropriate setting may be used to establish a clinical diagnosis of TB if isolation or identification of the organism is not achieved. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'General approach'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Treatment should be tailored to results of drug susceptibility testing when these results become available. Sputum culture and drug susceptibility testing should be repeated if the patient continues to produce culture-positive sputum after three months of therapy or develops positive cultures after a period of negative cultures. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Drug susceptibility testing'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Diagnostic evaluation for TB may be handled in the outpatient setting if clinical circumstances permit and the patient is not a danger to the public health. Criteria for ruling out infectious TB are as outlined above. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Infection control'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In the United States, tuberculosis is a reportable disease; a laboratory diagnosis or clinical suspicion of TB must be reported promptly to public health authorities, who can in turn facilitate case management, therapeutic follow-up, and institute contact investigation when necessary. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Reporting and public health'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/56/9098/abstract/1\">",
"      Taylor Z, Marks SM, R&iacute;os Burrows NM, et al. Causes and costs of hospitalization of tuberculosis patients in the United States. Int J Tuberc Lung Dis 2000; 4:931.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/56/9098/abstract/2\">",
"      Sotir MJ, Parrott P, Metchock B, et al. Tuberculosis in the inner city: impact of a continuing epidemic in the 1990s. Clin Infect Dis 1999; 29:1138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/56/9098/abstract/3\">",
"      Blumberg HM, Watkins DL, Berschling JD, et al. Preventing the nosocomial transmission of tuberculosis. Ann Intern Med 1995; 122:658.",
"     </a>",
"    </li>",
"    <li>",
"     Institute of Medicine. on Regulating Occupational Exposure to Tuberculosis. In: Tuberculosis in the workplace, Field MJ (Ed), National Academy Press, Washington, DC 2001.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/56/9098/abstract/5\">",
"      Jensen PA, Lambert LA, Iademarco MF, et al. Guidelines for preventing the transmission of Mycobacterium tuberculosis in health-care settings, 2005. MMWR Recomm Rep 2005; 54:1.",
"     </a>",
"    </li>",
"    <li>",
"     Centers for Disease Control and Prevention. Regional Training and Medical Consultation Centers (RTMCCs). Available at: file://www.cdc.gov/tb/education/rtmc/default.htm (Accessed on May 21, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/56/9098/abstract/7\">",
"      Pai M, Menzies D. Interferon-gamma release assays: what is their role in the diagnosis of active tuberculosis? Clin Infect Dis 2007; 44:74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/56/9098/abstract/8\">",
"      Dewan PK, Grinsdale J, Kawamura LM. Low sensitivity of a whole-blood interferon-gamma release assay for detection of active tuberculosis. Clin Infect Dis 2007; 44:69.",
"     </a>",
"    </li>",
"    <li>",
"     Centers for Disease Control and Prevention. Reported Tuberculosis in US, 2008. Available at: file://www.cdc.gov/tb/statistics/reports/2008/default.htm (Accessed on May 18, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/56/9098/abstract/10\">",
"      American Thoracic Society, CDC, Infectious Diseases Society of America. Treatment of tuberculosis. MMWR Recomm Rep 2003; 52:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/56/9098/abstract/11\">",
"      Centers for Disease Control and Prevention (CDC). Updated guidelines for the use of nucleic acid amplification tests in the diagnosis of tuberculosis. MMWR Morb Mortal Wkly Rep 2009; 58:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/56/9098/abstract/12\">",
"      Meyer M, Clarke P, O'Regan AW. Utility of the lateral chest radiograph in the evaluation of patients with a positive tuberculin skin test result. Chest 2003; 124:1824.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/56/9098/abstract/13\">",
"      Geng E, Kreiswirth B, Burzynski J, Schluger NW. Clinical and radiographic correlates of primary and reactivation tuberculosis: a molecular epidemiology study. JAMA 2005; 293:2740.",
"     </a>",
"    </li>",
"    <li>",
"     Radiographic Manifestations of Tuberculosis: A Primer for Clinicians, 2nd Edition, Francis, J (Ed). Curry National TB Center, 2006. Available at: file://www.nationaltbcenter.edu/radiographic/ (Accessed on May 18, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/56/9098/abstract/15\">",
"      Khan MA, Kovnat DM, Bachus B, et al. Clinical and roentgenographic spectrum of pulmonary tuberculosis in the adult. Am J Med 1977; 62:31.",
"     </a>",
"    </li>",
"    <li>",
"     Daley CL, Gotway MB, Jasmer RM. Radiographic manifestations of Tuberculosis: A Primer for Clinicians. 2nd ed, Francis J Curry National TB Center, 2006. Available at: file://www.nationaltbcenter.edu/products/product_details.cfm?productID=EDP-04 (Accessed on May 18, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/56/9098/abstract/17\">",
"      Perlman DC, el-Sadr WM, Nelson ET, et al. Variation of chest radiographic patterns in pulmonary tuberculosis by degree of human immunodeficiency virus-related immunosuppression. The Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA). The AIDS Clinical Trials Group (ACTG). Clin Infect Dis 1997; 25:242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/56/9098/abstract/18\">",
"      Havlir DV, Barnes PF. Tuberculosis in patients with human immunodeficiency virus infection. N Engl J Med 1999; 340:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/56/9098/abstract/19\">",
"      Jones BE, Young SM, Antoniskis D, et al. Relationship of the manifestations of tuberculosis to CD4 cell counts in patients with human immunodeficiency virus infection. Am Rev Respir Dis 1993; 148:1292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/56/9098/abstract/20\">",
"      Stumpe KD, Dazzi H, Schaffner A, von Schulthess GK. Infection imaging using whole-body FDG-PET. Eur J Nucl Med 2000; 27:822.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/56/9098/abstract/21\">",
"      Goo JM, Im JG, Do KH, et al. Pulmonary tuberculoma evaluated by means of FDG PET: findings in 10 cases. Radiology 2000; 216:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/56/9098/abstract/22\">",
"      Hara T, Kosaka N, Suzuki T, et al. Uptake rates of 18F-fluorodeoxyglucose and 11C-choline in lung cancer and pulmonary tuberculosis: a positron emission tomography study. Chest 2003; 124:893.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/56/9098/abstract/23\">",
"      Khan MS, Dar O, Sismanidis C, et al. Improvement of tuberculosis case detection and reduction of discrepancies between men and women by simple sputum-submission instructions: a pragmatic randomised controlled trial. Lancet 2007; 369:1955.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/56/9098/abstract/24\">",
"      Diagnostic Standards and Classification of Tuberculosis in Adults and Children. This official statement of the American Thoracic Society and the Centers for Disease Control and Prevention was adopted by the ATS Board of Directors, July 1999. This statement was endorsed by the Council of the Infectious Disease Society of America, September 1999. Am J Respir Crit Care Med 2000; 161:1376.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.cdc.gov/tb/amplification_tests/amplification_tests.pdf (Accessed on January 20, 2008).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/56/9098/abstract/26\">",
"      Nelson SM, Deike MA, Cartwright CP. Value of examining multiple sputum specimens in the diagnosis of pulmonary tuberculosis. J Clin Microbiol 1998; 36:467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/56/9098/abstract/27\">",
"      Craft DW, Jones MC, Blanchet CN, Hopfer RL. Value of examining three acid-fast bacillus sputum smears for removal of patients suspected of having tuberculosis from the \"airborne precautions\" category. J Clin Microbiol 2000; 38:4285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/56/9098/abstract/28\">",
"      Rieder HL, Chiang CY, Rusen ID. A method to determine the utility of the third diagnostic and the second follow-up sputum smear examinations to diagnose tuberculosis cases and failures. Int J Tuberc Lung Dis 2005; 9:384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/56/9098/abstract/29\">",
"      Al Zahrani K, Al Jahdali H, Poirier L, et al. Yield of smear, culture and amplification tests from repeated sputum induction for the diagnosis of pulmonary tuberculosis. Int J Tuberc Lung Dis 2001; 5:855.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/56/9098/abstract/30\">",
"      Davis JL, Cattamanchi A, Cuevas LE, et al. Diagnostic accuracy of same-day microscopy versus standard microscopy for pulmonary tuberculosis: a systematic review and meta-analysis. Lancet Infect Dis 2013; 13:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/56/9098/abstract/31\">",
"      Lee E, Holzman RS. Evolution and current use of the tuberculin test. Clin Infect Dis 2002; 34:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/56/9098/abstract/32\">",
"      Schoch OD, Rieder P, Tueller C, et al. Diagnostic yield of sputum, induced sputum, and bronchoscopy after radiologic tuberculosis screening. Am J Respir Crit Care Med 2007; 175:80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/56/9098/abstract/33\">",
"      Brown M, Varia H, Bassett P, et al. Prospective study of sputum induction, gastric washing, and bronchoalveolar lavage for the diagnosis of pulmonary tuberculosis in patients who are unable to expectorate. Clin Infect Dis 2007; 44:1415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/56/9098/abstract/34\">",
"      Anderson C, Inhaber N, Menzies D. Comparison of sputum induction with fiber-optic bronchoscopy in the diagnosis of tuberculosis. Am J Respir Crit Care Med 1995; 152:1570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/56/9098/abstract/35\">",
"      Conde MB, Soares SL, Mello FC, et al. Comparison of sputum induction with fiberoptic bronchoscopy in the diagnosis of tuberculosis: experience at an acquired immune deficiency syndrome reference center in Rio de Janeiro, Brazil. Am J Respir Crit Care Med 2000; 162:2238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/56/9098/abstract/36\">",
"      McWilliams T, Wells AU, Harrison AC, et al. Induced sputum and bronchoscopy in the diagnosis of pulmonary tuberculosis. Thorax 2002; 57:1010.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/56/9098/abstract/37\">",
"      Somu N, Swaminathan S, Paramasivan CN, et al. Value of bronchoalveolar lavage and gastric lavage in the diagnosis of pulmonary tuberculosis in children. Tuber Lung Dis 1995; 76:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/56/9098/abstract/38\">",
"      Light RW. Update on tuberculous pleural effusion. Respirology 2010; 15:451.",
"     </a>",
"    </li>",
"    <li>",
"     Pathology of Tuberculosis. The Internet Pathology Laboratory for Medical Education. Available at: file://www-medlib.med.utah.edu/WebPath/TUTORIAL/MTB/MTB.html (Accessed on March 23, 2006).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/56/9098/abstract/40\">",
"      Hobby GL, Holman AP, Iseman MD, Jones JM. Enumeration of tubercle bacilli in sputum of patients with pulmonary tuberculosis. Antimicrob Agents Chemother 1973; 4:94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/56/9098/abstract/41\">",
"      Steingart KR, Henry M, Ng V, et al. Fluorescence versus conventional sputum smear microscopy for tuberculosis: a systematic review. Lancet Infect Dis 2006; 6:570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/56/9098/abstract/42\">",
"      Harries AD, Maher D, Nunn P. An approach to the problems of diagnosing and treating adult smear-negative pulmonary tuberculosis in high-HIV-prevalence settings in sub-Saharan Africa. Bull World Health Organ 1998; 76:651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/56/9098/abstract/43\">",
"      Perlman DC, El-Helou P, Salomon N. Tuberculosis in patients with human immunodeficiency virus infection. Semin Respir Infect 1999; 14:344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/56/9098/abstract/44\">",
"      Shingadia D, Novelli V. Diagnosis and treatment of tuberculosis in children. Lancet Infect Dis 2003; 3:624.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/56/9098/abstract/45\">",
"      Peterson EM, Nakasone A, Platon-DeLeon JM, et al. Comparison of direct and concentrated acid-fast smears to identify specimens culture positive for Mycobacterium spp. J Clin Microbiol 1999; 37:3564.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/56/9098/abstract/46\">",
"      Warren JR, Bhattacharya M, De Almeida KN, et al. A minimum 5.0 ml of sputum improves the sensitivity of acid-fast smear for Mycobacterium tuberculosis. Am J Respir Crit Care Med 2000; 161:1559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/56/9098/abstract/47\">",
"      Marais BJ, Brittle W, Painczyk K, et al. Use of light-emitting diode fluorescence microscopy to detect acid-fast bacilli in sputum. Clin Infect Dis 2008; 47:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/56/9098/abstract/48\">",
"      Minion J, Sohn H, Pai M. Light-emitting diode technologies for TB diagnosis: what is on the market? Expert Rev Med Devices 2009; 6:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/56/9098/abstract/49\">",
"      Morgan MA, Horstmeier CD, DeYoung DR, Roberts GD. Comparison of a radiometric method (BACTEC) and conventional culture media for recovery of mycobacteria from smear-negative specimens. J Clin Microbiol 1983; 18:384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/56/9098/abstract/50\">",
"      Ichiyama S, Shimokata K, Takeuchi J. Comparative study of a biphasic culture system (Roche MB Check system) with a conventional egg medium for recovery of mycobacteria. Aichi Mycobacteriosis Research Group. Tuber Lung Dis 1993; 74:338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/56/9098/abstract/51\">",
"      Shinnick TM, Good RC. Diagnostic mycobacteriology laboratory practices. Clin Infect Dis 1995; 21:291.",
"     </a>",
"    </li>",
"    <li>",
"     Kent PT, Kubica GP. Public Health Mycobacteriology: A guide for the Level III Laboratory., Centers for Disease Control and Prevention, Atlanta 1985.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/56/9098/abstract/53\">",
"      Cheng VC, Yew WW, Yuen KY. Molecular diagnostics in tuberculosis. Eur J Clin Microbiol Infect Dis 2005; 24:711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/56/9098/abstract/54\">",
"      Cohen RA, Muzaffar S, Schwartz D, et al. Diagnosis of pulmonary tuberculosis using PCR assays on sputum collected within 24 hours of hospital admission. Am J Respir Crit Care Med 1998; 157:156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/56/9098/abstract/55\">",
"      Centers for Disease Control and Prevention (CDC). Nucleic acid amplification tests for tuberculosis. MMWR Morb Mortal Wkly Rep 1996; 45:950.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/56/9098/abstract/56\">",
"      Catanzaro A, Perry S, Clarridge JE, et al. The role of clinical suspicion in evaluating a new diagnostic test for active tuberculosis: results of a multicenter prospective trial. JAMA 2000; 283:639.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/56/9098/abstract/57\">",
"      Conaty SJ, Claxton AP, Enoch DA, et al. The interpretation of nucleic acid amplification tests for tuberculosis: do rapid tests change treatment decisions? J Infect 2005; 50:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/56/9098/abstract/58\">",
"      Lim TK, Mukhopadhyay A, Gough A, et al. Role of clinical judgment in the application of a nucleic acid amplification test for the rapid diagnosis of pulmonary tuberculosis. Chest 2003; 124:902.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/56/9098/abstract/59\">",
"      Wiener RS, Della-Latta P, Schluger NW. Effect of nucleic acid amplification for Mycobacterium tuberculosis on clinical decision making in suspected extrapulmonary tuberculosis. Chest 2005; 128:102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/56/9098/abstract/60\">",
"      Rapid diagnostic tests for tuberculosis: what is the appropriate use? American Thoracic Society Workshop. Am J Respir Crit Care Med 1997; 155:1804.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/56/9098/abstract/61\">",
"      Perry S, Catanzaro A. Use of clinical risk assessments in evaluation of nucleic acid amplification tests for HIV/tuberculosis. Int J Tuberc Lung Dis 2000; 4:S34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/56/9098/abstract/62\">",
"      Laraque F, Griggs A, Slopen M, Munsiff SS. Performance of nucleic acid amplification tests for diagnosis of tuberculosis in a large urban setting. Clin Infect Dis 2009; 49:46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/56/9098/abstract/63\">",
"      Campos M, Quartin A, Mendes E, et al. Feasibility of shortening respiratory isolation with a single sputum nucleic acid amplification test. Am J Respir Crit Care Med 2008; 178:300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/56/9098/abstract/64\">",
"      Cloud JL, Shutt C, Aldous W, Woods G. Evaluation of a modified gen-probe amplified direct test for detection of Mycobacterium tuberculosis complex organisms in cerebrospinal fluid. J Clin Microbiol 2004; 42:5341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/56/9098/abstract/65\">",
"      Rafi W, Venkataswamy MM, Ravi V, Chandramuki A. Rapid diagnosis of tuberculous meningitis: a comparative evaluation of in-house PCR assays involving three mycobacterial DNA sequences, IS6110, MPB-64 and 65 kDa antigen. J Neurol Sci 2007; 252:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/56/9098/abstract/66\">",
"      Lang AM, Feris-Iglesias J, Pena C, et al. Clinical evaluation of the Gen-Probe Amplified Direct Test for detection of Mycobacterium tuberculosis complex organisms in cerebrospinal fluid. J Clin Microbiol 1998; 36:2191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/56/9098/abstract/67\">",
"      Dinnes J, Deeks J, Kunst H, et al. A systematic review of rapid diagnostic tests for the detection of tuberculosis infection. Health Technol Assess 2007; 11:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/56/9098/abstract/68\">",
"      Boehme CC, Nabeta P, Hillemann D, et al. Rapid molecular detection of tuberculosis and rifampin resistance. N Engl J Med 2010; 363:1005.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/56/9098/abstract/69\">",
"      Steingart KR, Sohn H, Schiller I, et al. Xpert&reg; MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults. Cochrane Database Syst Rev 2013; 1:CD009593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/56/9098/abstract/70\">",
"      Boehme CC, Nicol MP, Nabeta P, et al. Feasibility, diagnostic accuracy, and effectiveness of decentralised use of the Xpert MTB/RIF test for diagnosis of tuberculosis and multidrug resistance: a multicentre implementation study. Lancet 2011; 377:1495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/56/9098/abstract/71\">",
"      O'Grady J, Bates M, Chilukutu L, et al. Evaluation of the Xpert MTB/RIF assay at a tertiary care referral hospital in a setting where tuberculosis and HIV infection are highly endemic. Clin Infect Dis 2012; 55:1171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/56/9098/abstract/72\">",
"      Guerra RL, Hooper NM, Baker JF, et al. Use of the amplified mycobacterium tuberculosis direct test in a public health laboratory: test performance and impact on clinical care. Chest 2007; 132:946.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/56/9098/abstract/73\">",
"      Guerra RL, Baker JF, Alborz R, et al. Specimen dilution improves sensitivity of the amplified Mycobacterium tuberculosis direct test for smear microscopy-positive respiratory specimens. J Clin Microbiol 2008; 46:314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/56/9098/abstract/74\">",
"      Pollock N, Westerling J, Sloutsky A. Specimen dilution increases the diagnostic utility of the gen-probe mycobacterium tuberculosis direct test. Am J Clin Pathol 2006; 126:142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/56/9098/abstract/75\">",
"      Tuberculosis control laws--United States, 1993. Recommendations of the Advisory Council for the Elimination of Tuberculosis (ACET). MMWR Recomm Rep 1993; 42:1.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.cdc.gov/tb/links/tboffices.htm (Accessed on May 18, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/56/9098/abstract/77\">",
"      Taylor Z, Nolan CM, Blumberg HM, et al. Controlling tuberculosis in the United States. Recommendations from the American Thoracic Society, CDC, and the Infectious Diseases Society of America. MMWR Recomm Rep 2005; 54:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/56/9098/abstract/78\">",
"      Wang JY, Hsueh PR, Jan IS, et al. Empirical treatment with a fluoroquinolone delays the treatment for tuberculosis and is associated with a poor prognosis in endemic areas. Thorax 2006; 61:903.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/56/9098/abstract/79\">",
"      Ginsburg AS, Woolwine SC, Hooper N, et al. The rapid development of fluoroquinolone resistance in M. tuberculosis. N Engl J Med 2003; 349:1977.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/56/9098/abstract/80\">",
"      Lautenbach E, Larosa LA, Kasbekar N, et al. Fluoroquinolone utilization in the emergency departments of academic medical centers: prevalence of, and risk factors for, inappropriate use. Arch Intern Med 2003; 163:601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/56/9098/abstract/81\">",
"      Gaba PD, Haley C, Griffin MR, et al. Increasing outpatient fluoroquinolone exposure before tuberculosis diagnosis and impact on culture-negative disease. Arch Intern Med 2007; 167:2317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/56/9098/abstract/82\">",
"      Devasia RA, Blackman A, Gebretsadik T, et al. Fluoroquinolone resistance in Mycobacterium tuberculosis: the effect of duration and timing of fluoroquinolone exposure. Am J Respir Crit Care Med 2009; 180:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/56/9098/abstract/83\">",
"      Bernardo J, Yew WW. How are we creating fluoroquinolone-resistant tuberculosis? Am J Respir Crit Care Med 2009; 180:288.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/56/9098/abstract/84\">",
"      Blumberg HM, Burman WJ, Chaisson RE, et al. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. Am J Respir Crit Care Med 2003; 167:603.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/56/9098/abstract/85\">",
"      Iseman MD, Heifets LB. Rapid detection of tuberculosis and drug-resistant tuberculosis. N Engl J Med 2006; 355:1606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/56/9098/abstract/86\">",
"      Shiferaw G, Woldeamanuel Y, Gebeyehu M, et al. Evaluation of microscopic observation drug susceptibility assay for detection of multidrug-resistant Mycobacterium tuberculosis. J Clin Microbiol 2007; 45:1093.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/56/9098/abstract/87\">",
"      Moore DA, Evans CA, Gilman RH, et al. Microscopic-observation drug-susceptibility assay for the diagnosis of TB. N Engl J Med 2006; 355:1539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/56/9098/abstract/88\">",
"      Arias M, Mello FC, Pav&oacute;n A, et al. Clinical evaluation of the microscopic-observation drug-susceptibility assay for detection of tuberculosis. Clin Infect Dis 2007; 44:674.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/56/9098/abstract/89\">",
"      Minion J, Leung E, Menzies D, Pai M. Microscopic-observation drug susceptibility and thin layer agar assays for the detection of drug resistant tuberculosis: a systematic review and meta-analysis. Lancet Infect Dis 2010; 10:688.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/56/9098/abstract/90\">",
"      Tyagi S, Kramer FR. Molecular beacons: probes that fluoresce upon hybridization. Nat Biotechnol 1996; 14:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/56/9098/abstract/91\">",
"      Musser JM. Antimicrobial agent resistance in mycobacteria: molecular genetic insights. Clin Microbiol Rev 1995; 8:496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/56/9098/abstract/92\">",
"      Riska PF, Jacobs WR Jr, Alland D. Molecular determinants of drug resistance in tuberculosis. Int J Tuberc Lung Dis 2000; 4:S4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/56/9098/abstract/93\">",
"      Telenti A, Imboden P, Marchesi F, et al. Detection of rifampicin-resistance mutations in Mycobacterium tuberculosis. Lancet 1993; 341:647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/56/9098/abstract/94\">",
"      Piatek AS, Tyagi S, Pol AC, et al. Molecular beacon sequence analysis for detecting drug resistance in Mycobacterium tuberculosis. Nat Biotechnol 1998; 16:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/56/9098/abstract/95\">",
"      Varma-Basil M, El-Hajj H, Colangeli R, et al. Rapid detection of rifampin resistance in Mycobacterium tuberculosis isolates from India and Mexico by a molecular beacon assay. J Clin Microbiol 2004; 42:5512.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/56/9098/abstract/96\">",
"      Helb D, Jones M, Story E, et al. Rapid detection of Mycobacterium tuberculosis and rifampin resistance by use of on-demand, near-patient technology. J Clin Microbiol 2010; 48:229.",
"     </a>",
"    </li>",
"    <li>",
"     Centers for Disease Control and Prevention. Laboratory User Guide. Available at: file://www.cdc.gov/tb/topic/laboratory/guide.htm (Accessed on May 21, 2010).",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8010 Version 18.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-122.72.76.133-2ED5F37753-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_56_9098=[""].join("\n");
var outline_f8_56_9098=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H24\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      GENERAL APPROACH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Adults and older children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Children under five",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      CHEST RADIOGRAPHY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      LABORATORY EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Clinical specimens",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Sputum",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Bronchoscopy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Gastric secretions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Body fluids",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Tissue biopsy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Diagnostic microbiology",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Stained smears",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4856569\">",
"      - Culture",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4856355\">",
"      - Molecular tests",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Nucleic acid amplification",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H4856396\">",
"      Xpert MTB/RIF assay",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Preliminary results",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Presumptive diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      WHILE LABORATORY DIAGNOSTICS ARE PENDING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Infection control",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Reporting and public health",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Empiric therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Drug susceptibility testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/8010\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/8010|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?31/20/32079\" title=\"diagnostic image 1A\">",
"      Adult TB case 1 PA view",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?30/21/31056\" title=\"diagnostic image 1B\">",
"      Adult TB case 1 lateral view",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?14/35/14897\" title=\"diagnostic image 1C\">",
"      Adult TB case 2 PA view",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?0/53/863\" title=\"diagnostic image 1D\">",
"      Adult TB case 2 lateral view",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/8010|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?36/51/37680\" title=\"picture 1\">",
"      Sputum Ziehl Neelsen stain",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?17/38/18030\" title=\"picture 2\">",
"      Fluorochrome stain of sputum",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/8010|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?38/31/39420\" title=\"table 1\">",
"      Evaluation for TB",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/47/39673?source=related_link\">",
"      Clinical manifestations and evaluation of pulmonary tuberculosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/21/20826?source=related_link\">",
"      Clinical manifestations, diagnosis, and treatment of extrapulmonary and miliary tuberculosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/10/20648?source=related_link\">",
"      Diagnosis of latent tuberculosis infection in HIV-negative adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/52/32586?source=related_link\">",
"      Diagnosis, treatment, and prevention of drug-resistant tuberculosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/13/18649?source=related_link\">",
"      Epidemiology of tuberculosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/10/1194?source=related_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of tuberculosis in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/21/19802?source=related_link\">",
"      Treatment of pulmonary tuberculosis in HIV-negative patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/35/19002?source=related_link\">",
"      Treatment of pulmonary tuberculosis in the HIV-infected patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/4/23625?source=related_link\">",
"      Tuberculosis disease in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/52/20294?source=related_link\">",
"      Tuberculosis transmission and control",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/47/22261?source=related_link\">",
"      Tuberculous pleural effusions in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/35/12856?source=related_link\">",
"      Tuberculous pleural effusions in HIV-negative patients",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f8_56_9099="Crutches instructions";
var content_f8_56_9099=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F63565&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=8\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F63565&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=8\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Patient instructions for the use of crutches",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Keep the upper padded part of the crutch two adult finger breadths below the axillae",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        To avoid tenderness of the axillae, bear weight with the hands at the hand support, not at the axillae. (Do not rest the axillae on the upper pads).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        To maintain strength in the hip flexor/quadriceps muscles and avoid tightness in the hamstring muscles, keep the injured leg ahead of you as you walk",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        To walk up stairs: place the uninjured leg on the higher step, lift your body up, then bring the injured leg and the crutches up together",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        To walk down stairs: put the injured leg and the crutches on the lower step, support the body, then step down with the uninjured leg",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Hergenroeder, AC. Acute shoulder, knee, and ankle injuries Part 2: Rehabilitation. Adolescent Health Update 1996; 8:3.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_56_9099=[""].join("\n");
var outline_f8_56_9099=null;
var title_f8_56_9100="Treatment of adrenal crisis";
var content_f8_56_9100=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F67329&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F67329&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Treatment of acute adrenal insufficiency (adrenal crisis) in adults",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Emergency measures",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1. Establish intravenous access with a large-gauge needle.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2. Draw blood for immediate serum electrolytes and glucose and routine measurement of plasma cortisol and ACTH. Do not wait for lab results.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3. Infuse 2 to 3 liters of isotonic saline or 5 percent dextrose in isotonic saline as quickly as possible. Frequent hemodynamic monitoring and measurement of serum electrolytes should be performed to avoid iatrogenic fluid overload.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        4. Give 4 mg dexamethasone as intravenous bolus over one to five minutes and every 12 hours thereafter. Dexamethasone is the drug of choice because it does not interfere with the measurement of plasma cortisol. If dexamethasone is unavailable, intravenous hydrocortisone, 100 mg immediately and every six hours thereafter, may be used.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        5. Use supportive measures as needed.*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Subacute measures after stabilization of the patient",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1. Continue intravenous isotonic saline at a slower rate for next 24 to 48 hours.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2. Search for and treat possible infectious precipitating causes of the adrenal crisis.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3. Perform a short ACTH stimulation test to confirm the diagnosis of adrenal insufficiency, if patient does not have known adrenal insufficiency.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        4. Determine the type of adrenal insufficiency and its cause if not already known.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        5. Taper parenteral glucocorticoid over one to three days, if precipitating or complicating illness permits, to oral glucocorticoid maintenance dose.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        6. Begin mineralocorticoid replacement with fludrocortisone, 0.1 mg by mouth daily, when saline infusion is stopped.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Electrolyte abnormalities may include hyponatremia, hyperkalemia or rarely hypercalcemia. Hyponatremia is rapidly corrected by cortisol and volume repletion.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_56_9100=[""].join("\n");
var outline_f8_56_9100=null;
var title_f8_56_9101="Antibiotic prophylaxis derm surgery";
var content_f8_56_9101=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F69096&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F69096&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Antibiotic prophylaxis in dermatologic surgery",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Situation",
"       </td>",
"       <td class=\"subtitle1\">",
"        Agent",
"       </td>",
"       <td class=\"subtitle1\">",
"        Regimen: single dose 30 to 60 min before procedure",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Prevention of surgical site infection",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"7\">",
"        Surgery involving lips, ear, or nose",
"       </td>",
"       <td>",
"        Cephalexin",
"       </td>",
"       <td>",
"        2 g",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\" colspan=\"2\">",
"        <strong>",
"         OR",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Clindamycin",
"       </td>",
"       <td>",
"        600 mg",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\" colspan=\"2\">",
"        <strong>",
"         OR",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Azithromycin",
"       </td>",
"       <td>",
"        500 mg",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\" colspan=\"2\">",
"        <strong>",
"         OR",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Clarithromycin",
"       </td>",
"       <td>",
"        500 mg",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"5\">",
"        Surgery involving groin or lower extremities",
"       </td>",
"       <td>",
"        Cephalexin",
"       </td>",
"       <td>",
"        2 g",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\" colspan=\"2\">",
"        <strong>",
"         OR",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Trimethoprim-sulfamethoxazole",
"       </td>",
"       <td>",
"        160 mg trimethoprim/800 mg sulfamethoxazole",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\" colspan=\"2\">",
"        <strong>",
"         OR",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Levofloxacin",
"       </td>",
"       <td>",
"        500 mg",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Any site, increased risk of MRSA infection",
"       </td>",
"       <td>",
"        Clindamycin",
"       </td>",
"       <td>",
"        600 mg",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Prevention of infective endocarditis or hematogenous total joint infection",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"7\">",
"        Surgery involving the oral mucosa",
"       </td>",
"       <td>",
"        Amoxicillin",
"       </td>",
"       <td>",
"        2 g",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\" colspan=\"2\">",
"        <strong>",
"         OR",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Clindamycin",
"       </td>",
"       <td>",
"        600 mg",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\" colspan=\"2\">",
"        <strong>",
"         OR",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Azithromycin",
"       </td>",
"       <td>",
"        500 mg",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\" colspan=\"2\">",
"        <strong>",
"         OR",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Clarithromycin",
"       </td>",
"       <td>",
"        500 mg",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"7\">",
"        Surgery involving non-oral sites",
"       </td>",
"       <td>",
"        Cephalexin",
"       </td>",
"       <td>",
"        2 g",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\" colspan=\"2\">",
"        <strong>",
"         OR",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Clindamycin",
"       </td>",
"       <td>",
"        600 mg",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\" colspan=\"2\">",
"        <strong>",
"         OR",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Azithromycin",
"       </td>",
"       <td>",
"        500 mg",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\" colspan=\"2\">",
"        <strong>",
"         OR",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Clarithromycin",
"       </td>",
"       <td>",
"        500 mg",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Any site, increased risk of MRSA infection",
"       </td>",
"       <td>",
"        Clindamycin",
"       </td>",
"       <td>",
"        600 mg",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     MRSA: methicillin resistant Staphylococcus aureus.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_56_9101=[""].join("\n");
var outline_f8_56_9101=null;
var title_f8_56_9102="AP view midshaft femur fracture with intramedullary rod";
var content_f8_56_9102=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F77974&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F77974&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    AP view of midshaft femur fracture with intramedullary rod",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 241px; height: 360px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    According to many orthopedic sources, standard treatment of a femoral shaft fracture is an antegrade reamed intramedullary nail, shown in the radiograph above. This technique enables rigid fixation and is associated with a 98 to 99 percent union rate.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Thomas J Mezzanotte, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_56_9102=[""].join("\n");
var outline_f8_56_9102=null;
var title_f8_56_9103="Diagnosis erythrocytosis I";
var content_f8_56_9103=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F52465&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F52465&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 494px\">",
"   <div class=\"ttl\">",
"    Diagnostic approach to suspected erythrocytosis in the presence of polycythemia vera-related features",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 474px; height: 520px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     PV: polycythemia vera; EPO: erythropoetin; Hb: hemoglobin; EEC: endogenous erythroid colony formation.",
"     <br/>",
"     * PV-related features include increased red cell mass with arterial oxygen saturation &ge;92 percent, splenomegaly, thrombocytosis, and leukocytosis.",
"     <br/>",
"     <span class=\"bullet\">",
"      &bull;",
"     </span>",
"     If PV is strongly suspected and the initial EPO level is normal, repeat testing in three months is suggested before additional testing is performed.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_56_9103=[""].join("\n");
var outline_f8_56_9103=null;
